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A POSSIBLE ROLE FOR sPLA2 IN OLIGODENDROCYTE DEATH AND SPINAL 
CORD INJURY 
William Lee Titsworth 
July 10, 2008 
Spinal cord injury (SCI) can be divided into two distinct stages, an initial 
mechanical impact and a later “secondary injury” resulting from a cascade of cytokines 
triggering a spreading demyelination and apoptosis of neurons and glia within the spinal 
cord.  It is believed that blockade of this “secondary injury” could improve functional and 
histological recovery following SCI.  Here we propose that sPLA2 might be one of the 
crucial mediators of the secondary injury.  To test this possibility we first elucidated that 
the mRNA and protein of several isozymes of sPLA2 are present in the rodent spinal cord 
and that the group II enzymes are upregulated following SCI with a peak expression at 4 
hours.  Next, we showed that injuring differentiated cultures of oligodendrocyte precursor 
cells with H2O2 or TNFα and IL-1β induces sPLA2 expression and pharmacological 
inhibition with a sPLA2 inhibitor, S3319, creates partial reversal of this injury.  We 
further showed that a nanogram injection of sPLA2 into the naïve dorsolateral funiculus 
of the cervical spinal cord is sufficient to produce demyelination, axonopathy, and glial 
death as well as a dose dependent loss of function as measured by pellet retrieval.  Finally 
we showed that inhibition of sPLA2 by either i.p. injections of S3319 or a frame shift 
 vii
mutation in the sPLA2-IIA gene creates functional improvements in overground 
locomotion and bladder function.  The functional recovery correlates well with increased 
white matter sparing and oligodendrocyte numbers within in the spinal cord, increased 
axon numbers at the lesion epicenter, and decreased inflammation and lesion cavity 
volume.   These findings suggest that sPLA2 may play an important role in secondary SCI 
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SCI: The Human Cost 
Modern advances in treatment for spinal cord injury (SCI) have resulted in the 
saving of lives but with only limited gains in function.  This in turn has contributed to an 
increasing societal cost.  The National Spinal Cord Injury Statistical Center at the 
University of Alabama in Birmingham estimated in the 1970’s that there were 12,000 
new cases of spinal cord injury (SCI) each year.  Data from 2007 indicates that between 
230,000 and 300,000 people are currently living with a SCI.  In 2005, the average length 
of stay in a hospital was 15 days following a SCI with an additional 36 days in a rehab 
unit.  The average yearly health care and living expenses for a 25 year old patient with 
high tetraplegia is $775,567 with an estimated direct lifetime cost of $3,059,184  
(NSCISC, 2008). 
Many of the current theories involving spinal cord injury (SCI) divide the process 
into two stages, an initial mechanical damage to the cord tissue followed by a cascade of 
“secondary injury.”  The secondary injury is thought to be an immune response to 
damaged tissue that in turn leads to widespread neuronal and glial cell death as well as 
demyelination (McTigue et al., 2001, Cao et al., 2005, Totoiu and Keirstead, 2005).  
Notably, oligodendrocytes are particularly sensitive to apoptosis during secondary injury, 
which results in a loss of myelin around surviving axons peripheral to the lesion epicenter 
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(Blight, 1985, Crowe et al., 1997, Totoiu and Keirstead, 2005).  By seven days post 
injury, 93% of the oligodendrocytes at the impact site are lost (McTigue et al., 2001).  
Since only accident prevention can attenuate the initial mechanical damage from SCI, it 
is hypothesized that therapeutic manipulation of the inflammatory “secondary injury” 
could result in increased oligodendrocyte survival after neurotrauma and that this 
represents a viable approach to restore functional conduction of intact but demyelinated 
axons (Jones et al., 2005b).   
Therefore, much of the current work in SCI has revolved around muting the 
inflammatory response.  Examples of this work include blockade of the TNFα receptor 
(Demjen et al., 2004), injection of the anti-inflammatory antibiotic minocycline (Wells et 
al., 2003), the systemic depletion of macrophages (Popovich et al., 1999) and neutrophils 
(Taoka et al., 1997), use of immunosuppressant pharmaceuticals such as cyclosporine A 
(Rabchevsky et al., 2001).  However, the complex role of inflammation suggests that 
other inflammatory mediators could be present following SCI and their blockade could 
result in therapeutic interventions, possibly even a multi-modal approach.  Therefore we 
have suggested that phospholipases A2, an immerging class of proinflammatory 
molecules, might play a role in secondary SCI. 
Phospholipases A2 (EC 3.1.1.4) are enzymes that catalyze the hydrolysis of the 
sn-2 position of membrane glycerophospholipids, leading to the production of free fatty 
acids and lysophospholipids.  These enzymes are of particular interest since free fatty 
acids can be converted to bioactive eicosanoids via the cyclooxygenase pathway leading 
to increased inflammation.  Additionally, the other reaction product, lysophospholipids, 
such as lysophosphatidic acid and lysophosphatidylcholine (LPC), are also bioactive 
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(Lauber et al., 2003) and can be converted into platelet-activating factor (PAF).  Since 
lipids compose a disproportionately large amount of the CNS and phospholipids 
constitute 44% of myelin (Morell, 1984), understanding the role of phospholipases in 
CNS disorders becomes a major priority.    
To date, more than 27 mammalian isoforms of PLA2 have been found which can 
be classified into four major categories: secretory PLA2 (sPLA2), cytosolic PLA2 
(cPLA2), Ca2+-independent PLA2 (iPLA2), and PAF acetylhydrolases (PAF-AH) 
(Murakami et al., 1997, Murakami and Kudo, 2001, Kudo and Murakami, 2002, 










Figure 1. Classification of the Mammalian PLA2 Isoforms. 
 The top panel shows a branching diagram indicating the relative subdivisions of 
the PLA2 subfamily and their years of discovery.  The mammalian PLA2 family of 
enzymes is grossly divided into the sPLA2, cPLA2, iPLA2, and PAF-AH.  The sPLA2 
subfamily is further divided into groups IB, group II and V, group X, and group III and 
XII based on structural and functional differences presented in the table below. HSPG: 
heparin sulfate proteoglycans 
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Our previous work demonstrated that both total PLA2 activity and cPLA2α 
(PLA2-IVα)  protein expression increased following SCI (Liu et al., 2006).  However, 
total PLA2 activity peaked at 4 hr while cPLA2α (PLA2-IVα) protein did not significantly 
increase until 7 days post injury.  This paradox suggests that another isoform of PLA2 
might be responsible for the increase in total phospholipases activity after SCI.  For this 
reason we chose to investigate the role that the various sPLA2 isoforms might play 
following SCI. 
The 11 mammalian isozymes in the sPLA2 subfamily all have a low molecular 
mass of about 14-18 kD, require the presence of submillimolar to millimolar 
concentrations of Ca2+ for effective hydrolysis of a substrate phospholipid, and lack fatty 
acid selectivity (Dennis, 1994, Kudo and Murakami, 2002, Schaloske and Dennis, 2006).  
The functions of sPLA2s are far reaching, including digestion, exocytosis (Matsuzawa et 
al., 1996), and anticoagulation (Kini and Evans, 1987). However, sPLA2s most prominent 
role is in inflammation following pathological conditions such as infections (Laine et al., 
1996, Weinrauch et al., 1996, Laine et al., 2000), ischemia (Lauritzen et al., 1994), 
atherosclerosis (Ivandic et al., 1999, Leitinger et al., 1999, Tietge et al., 2000), and cancer 
(MacPhee et al., 1995, Cormier et al., 1997, Morioka et al., 2000a, Takaku et al., 2000).  
 
Role in General Inflammation 
sPLA2 has had an established role in inflammation and inflammatory diseases for 
some time (Nevalainen et al., 2000).  The blockade of PLA2 holds a particular interest for 
pharmacologists since inhibition of sPLA2 would in theory prevent the formation of 
inflammatory eicosanoids prior to the cyclooxygenase (COX; EC 1.14.99.1) reaction.  In 
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fact, PLA2 is the rate limiting precursor in arachidonic acid (AA) production (Schaefers 
et al., 1996).  Therefore its blockade should eliminate the need for COX-1 versus COX-2 
specificity in anti-inflammatory therapeutics.  This theory has spurred the development of 
a large number of sPLA2 inhibitors that unfortunately, have not produced the desired 
clinical efficacy to date (Reid, 2005).   
sPLA2s have been linked to many inflammatory diseases.  sPLA2 activity is 
elevated in several body fluids of patients with acute pancreatitis (Makela et al., 1990).  
Synovial fluid from arthritic joints of rheumatic patients contains sPLA2-IIA (Kramer et 
al., 1989, Seilhamer et al., 1989).  Total PLA2 activity and sPLA2-IIA protein is enhanced 
in bronchoalveolar lavage fluids from patients with adult respiratory distress syndrome 
(Kim et al., 1995).  Increased levels of sPLA2-IIA were seen in the skin of patients with 
psoriasis (Andersen et al., 1994).  Increased group II, PLA2 expression was found in 
colonic mucosa of patients with Crohn’s Disease and ulcerative colitis (Minami et al., 
1994) and experimental models of ischemic bowel disease in rodents (Otamiri et al., 
1988, Fabia et al., 1993). Additionally, serum levels of sPLA2, particularly group IIA, 
increase in patients with sepsis (Green et al., 1991, Keuter et al., 1995) and injuries (Uhl 
et al., 1990, Nevalainen et al., 2000), and following many types of surgeries such as 
cardiac surgery (Gronroos et al., 1995), aortobifemoral reconstruction (Gronroos et al., 
1995), and splenectomy (Laine et al., 1996).  Levels of serum sPLA2-IIA correlate with 
C-reactive protein in several disease states, supporting the notion that sPLA2-IIA is an 
acute phase protein (Crowl et al., 1991).  Some suggest that elevations in serum levels of 
sPLA2-IB are a specific marker of pancreatic damage whereas elevation in sPLA2-IIA are 
a more general marker of inflammation (Nevalainen et al., 2000). 
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sPLA2 has been either found in or produced by various inflammatory cells 
including platelets (Horigome et al., 1987), mast cells (Murakami et al., 1992), fibroblasts 
(Shinohara et al., 1992), macrophages (Wightman et al., 1981, Hidi et al., 1993) and 
neutrophils (Kim et al., 2001).  Macrophages isolated from peritoneal exudates of mice 
and rabbits secrete PLA2 (Wightman et al., 1981).  Additionally, sPLA2-IIA is 
constitutively expressed in immune tissues, such as the spleen, thymus, tonsils, and bone 
marrow (Kramer et al., 1989, Seilhamer et al., 1989).  Proinflammatory cytokines such as 
interferon gamma (IFN-γ), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor 
necrosis factor-α (TNF-α) can induce its production in a variety of cell types such as 
human arterial smooth muscle cells, HepG2,  HEK293, and BRL-3A in culture  (Suga et 
al., 1993, Kuwata et al., 1998, Peilot et al., 2000).  Interestingly the AA release from cells 
treated with IIA, IID, IIE and V were found to be dependent on IL-1, while treatment 
with group X released AA irrespective of IL-1 (Kudo and Murakami, 2002).  More 
relevant to the CNS, TNFα, IL-1, and lipopolysaccharide (LPS) were shown to induce 
sPLA2-IIA production in cultured astrocytes and direct injection of LPS into brain 
increased IIA mRNA (Oka and Arita, 1991).  Similarly LPS injections have been shown 
to increase sPLA2-IIE production (Murakami et al., 2002b).  Consistent with its inducible 
nature, the promoter region of sPLA2-IIA gene contains TATA and CAAT boxes as well 
as several elements homologous with consensus sequences for binding of transcription 
factors such as AP-1, C/EBPs, CREB, NF-κB, STAT, and PPARγ (Crowl et al., 1991, 
Couturier et al., 1999).  Finally, sPLA2 induction can be blocked by anti-inflammatory 
cytokines, such as platelet-derived growth factor, transforming growth factor β,  and IL-
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10 as well as glucocorticoids (Muhl et al., 1991, Schalkwijk et al., 1992, Touqui and 
Alaoui-El-Azher, 2001).  
 
Classification, Structure, and Properties of sPLA2 
 Eleven mammalian sPLA2s exist which are further divided into groups I, II, III, 
V, X, XII, and XIII (Fig. 1).  All sPLA2s are structurally related, and generally are 14-17 
kD secreted enzymes, with six absolutely conserved disulfide bonds, which contribute to 
the high degree of stability of these enzymes.  The enzymes do not have strict fatty acid 
specificity, unlike cPLA2, but instead tend to act on anionic phospholipids in the presence 
of high concentrations of Ca2+.  The central, core protein consists of a highly conserved 
Ca2+-binding loop (XCGXGG) and a catalytic site (DXCCXXHD) (Kudo and Murakami, 
2002).  Group differentiations are then made based on the presence or absence of up to 
two additional unique disulfide bonds, the presence or absence of an N- or C-terminal 
extension, and alterations in the conserved catalytic site.    
 
Intracellular Handling 
The site of sPLA2 activity has been a point of exhaustive study in recent years.  
While all sPLA2 isoforms are capable of secretion by definition, recent work has 
indicated that some heterogeneity exists among their site of activity (Bezzine et al., 
2000).  Recent studies in CHO and HEK293 cell lines that were stably transfected with 
human groups IIA and X have shed light on this subject.  Following stimulation by fetal 
bovine serum and IL-1β, both sPLA2-IIA and X are transcribed within the cell nucleus 
and synthesized in the endoplasmic reticulum prior to packaging in the Golgi apparatus 
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(Mounier et al., 2004).  See Fig. 2. This post synthesis packaging most likely results in 
the perinuclear puncta observed after stimulation, an observation which was previously 
ascribed to invagination of heparin sulfate proteoglycans (HSPG)-bound sPLA2, a 
process described later.  It is within the Golgi apparatus and later microvesicles, prior to 
initial secretion, that sPLA2-IIA is primarily active (Bezzine et al., 2000).  The reason for 
this is that most group II sPLA2s as well as sPLA2-IB show a marked preference for 
anionic phospholipids, such as phosphatidylglycerol, phosphatidylethanolamine  and 
phosphatidylserine, which are generally segregated to the inner leaflet of plasma 
membranes (Porcellati, 1983).  In contrast, sPLA2-V and X can hydrolyze both anionic 
phospholipids and charged-neutral phosphatidylcholines.  These difference in 
phospholipid preference results in secreted groups I and II having decreased abilities to 
act on the outer layer of plasma membranes (Bezzine et al., 2000, Murakami and Kudo, 
2001).  Once secreted, sPLA2 isoforms can then 1) metabolize the external plasma 
membrane, 2) bind to the sPLA2 receptor (sPLA2-R), or 3) be internalized by the HSPG 
shuttle.  Again, each of these actions is governed by isoform and species specificity, (see 






Figure 2. Intracellular Handling and sPLA2 Activity 
 Following stimulation by various cytokines [1], sPLA2 is synthesized in the 
nucleus [2] and endoplasmic reticulum prior to packaging for secretion in the Golgi 
apparatus [3].  It is within the Golgi apparatus and later micro vesicles that certain 
isoforms, particularly IIA, are predominantly active.  Following secretion [4], sPLA2 can 
metabolize the extracellular lipid membrane directly, bind to the sPLA2 receptor (sPLA2-
R), and/or be endocytosed via the heparin sulfate proteoglycan shuttle (HSPG shuttle).  
Of course, each of these actions is governed by species and isoform specificity.  The inset 
shows the general metabolism of phospholipids by sPLA2.  sPLA2 first hydrolyzes the 
acyl bond at the sn-2 position of glycerophospholipids to produce free fatty acids (such as 
arachidonic acid) and lysophospholipid (Lyso-PL).  Arachidonic acid can then be further 
modified by COX to form prostaglandins, lipoxygenase to form leukotrienes, or 
cytochrome P450 to form epoxides.  Prostaglandins can be further modified to form 
thromboxanes.  These eicosanoids have metabolic activities including proinflammatory 
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Some of the group II subfamily of sPLA2s, including IIA, IID, and V are highly 
cationic and bind tightly to anionic heparinoids such as heparin and heparin sulfate 
(Murakami et al., 1996, Murakami et al., 1998)  (See Fig. 2).  Since cell surfaces are 
usually rich in heparin sulfate proteoglycans (HSPG), significant portions of these 
sPLA2s are membrane-bound rather than being secreted into the culture media 
(Murakami et al., 1999b, Murakami et al., 2001).  Other sPLA2s (IB, IIC, and X) with 
neutral to acidic pHs show no, or very low, heparinoid affinity and are secreted into the 
medium.  Some authors suggest that this binding facilitates phospholipid digestion since 
treatment of stably transfected cells with heparinase, exogenous heparin, and GPI-
specific phospholipase C, (Murakami et al., 1993, Suga et al., 1993, Kuwata et al., 1998, 
Murakami et al., 1999a) or mutation of the heparin binding domain in sPLA2-IIA 
(Murakami et al., 1996, Murakami et al., 1998, Murakami et al., 2001) markedly 
attenuates sPLA2-IIA-mediated prostaglandin generation.  In contrast, one recent study 
found that treatment of cells with heparin had little or no effect on sPLA2-IIA activity 
(Mounier et al., 2004).  Also of note, HSPG has been shown to increase following 
cerebral stab injury with an implicated role in storage, nuclear trafficking, and cell-
specific injury responses in CNS wounds (Leadbeater et al., 2006).  The closely related 
chondroitin sulfate proteoglycans are also greatly expressed following SCI (Tang et al., 
2003, Chau et al., 2004). 
 
Receptor Binding Domain 
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  In addition to its enzymatic function, some sPLA2s mediate their biological 
function through a membrane receptor.  Two sPLA2 receptors have been identified to 
date, the M-type (Hanasaki and Arita, 1992b, Ishizaki et al., 1994, Lambeau et al., 1994) 
and the N-type (Lambeau and Lazdunski, 1999), named for their discovery in muscle and 
neural tissue respectively.  However, mammalian sPLA2s only bind to the M-type which 
was later discovered to be relatively widespread and not merely confined to muscle 
(Hanasaki and Arita, 1999).  Since only the M-type has the ability to initiate an 
intracellular signal we will restrict our discussion to its properties and further refer to it as 
sPLA2-R.  The receptor is a type 1 transmembrane glycoprotein with a molecular mass of 
180-220 kDa and is a member of the C-type animal lectin family (subgroup VI) (Ohara et 
al., 1995).  The intracellular region consists of approximately 40 amino acids and 
contains both a consensus sequence for casein-kinase II phosphorylation (Ancian et al., 
1995) and a consensus sequence for coated-pit-mediated endocytosis (Ohara et al., 1995).  
Accordingly, the receptor undergoes internalization after sPLA2 binding (Hanasaki and 
Arita, 1992a).  Interestingly the isozymes of sPLA2 show varying affinities for the 
sPLA2-R in different species.  For example, the rabbit sPLA2-R is very promiscuous, 
binding to almost all sPLA2 tested to date.  The mouse sPLA2-R on the other hand binds 
only IB, IIA, and X, while the rat sPLA2-R only binds sPLA2-IB (Cupillard et al., 1999), 
(See Fig. 1). Likewise sPLA2-IIA does not seem to bind to the sPLA2-R in humans 
(Cupillard et al., 1999).  In general, sPLA2-IB and X appear to be the predominant ligand 
of this receptor (Morioka et al., 2000b) and most of the research has therefore focused on 
their effects (Ancian et al., 1995, Hernandez et al., 1998, Fonteh et al., 2000).  This 
specificity suggests that the biological function of sPLA2-R could vary wildly among 
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species.  However, the generalized functions of the sPLA2-R are far reaching including 
cell growth (Arita et al., 1991), proliferation (Kinoshita et al., 1997), and migration 
(Kanemasa et al., 1992).  It has also been suggested that sPLA2-R functions in the 
clearance of extracellular sPLA2s to protect against enzymatic over activity, particularly 
sPLA2-X which has potent activity against the extracellular membrane, unlike IB and IIA 
as stated above (Lambeau and Lazdunski, 1999, Yokota et al., 2001).  Additionally, 
sPLA2-R knockout mice have significantly reduced levels of TNFα and IL-1β after 
systemic LPS administration suggesting an inflammatory role (Hanasaki et al., 1997).  
For an excellent review on the role of the sPLA2-R in sPLA2 function, please see 
(Lambeau and Lazdunski, 1999, Hanasaki and Arita, 2002).   
 
Group I –  
 
sPLA2-IB was the first sPLA2 to be discovered and is predominantly present in 
pancreatic juices (Seilhamer et al., 1986).  sPLA2-IB lacks a C-terminal extension and is 
secreted as a catalytically inactive propeptide that is later proteolytically cleaved (Verheij 
et al., 1981).  Group IB has a unique five amino acid extension termed the pancreatic 
loop in the middle of the molecule as well as a group specific disulfide bond between 
Cys11 and Cys77 (Verheij et al., 1981, Seilhamer et al., 1986).   sPLA2-IB is almost 
exclusively secreted into the medium of transfected cells (Kudo and Murakami, 2002).  
Interestingly, sPLA2-IB shows low affinity for both heparinoids and phosphatidylcholine 
(PC) on the external membrane leaflet.  Subsequently, it was discovered that sPLA2-IB 
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can only release AA indirectly through the M-type sPLA2 receptor-dependent pathway 
via cPLA2α activation (Ancian et al., 1995, Hernandez et al., 1998, Fonteh et al., 2000).  
 
Groups II and V –  
The second member of the sPLA2 family, later named group IIA, was first cloned 
in 1989 (Komada et al., 1989) and is constitutively expressed in immune tissues, such as 
the spleen, thymus, tonsils and bone marrow (Kramer et al., 1989, Seilhamer et al., 1989) 
as well as the digestive system of some mouse strains (Kennedy et al., 1995).  sPLA2-IIA 
(Komada et al., 1989, Kramer et al., 1989, Seilhamer et al., 1989), IID (Ishizaki et al., 
1999, Valentin et al., 1999), and IIE (Suzuki et al., 2000, Valentin et al., 2000a) are the 
archetypical group II enzymes.  Typically, the enzymes have a C-terminal extension and 
a disulfide bond linking Cys50 with a Cys in the C-terminus.  IIC (Chen et al., 1994) and 
IIF (Valentin et al., 2000b) have minor variations in amino acids and disulfide structure.  
Similar to IIA, sPLA2-IIE is constitutively expressed in human lung and mouse uterus, 
brain, heart, liver and testis at low levels (Valentin et al., 1999, Suzuki et al., 2000, 
Murakami et al., 2002b).  However, LPS has been shown to induce IIE expression in 
macrophages, suggesting an inflammatory role as well (Suzuki et al., 2000).  sPLA2-IIF 
is highly expressed in the mouse embryo, suggesting a roll in development and it is 
upregulated by LPS as with other group II enzymes (Valentin et al., 1999, Murakami et 
al., 2002a).  Finally, groups IIA, IIC, IID, IIE, and V all utilize the HSPG-shuttling 
pathway. 
Often considered in the same breath with group II enzymes is group V.   Group V 
shows the highest homology with the group II enzymes and is similarly located on human 
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chromosome 1 (1p34-36) (Valentin et al., 2000b).  However group V lacks the typical 
group II C-terminal region, thus justifying its isolation.  sPLA2-V functions as the 
primary mouse sPLA2.  This is since mice express group V at higher levels than any of 
the group II enzymes (Sawada et al., 1999) and since some species of mice have a frame 
shift mutation resulting in a natural sPLA2-II knock out (Kennedy et al., 1995).  
However, as with group II, group V is closely linked with inflammation as well being 
found in mast cells (Sawada et al., 1999), macrophages (Balboa et al., 2003), and type 2 
T helper cells (Ho et al., 2001).  As with group II, group V is upregulated by LPS 
(Sawada et al., 1999).       
 
Group X –  
Group X possesses characteristics of both group I and group II enzymes.  sPLA2-
X contains the disulfide bonds of both group I and group II as well as the group II, C-
terminal extension (Cupillard et al., 1997).  Additionally, like group I, it is secreted as a 
zymogen with cleavage of the N-terminal propeptide for activation (Hanasaki et al., 
1999).  Like sPLA2-IB, cells transfected with group X, secrete this sPLA2 almost 
exclusively into the culture medium rather than having it bound to the membrane like 
group II enzymes (Kudo and Murakami, 2002).  This is not surprising since unlike group 
II, group X does not readily bind HSPG and shows high activity towards PC, a dominant 
phospholipid enriched in the outer leaflet of the plasma membrane (Hanasaki et al., 1999, 
Murakami et al., 1999a, Morioka et al., 2000a, Morioka et al., 2000b, Murakami et al., 
2001).    Typically, sPLA2-X is expressed in the digestive organs such as intestine, colon 
and stomach and in some immune organs (Cupillard et al., 1997).  However, unlike group 
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II, group X is constitutively expressed with little or no change in most tissues (Kudo and 
Murakami, 2002).   
 
Groups III and XII –  
A distinct class of soluble sPLA2s, distantly related to groups I and II, were later 
discovered in bee and lizard venom and are classified as group III.  A mammalian 
homolog of group III was discovered in 2000 (Valentin et al., 2000a) .  Groups III and 
XII only share the Ca2+-binding loop and catalytic site with groups I, II, V, and X.  At 
55kDa, Group III is considerably large than all the other sPLA2 isozymes.  While 
maintaining all the sPLA2 signature characteristics such as, 10 cystines, the Ca2+-biniding 
loop, and catalytic site, it additionally has a large N- and C- terminal flanking regions that 
add to its molecular weight (Valentin et al., 2000a).  Within humans, sPLA2-III was 
found to be in high abundance in heart, skeletal muscle, liver, and kidney, but had only 
weak expression in the brain (Valentin et al., 2000a).  Group-XII is a much smaller 
enzyme than group III (19 kDa), lacks an N- or C-terminal flanking regions, and has 
deviations in the Ca2+ bind loop, that are inconsistent with other sPLA2s (Gelb et al., 
2000, Ho et al., 2001).  Group XII is expressed in human kidney, heart, and skeletal 
muscle (Gelb et al., 2000, Valentin et al., 2000a).  Relatively little is known about the 
function of either group III or XII in the mammalian system. 
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Suggested Mechanisms underlying sPLA2-Induced CNS Injury 
 The sPLA2 family of enzymes could damage the CNS by multiple injury 
mechanisms.  First, sPLA2 could damage cells directly by attacking cellular membranes 
and triggering apoptosis.  Secondly, the products of lipid metabolism, lysophospholipids 
and free fatty acids, are detrimental to the CNS and can produce pro-inflammatory 
mediators, generate free radicals, and increase excitotoxicity (O'Regan et al., 1995b, 
Farooqui et al., 1997b, Klein, 2000).   Interestingly often the injurious agents produced 
by sPLA2 metabolism in turn initiate synthesis of sPLA2 resulting in a positive feedback 
loop.  See Fig. 3. Our discussion will begin by looking the direct effects of sPLA2 on 
cells and then how oxidative stress, inflammatory cytokines, and excitotoxic 




Figure 3.  Overview of sPLA2’s Role in Spinal Cord Injury. 
 The toxicity of sPLA2 is compounded by three factors. 1) sPLA2 is upregulated by 
commonly known neurotoxic mechanisms such as oxidative stress, cytokines, and EAA.  
2) Both the primary metabolites of sPLA2 activity, such as free fatty acids and 
lysophospholipids, and the secondary metabolites, such as eicosanoids and platelet 
activating factor, are toxic to the CNS.  3) Finally, sPLA2 has been shown to reciprocally 
upregulate oxidative stress, cytokines, and EAA thus propagating a positive feedback 
loop resulting in cytotoxicity and secondary SCI.  It must also be noted that sPLA2 does 
not work in isolation from cPLA2 and iPLA2, rather a reciprocal activity is often 
demonstrated among the PLA2 subfamilies. 
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Membrane Breakdown and Metabolites 
          Phospholipids are the main components of the neural cell bi-layer membrane. In 
addition, they provide the membrane with the necessary environment, fluidity, and ion 
permeability that are required for the proper function of integral membrane proteins, 
receptors, and ion channels. PLA2 directly hydrolyses phospholipids resulting in 
membrane breakdown.  This results in alterations of membrane function such as fluidity 
and permeability, behavior of transporters and receptors, and ion homeostasis, and can 
eventually lead to functional failure of excitable membranes (Farooqui et al., 1997b, 
Klein, 2000, Farooqui et al., 2004).   
In addition to the direct effects of membrane breakdown on cell survival, the 
products of sPLA2 enzymatic, activity also exhibit neurotoxic profiles.  sPLA2 cleaves 
phospholipids into the primary metabolites free fatty acid, such as AA, and 
lysophospholipids such as lysophosphatidyl choline (LPC, a.k.a. lysolechithin).  See 
insert of Fig. 2 and Fig. 3.  Both of these agents have been shown to create injury and 
cytotoxicity in the CNS.  AA induces oxidative injury and death in cultured spinal cord 
neurons (Toborek et al., 1999).  AA can later form epoxides via the cytochrome P450 
pathway, leukotrienes via the lipoxygenase pathway, or thromboxanes or prostaglandins 
via the COX pathway.  See insert of Fig. 2.  Many of these products, such as 
prostaglandin E2 (PGE2) can subsequently act as potent chemoattractants increasing 
endogenous immune responses and subsequent secondary damage.  Additionally, the 
expression of eicosanoids, such as thromboxane A2 (TXA2) and PGE2 following SCI 
have been linked to trauma induced ischemia (Tonai et al., 1999).  LPC produced by 
sPLA2 –induced hydrolysis  is also implicated in CNS damage (Dutta et al., 1979).  
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Interestingly, direct LPC injection has been shown to create a demyelination and 
infiltration of macrophages in the spinal cord, brain, and peripheral nervous system with 
a later remyelination by Schwann cells, the myelinating cells of the peripheral nervous 
system (Blakemore et al., 1977, Blakemore, 1978, Blakemore, 1982, Jeffery and 
Blakemore, 1995).  This demyelination and remyelination by Schwann cells mimics that 
produced by direct injection of sPLA2, however, sPLA2 has the added cost of severe 
axonopathy and death of oligodendrocytes prior to remyelination (Titsworth et al., 2007).  
It has been hypothesized that LPC may mediate the demyelinating effects of sPLA2 
injections.  Additionally, a recent study by Lauber, et al., found that LPC, generated by 
iPLA2, was the main chemoattractant for monocytic cells and primary macrophages 
released by apoptotic cells thus facilitating the efficient phagocytosis of cellular debris 
(Lauber et al., 2003).    
 
Apoptosis 
In recent years, apoptosis has been identified as an important mechanism of cell 
death in many neurological disorders including SCI. Cells undergoing apoptosis 
generally release free fatty acids including AA, which parallels the reduction in cell 
viability (Taketo and Sonoshita, 2002, Balsinde et al., 2006), suggesting the involvement 
of PLA2 in apoptosis.  Recently, sPLA2-IB, IIA, and III have all been shown to induce 
neuronal apoptosis (Yagami et al., 2002a, Yagami et al., 2002b, Yagami et al., 2002c, 
DeCoster, 2003). In contrast, recombinant sPLA2 appears to prevent apoptosis of mast 




 Oxidative injury is a common pathological mechanism in neurological disorders.  
Free radicals induce not only lipid peroxidation of neural membranes, but also the 
oxidation of proteins, RNAs, and DNAs.  Reactive oxygen species (ROS) including 
hydrogen peroxide (H2O2) and superoxide radicals are produced by a number of cellular 
oxidative and metabolic processes including metabolism of AA.  PLA2 metabolism of 
phospholipids is a well-established source of ROS (Adibhatla and Hatcher, 2006, Nanda 
et al., 2007).  Application of pathophysiological concentrations of free fatty acids has 
been demonstrated to induce oxidative injury to cultured spinal cord neurons (Toborek et 
al., 1999). Microinjections of PLA2 into the normal spinal cord induced expression of 4-
hydroxynonenal, a product of lipid peroxidation and marker for oxygen free radical-
mediated membrane injury (Liu et al., 2006).  Nethery, et al., (Nethery et al., 1999) found 
that ROS production in contracting muscle required the presence of sPLA2 but not cPLA2 
or iPLA2.  In the presence of 15-lipoxygenase the addition of sPLA2-IIA or IB greatly 
enhances the accumulation of hydroperoxides of oxidized free fatty acids (Neuzil et al., 
1998).  Finally, it can be assumed that the proinflammatory effects of sPLA2 would result 
in an immigration of immune cells, which will release copious amounts of ROS (Blight, 
1985, Popovich et al., 1997, Park et al., 2004, Jones et al., 2005a, Fleming et al., 2006, 
Wang et al., 2006).  For a review of the ROS species produced by the enzymatic effects 
of sPLA2 please see (Nanda et al., 2007).  
While sPLA2 production of ROS is well established, the induction of sPLA2 by 
ROS is an immerging concept.  One study found that mesangial cells treated with H2O2 
utilized both cPLA2 and sPLA2 during AA release and that elimination of sPLA2 greatly 
 37
inhibited AA release (Han et al., 2003), thus suggesting the first of many positive 
feedback loops. 
 
Inflammation and Inflammatory Cytokines 
Inflammation has been implicated in many CNS neurological disorders including 
SCI. PLA2 may serve as a key molecule that controls the biosynthesis of several well-
known bioactive mediators of inflammation such as eicosanoids (prostaglandins, 
thromboxanes, leukotrienes and lipoxins) and PAF in a rate-limiting manner (Farooqui et 
al., 1997b, Farooqui et al., 1999a). In addition, our recently findings showed that sPLA2 
induced expression of cytokines including  TNF-α and IL-1β in the injured spinal cord 
(Liu et al., 2006). On the other hand, there is also strong evidence to suggest that 
cytokines upregulate sPLA2-IIA in vitro and in vivo.  sPLA2-IIA is up-regulated by TNF-
α and IL-1α/β after transient focal cerebral ischemia in rats (Adibhatla and Hatcher, 
2007).  sPLA2-IIA mRNA is expressed in cultured astrocytes and can be induced in 
response to proinflammatoy cytokines TNFα, IL-1β, and, INFγ (Oka and Arita, 1991, 
Tong et al., 1995, Li et al., 1999, Xu et al., 2003).  Astrocytes isolated from C57Bl/6 
mice, which lack the sPLA2-IIA gene, were less responsive to cytokines in the production 
of PGE2 than were astrocytes expression sPLA2-IIA (Xu et al., 2003).   Additionally, IL-
1β and TNFα can also activate COX-2 continuing the proinflammatory pathways 
(Kuwata et al., 1998, Murakami et al., 1999b, Sawada et al., 1999, Morioka et al., 2000a, 
Morioka et al., 2002).  sPLA2 also induced AA release and COX-2 expression in cultured 




Elevated levels of excitatory amino acids (EAA) have been implicated in the 
pathogenesis of neural injury and death in many disorders and evidence suggests that 
sPLA2 may stimulate the release of EAA following CNS trauma.  First, injections of 
sPLA2 into the brain caused epileptic seizures and neurotoxicity in vivo (Dorandeu et al., 
1998).  Secondly, application of sPLA2 to the rat ischemic cerebral cortex resulted in a 
significant increase in EAA levels and inhibition with mepacrine, a global PLA2 
inhibitor, significantly decreased the ischemia-evoked efflux of EAA into cortical 
superfusates (O'Regan et al., 1995a).  Group IIA sPLA2 stimulates exocytosis and 
neurotransmitter release in pheochromocytoma-12 cells and cultured rat hippocampal 
neurons (Wei et al., 2003).  sPLA2-induced neuronal death was blocked by MK-801, an 
N-methyl-D-aspartic acid (NMDA) receptor antagonist, both in vitro and in vivo (Kolko 
et al., 2002).  Finally, administration of the nonselective PLA2 inhibitor, 4-
bromophenacyl bromide, inhibited glutamate release in the spinal cord (Sundstrom and 
Mo, 2002).  Only one study so far has suggested that excessive EEA concentrations 
induce sPLA2 levels in the CNS.  Interocerebroventricular injection of kainic acid (KA) 
resulted in an increase in both total PLA2 and sPLA2 activity and this activity could be 
blocked by a synthetic short inhibitor peptide for sPLA2-IIA (Thwin et al., 2003).   
The exact mechanism of sPLA2 action on EAA release remains unknown. It has 
been suggested that PLA2 disrupts an artificial planar lipid bilayer in a Ca2+-dependent 
manner (O'Regan et al., 1996).  Matsuzawa demonstrated the role of sPLA2-IIA in EEA 
release in a set of elegant experiments.  First, sPLA2-IIA was detected in purified brain 
synaptosomes.  Secondly, sPLA2-IIA was released upon depolarization of neurons with 
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either high concentrations of potassium or neurotransmitters.  Third, addition of sPLA2-
IIA to cultures triggered neurotransmitter release.  Finally, sPLA2-IIA inhibition 
suppressed neurotransmitter secretion (Matsuzawa et al., 1996).  The role of sPLA2 in 
neurotransmitter release is further supported by the fact that exogenously added sPLA2 
paralyzed neuromuscular junction preparations by inducing total neurotransmitter release 
(Rigoni et al., 2005).  Interestingly, an equimolar mixture of lysophospholipids and fatty 
acids closely mimicked the sPLA2 paralysis (Rigoni et al., 2005).  These studies further 
suggest that changes in the local lipid composition within the synaptic buton trigger 
neurotransmitter release which would lead to excitotoxicity (Piomelli et al., 2007).  
Inhibitors of total PLA2 activity such as 4-bromophenacyl bromide, a nonselective PLA2 
inhibitor, 7,7-dimethyleicosadienoic, a sPLA2 specific inhibitor, AACOCF3, a cPLA2 
specific inhibitor, and HELSS, an iPLA2 specific inhibitor, all reduced the efflux of both 
glutamate and aspartate in vivo suggesting the involvement of multiple isoforms of PLA2 
in EAA release not merely sPLA2 (Phillis and O'Regan, 1996).  
 
Role of sPLA2 in CNS Disorders 
Localization within the CNS   
sPLA2s are present in all regions of the mammalian brain. The highest sPLA2 
activities are found in medulla oblongata, pons, and hippocampus; moderate activities in 
the hypothalamus, thalamus, and cerebral cortex; and lowest activities in the cerebellum 
and olfactory bulb (Thwin et al., 2003). Molloy, et al., utilizing RT-PCR found that 
mRNAs for sPLA2-IIA and IIC were expressed in all regions of normal rat brain, sPLA2-
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V was found at low levels in most areas of the brain, but at very high levels in the 
hippocampus, and sPLA2-IB was not detected in the rat brain at all (Molloy et al., 1998).  
In contrast, Kolko, et al., reported that sPLA2-IB mRNA was detected in the rat and 
human brain at very high levels as well as in neurons in primary cultures using various 
detection methods. The distribution of sPLA2-IB seems to be mainly neuronal, with the 
highest abundance occurring in the cerebral cortex and hippocampus (Kolko et al., 2005). 
sPLA2-IIA and V were also detected in the rat cerebellum using immunostaining and in 
situ hybridization methods (Shirai and Ito, 2004). sPLA2-IIA is associated with the 
endoplasmic reticulum in perinuclear regions of Purkinje cell somata and sPLA2-V was 
localized in Bergmann glia cells (Shirai and Ito, 2004). Recently, Kolko, et al., found the 
presence of sPLA2-IIE, V, and X in the rat brain as well as in neurons in primary cultures 
using RT-PCR, in situ hybridization, and immunohistochemistry (Kolko et al., 2006). 
The distribution of sPLA2-IIE, V, and X seems to be mainly neuronal, with the highest 
abundance occurring in the cerebral cortex and hippocampus (Kolko et al., 2006). In the 
spinal cord, sPLA2 activity was detected in the normal rat spinal cord homogenate 
(Svensson et al., 2005). Western blots revealed that sPLA2-IIA and V are expressed in the 
normal rat spinal cord (Svensson et al., 2005). mRNAs of sPLA2s (IB, IIA, IIC and V) 
are also detected in the normal rat spinal cord with RT-PCR (Lucas et al., 2005). 
As stated above, the presence of sPLA2 in the CNS, particularly neurons, appears 
to be both constitutive (groups IB, IIA, V, and X) and inducible (group IIA).  While it is 
assumed that the inducible sPLA2 expression is associated with inflammation, the normal 
physiological role of constitutively expressed sPLA2 is believed to play a crucial role in 
exocytosis of synaptic vesicles (Matsuzawa et al., 1996, Phillis and O'Regan, 2004).  
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Support for this theory arises from studies by Matsuzawa, et al., in which differentiated 
PC12 cells were shown to release sPLA2-IIA after depolarization and that inhibition of 
IIA resulted in decreased catecholamine secretion (Matsuzawa et al., 1996).  
Additionally, snake PLA2 neurotoxins cause paralysis of neuromuscular junctions by 
triggering a massive release of all presynaptic vesicles (Rigoni et al., 2005).  Finally, the 
concentration of group V in the hippocampus and studies by Chabot, et al., indicate that 
sPLA2-V may play a role in the regulation of long-term potentiation and long-term 
depression (Chabot et al., 1998). 
Spinal Cord Injury 
Damage from acute SCI occurs in two phases, an initial mechanical injury 
followed by a secondary injury mediated by multiple processes including inflammation, 
free radical induced cell death, cytokine production, and glutamate excitotoxicity (Hall 
and Braughler, 1986, Young, 1993, Buki et al., 2000, Park et al., 2004).  Following SCI, 
inflammatory cells such as polymorphonuclear neutrophils, macrophages, and 
lymphocytes quickly infiltrate into the traumatized cord, and flood the interstitial tissue 
with proinflammatory cytokines such as TNF-α and IL-1β, and neurotoxic factors from 
leukocytes such as nitric oxide, hydrogen peroxide, and myeloperoxidase (Blight, 1985, 
Popovich et al., 1997, Park et al., 2004, Jones et al., 2005a, Fleming et al., 2006, Wang et 
al., 2006).  Free radical generation and lipid peroxidation were also found to be early 
events subsequent to SCI (Hall and Braughler, 1986, Hall et al., 1992, Springer et al., 
1997).  EAAs such as glutamate and aspartate are released rapidly following SCI and 
their extracellular concentrations increased to neurotoxic levels within minutes post SCI 
(Panter et al., 1990, Farooque et al., 1996, Liu et al., 1999b, McAdoo et al., 1999).  The 
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interplay between multiple harmful substances likely perpetuates the progressive course 
of secondary injury, resulting in cell death, axonal destruction, demyelination and 
functional loss.  Evidence suggests that these harmful substances generated in the injured 
cord might induce sPLA2 expression which in turn exacerbates SCI.  This hypothesis is 
supported by in vitro and in vivo experiments that indicate that increases in PLA2 activity 
and its metabolic products can in turn exacerbate inflammation (Bonventre, 1996, 
Murakami et al., 1997), oxidation (Bonventre, 1996, Murakami et al., 1997), 
demyelination (Titsworth et al., 2007), and neurotoxicity (Clapp et al., 1995, Bonventre, 
1996) suggesting that sPLA2 may serve as a common mediator in the progression of 







Figure 4. sPLA2 Activity Within Spinal Cord Injury. 
Following SCI, oxidative stress, cytokines, and EAA are upregulated.  These 
toxic factors then up regulate the synthesis of sPLA2.  Subsequently sPLA2 mediates the 
hydrolysis of phospholipids into lysophospholipids (Lyso-PL), such as LPC, and free 
fatty acids (FFA), such as AA.  Independent of other factors, sPLA2 and LPC demyelinate 
axons in the spinal cord and sPLA2 and AA have been shown to trigger apoptosis in 
neurons and oligodendrocytes.  The metabolism of AA results in increased oxidative 
stress from lipid peroxidation and increased eicosanoids which have been shown to 
increase inflammation and ischemia.  LPC also increases inflammation while its 
metabolite, PAF, triggers ischemia.  Infiltrating polymorphonuclear neutrophils (N), 
lymphocytes (L), and macrophages (Mφ) then flood the CNS with more sPLA2, oxidants, 
and cytokines thus exacerbating the positive feedback loop, while the upregulation in 

















Recently, we showed that PLA2 activity increased following SCI, peaking at 4 h 
post injury, and remaining elevated for one week.  In the same study, we found that 
cPLA2 expression did not peak until 7 days post injury (Liu et al., 2006).  In vitro 
experiments showed that both sPLA2 and melittin, an activator of endogenous PLA2, 
induced spinal neuronal death in a dose-dependent manner, an effect that could be 
substantially reversed by mepacrine, a PLA2 inhibitor (Liu et al., 2006).  Similarly direct 
injection of sPLA2 also lead to demyelination that could be effectively attenuated with 
mepacrine, an inhibitor of all PLA2 isoforms (Liu et al., 2006). Injections of sPLA2 also 
induced the expression of inflammatory cytokines TNF-α and IL-1β, as well as 4-
hydroxynonenal, a product of lipid peroxidation and a marker for oxygen free radical-
mediated membrane injury (Liu et al., 2006).  Indeed, in vivo and in vitro experiments 
show that exogenous administration of sPLA2 can induce neuronal death, 
oligodendrocyte death, and tissue damage (Clapp et al., 1995, Kolko et al., 1996, Kolko 
et al., 1999, Yagami et al., 2002a, Yagami et al., 2002b, Yagami et al., 2002c, Liu et al., 
2006, Titsworth et al., 2007).  Importantly, no study to date has directly observed whether 
sPLA2 mRNA or protein expression increases following SCI. 
The induction of sPLA2 following SCI is supported by the fact that the substrate 
of PLA2 metabolism, phospholipids, decreases acutely following SCI.  There is a 
dramatic loss of membrane phospholipids following CNS trauma.  During the first 
minute of compression trauma to the spinal cord, 10% of the plasmenylethanolamine  is 
reduced with an overall loss of 18% found at 30 min post compression injury (Horrocks 
et al., 1985). The hydrolysis of membrane phospholipids by PLA2 is a rate-limiting step 
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for generation of proinflammatory mediators, eicosanoids, and PAF (Farooqui et al., 
1997b, Farooqui et al., 1999b).   
Additionally, there is an increase in free fatty acids, eicosanoids, lipid peroxides, 
and lysophospholipids following SCI (Demediuk et al., 1985, Demediuk et al., 1989, 
Lukacova et al., 1996).  Severe trauma was associated with  biphasic increases in free 
fatty acids levels, with levels peaking at 15 min and 24 hr post-trauma before declining 
over the next 6 days (Demediuk et al., 1989).  Within the first few minutes of SCI, free 
fatty acids have increased in the grey matter and later increase within the white matter 
suggesting acute PLA2 activity (Demediuk et al., 1985, Faden et al., 1987, Demediuk et 
al., 1989).  The production of free fatty acid represents a source of potentially dangerous 
ROS by initiating lipid peroxidation.  Hydroxyl radicals can attack polyunsaturated fatty 
acids in membrane glycerophospholipids forming peroxyl radicals and propagating the 
chain reaction of lipid peroxidation products (Muralikrishna Adibhatla and Hatcher, 
2006, Sun et al., 2007). The generation of free fatty acids in SCI is closely associated 
with increases in free radical formation observed in the lesion of the injured spinal cord 
(Hamada et al., 1996, Azbill et al., 1997). Application of pathophysiological 
concentrations of free fatty acids has been demonstrated in vitro to induce oxidative 
injury in spinal cord cell cultures (Toborek et al., 1999).  The neurotoxic effects of AA 
have also been observed in hippocampal neurons and cortical neurons (Li et al., 1997) as 
well as oligodendrocytes (Wang et al., 2004).  
Later products of free fatty acid metabolism also increase within the injured spinal 
cord.  COX, also known as prostaglandin G/H synthase, is the rate-limiting step in the 
production of prostaglandins.  See insert of Fig. 2.  COX-2 mRNA and protein expression 
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are increased from 2 to 48 hr following SCI and the selective inhibition of COX-2 results 
in histological and functional sparing as assessed by the Basso, Beattie, and Bresnahan 
locomotion score (Resnick et al., 1998, Hoffmann, 2000, Schwab et al., 2000, Hains et 
al., 2001).  COX-1 has also been shown to increase following SCI, persisting for as long 
as 4 weeks (Schwab et al., 2000).  This upregulation in COX in the presence of free fatty 
acids, such as AA, logically progresses to an upregulation of eicosanoids.  Bioactive 
eicosanoids, derived from PLA2-induceds production of AA, have been implicated as 
mediators of secondary injury via a host of mechanisms.  The expression of eicosanoids, 
such as TXA2 and PGE2 increased in the injured cord tissue within hours of SCI and their 
vasoactive properties are thought to create microemboli in addition to PGE2’s well known 
pro-inflammatory effects (Tonai et al., 1999, Resnick et al., 2001).  Increased production 
of TXA2, PGI2, LTC4 and 5-HETE has also been confirmed in experimental SCI (Jacobs 
et al., 1987, Mitsuhashi et al., 1994).  PGF2α increases three fold following SCI, and 
when exogenously added caused significant cell loss, increased hydroxyl radicals, and 
malondialdehyde - an end product of membrane lipid peroxidation (Liu et al., 2001). 
The effect of lysophospholipids on spinal cord tissue has been extensively studied 
and lysophospholipids such as LPC and its later metabolites, such as PAF, are 
metabolically active in the CNS.  For over 30 years it was known that injections of LPC 
into the spinal cord causes demyelination (Blakemore et al., 1977, Blakemore, 1978, 
Blakemore, 1982, Toborek et al., 1999) as well as expression of a number of chemokines 
and cytokines, similar to those produced following SCI (Ousman and David, 2000, 
Ousman and David, 2001).  While lysophospholipid levels following SCI or traumatic 
brain injury (TBI) have not been assessed directly, their presence is strongly implied from 
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the generous production of free fatty acids and a decrease in phospholipids.  PAF, a 
metabolite of lysophospholipids, increases 20-fold after SCI induced by stroke 
(Lindsberg et al., 1990, Faden and Halt, 1992, Xiao et al., 1995, Xiao et al., 1996, 
Hostettler and Carlson, 2002).  Intrathecal administration of PAF leads to reduced spinal 
cord blood flow and motor deficits, an effect which can be blocked by the PAF receptor 
antagonist, WEB 2170 (Faden and Halt, 1992). Treatment with WEB 2170 after acute 
spinal cord contusion resulted in significant increases in white matter sparing as well as 
decreases in proinflammatory cytokine mRNA levels within the lesion epicenter 
(Hostettler and Carlson, 2002, Hostettler et al., 2002).  Treatment with the PAF receptor 
antagonist BN52021 also improves behavioral function after SCI (Xiao et al., 1998).  In 
vitro experiments showed that low concentrations of PAF resulted in neuronal 
differentiation and sprouting, while higher concentrations were neurotoxic (Kornecki and 
Ehrlich, 1988).  PAF-induced death of not only cultured neuronal cells in a concentration 
-dependent manner (Xu and Tao, 2004, Bate et al., 2007) but also that of 
oligodendrocytes and astrocytes (Hostettler et al., 2002).   
Oxidative stress is well established following SCI (Liu et al., 1999a, Liu et al., 
2001, Liu et al., 2003, Bao and Liu, 2004, Liu et al., 2004a).  Work by Liu et al., has 
shown that H2O2 (Liu et al., 1999a), iron (Liu et al., 2004a), and hydroxyl radicals  (Liu 
et al., 2004a) are formed following SCI.  Furthermore pathophysiological doses of these 
oxidants administered exogenously in vivo created significant cell death at 24 hr that 
could be blocked by a broad spectrum reactive species scavenger (Liu et al., 2004a).  
Administration of PGF2α resulted in a 3- fold increase in hydroxyl radicals and a 2-fold 
increase in malondialdehyde, an end product of membrane lipid peroxidation (Liu et al., 
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2001).  It has also been shown that H2O2 is toxic to neurons (Whittemore et al., 1994, 
Hoyt et al., 1997, Samanta et al., 1998, Lim et al., 2002, Fatokun et al., 2007), astrocytes 
(Rouach et al., 2004, de Almeida et al., 2007), and oligodendrocytes (Richter-Landsberg 
and Vollgraf, 1998, Vollgraf et al., 1999, Mronga et al., 2004).  Oxidative stressors, such 
as H2O2 administration, also increase AA release in neurons and mesangial cells 
(Samanta et al., 1998, Han et al., 2003).  It has recently been suggested that generation of 
ROS and polyunsaturated fatty acids, via cPLA2, following CNS injury mediates NF-κB 
migration from the cytosolic to the nucleus where it induces gene expression of sPLA2 
and other lipid enzymes, thus potentiates a positive feedback loop (Sun et al., 2007). 
High levels of EAAs such as glutamate and aspartate in experimental SCI are also 
an important mechanism inducing secondary injury (Park et al., 2004). Growing evidence 
indicates that sPLA2 could mediate EAA-induced neuronal death and tissue damage.  
Marked increases in PLA2 activity and AA release have been reported after treatments of 
neuronal cultures with glutamate, NMDA and KA) (Dumuis et al., 1988, Farooqui et al., 
2001).  In addition, glutamate release in the spinal cord can be suppressed by PLA2 
inhibitors such as indomethacin by 40%, AACOCF3 by 45%, and 4-bromophenacyl 
bromide by 36%, suggesting that increased PLA2-mediated EAA release is part of a 
positive feedback mechanism (Sundstrom and Mo, 2002).  Additionally, application of 
sPLA2 to the ischemic rat cerebral cortex resulted in a significant increase in EAA levels 
and a general PLA2 inhibitor mepacrine significantly decreased the ischemia evoked 
efflux of EAA into cortical superfusates (O'Regan et al., 1995a).  Thus, the excessive 
stimulation of NMDA receptors, as occurs in the spinal cord trauma, may result in 
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stimulation of sPLA2 activity leading to alterations in membrane composition, 
permeability, and fluidity leading to neuronal and glial cell death.  
In summary, sPLA2 can be induced by several key injury mediators such as 
inflammatory cytokines, free radicals, and EAAs that have been shown to increase 
following traumatic SCI.  Furthermore, this increase in sPLA2 activity can further 
increase inflammation, oxidation, and EAA release. This indicates that sPLA2 activation 
may play a central role in a positive feedback loop triggered by traumatic SCI resulting in 
neuronal and glial cell death, tissue damage, and corresponding behavioral impairments.  
If sPLA2 is present and increased following SCI then it may act as a convergence 
molecule that mediates multiple key mechanisms of secondary spinal cord injury and 




Similar to SCI, TBI also triggers secondary or delayed cell death by multiple 
injury processes including ischemia, inflammation, generation of free radicals, and 
glutamate release, all of which have been showed to induce PLA2 activity (Phillis and 
O'Regan, 2004, Mattson, 2005, Farooqui et al., 2006).  Like SCI, there is clear evidence 
that TBI induces PLA2 activity resulting in membrane phospholipid degradation, 
generation of proinflammatory mediators, such as eicosanoids and PAF, formation of free 
radicals, and subsequent lipid peroxidation.  Following closed head injury in rats, total 
PLA2 activity increased (Shohami et al., 1989).  Additionally, after open traumatic brain 
injury, free fatty acids, such as AA, were released and membrane phospholipid 
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degradation was found (Dhillon et al., 1994, Homayoun et al., 1997, Homayoun et al., 
2000).  In humans, an increase in free fatty acids in cerebrospinal fluid (CSF) following 
brain injury has been reported (Pilitsis et al., 2003).   
No report to date has investigated the expression of sPLA2 following traumatic 
brain injury either, however, cPLA2 and 4-hydroxynonenal were expressed in the 
transected brain (Lu et al., 2001).  Additional reports have confirmed the presence of 
down stream metabolites of AA.  Pronounced increases in prostaglandin F2α, 
prostaglandin D2, leukotrienes, and thromboxane B2 have all been reported to occur in 
brain tissues after KA injection (Baran et al., 1987) and increases in PGE2 following 
closed head injury (Shohami et al., 1989). 
Conditions that increase sPLA2 have been shown following TBI, just as in SCI.  
Cerebral penetration and contusive injury both increase oxidative stress in the brain 
(Layton et al., 1997, Kline et al., 2004) and blockade of oxidative stress increases 
learning and histological sparing (Kline et al., 2004).  Under both experimental and 
clinical settings, the level of extracellular EAAs such as glutamate and aspartate 
increased following TBI (Faden et al., 1989; Palmer et al., 1993; Globus et al., 1995; 
Bullock et al., 1998).  Additionally, both competitive and noncompetitive NMDA and 
non-NMDA receptor antagonists are efficacious in the treatment of experimental brain 
injury (Bullock and Fujisawa, 1992).  Several studies showed that glutamate, NMDA, 
and KA result in a dose-dependent increase in AA release in hippocampal neuronal 
cultures (Dumuis et al., 1988) and PLA2 activity in neuron enriched spinal cord cultures 
(Farooqui et al., 2001). In vivo intercerebroventricular injections of KA were shown to 
increase total PLA2 and sPLA2 activity in the rodent brain (Thwin et al., 2003).  Increased 
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levels of extracellular glutamate following TBI causes overstimulation of glutamate 
receptors that may result in secondary events such as sPLA2 release, degradation of 
membrane phospholipids, and accumulation of free fatty acids, leading to neuronal cell 
death as well as increased levels of eicosanoids and leukotrienes (McIntosh et al., 1998, 
Park et al., 2004).  As suggested above oxidative stress, EAA, and cytokines could induce 
sPLA2 release and abnormal phospholipid metabolism and may represent a common 
mechanism involved in traumatic spinal cord and brain injuries.   
 
Ischemia   
sPLA2 has been more thoroughly studies in ischemia.  Additionally, ischemia is a 
component of secondary injury after CNS trauma (Tator, 1991, Tator and Fehlings, 1991, 
Gennarelli, 1993).  Posttraumatic ischemia may result in energy failure that initiates a 
complex series of metabolic events, ultimately causing neuronal death. One such critical 
metabolic event is the activation of PLA2 which can result in hydrolysis of membrane 
phospholipids, release of free fatty acids, generation of oxygen free radicals, and 
formation of eicosanoids (Nakano et al., 1990, Phillis and O'Regan, 2004, Muralikrishna 
Adibhatla and Hatcher, 2006).  
In both experimental models of brain (Yoshida et al., 1983, Abe et al., 1988, 
Nakano et al., 1990, Narita et al., 2000) and spinal cord ischemia (Halat et al., 1987) 
significant increases in the level of free fatty acids, indirectly reflecting PLA2 activity, 
were found.  Significant increases in sPLA2 activities were also reported in vivo 
following brain ischemia (Lauritzen et al., 1994, Yagami et al., 2002b, Adibhatla et al., 
2006) and in astrocytes cultured under ischemic conditions such as oxygen and glucose 
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deprivation (Lin et al., 2004).  Biphasic increased expression of sPLA2-IIA is observed in 
ischemic rat forebrain (Lauritzen et al., 1994). An early increase in sPLA2-IIA mRNA 
occurred at 1-6 h post-ischemia and a late phase of greater induction of sPLA2-IIA 
appeared between 7 and 20 days post-ischemia. Recently, increased expression of sPLA2-
IIA has been confirmed at both mRNA and protein levels after brain ischemia (Lin et al., 
2004, Adibhatla et al., 2006). Cytokines such as TNF-α and IL-1β have been shown to 
mediate the ischemia induced PLA2 activation and sPLA2-IIA expression in transient 
focal rat cerebral ischemic model (Adibhatla et al., 2006, Adibhatla and Hatcher, 2007).  
Indoxam, a specific sPLA2 inhibitor, was shown to offer protection against the ischemia 
induced damage (Yagami et al., 2002b).  Quinacrine / mepacrine, a non-specific inhibitor 
of PLA2 activity, also showed sparing of hippocampal neurons (Phillis, 1996) and 
reduced infarct size following transient focal ischemia (Estevez and Phillis, 1997).  In 
vitro experiments showed that increased sPLA2 activity was associated with ischemia-
induced apoptosis (Yagami et al., 2002b).  Other studies have shown cPLA2 increases 
following ischemia (Owada et al., 1994, Bonventre et al., 1997, Saluja et al., 1997, 
Stephenson et al., 1999, Tabuchi et al., 2003) and other authors suggest that cPLA2 rather 
than sPLA2 mediates neuronal death in ischemia (Arai et al., 2001).  In summary, 
ischemia induces PLA2 activation which could result in deleterious effects such as the 
loss of membrane integrity through excessive phospholipids hydrolysis, formation of 
eicosanoids, cytotoxic products, ROS, and induction of apoptosis of affected cells 
(Sapirstein and Bonventre, 2000, Farooqui et al., 2006). 
 
Other Degenerative Diseases  
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Beyond neurotrauma, sPLA2 has been suggested as a mediator of 
neurodegenerative disorders such as Alzheimer’s disease (AD) (Moses et al., 2006), 
Multiple Sclerosis (Pinto et al., 2003, Marusic et al., 2005), and Parkinson’s disease 
(Tariq et al., 2001).  AD is characterized by an increased deposition of amyloid plaques 
infiltrated by reactive astrocytes and microglia. Aggregated forms of amyloid β (Aβ) 
peptides, particularly A β 1-42, have been shown to elicit cytotoxic effects resulting in 
neuron cell death (Sun et al., 2004).  There is evidence for alterations in phospholipid 
levels in patients with AD (Farooqui et al., 1997a).  In two separate studies, a decrease in 
PLA2 activity was found in the parietal and temporal cortices (Ross et al., 1998), as well 
as in the prefrontal cortex of the AD brain (Talbot et al., 2000).  Contrary to these studies, 
immunohistochemical experiments showed increases in both sPLA2–IIA (Moses et al., 
2006) and cPLA2 (Stephenson et al., 1996) in astrocytes of the AD brain.  A recent gene 
array study in AD patients indicated an increase in cPLA2 and COX-2 expression, as well 
as upregulation of a number of apoptotic and proinflammatory genes, but no mention was 
made of sPLA2 (Colangelo et al., 2002). These findings are in agreement with the 
increased oxidative and inflammatory responses and presence of reactive astrocytes 
associated with AD pathology (Butterfield et al., 2002).  In vitro studies demonstrated the 
ability of Aβ to enhance the activity of a number of phospholipases (Kanfer et al., 1998).  
Nicotine, a cholinergic agonist, inhibited an Aβ-induced increase in PLA2 activation 
(Singh et al., 1998).  The ability of PLA2 inhibitors to attenuate Aβ-induced ROS 
production could indicate the involvement of PLA2 in Aβ cytotoxicity (Andersen et al., 
2003).  For a more thorough review please see (Sun et al., 2004). 
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 Evidence also linked sPLA2 generation to white matter disorders and their 
experimental equivalents.  An early study by Huterer, et al., in the post mortem brains of 
Multiple Sclerosis patients found no difference in sPLA2-IIA activity and a decrease in 
cPLA2 activity within white matter lesions (Huterer et al., 1995).  However, more recent 
studies found that cPLA2α -/- mice were more resistant to experimental autoimmune 
encephalomyelitis a rodent model of Multiple Sclerosis.  Additionally, cPLA2α appeared 
to play a role in both the induction and effecter phases as well as increasing inflammation 
in the white matter lesions (Marusic et al., 2005).  Pinto, et al., found that extracellular 
inhibitors of sPLA2 were able to decrease CNS inflammation, prevent the induction of 
proinflammatory cytokines and ameliorate experimental autoimmune encephalomyelitis 
(Pinto et al., 2003).  Finally, in the brains of patients with Krabbe Disease, a 
demyelinating disease of the CNS, sPLA2 was increased in post mortem human samples, 
and in twitcher mice, its rodent equivalent.  Additionally, the use of a sPLA2 specific 
inhibitor reduced psychosine-induced oligodendrocyte death in vitro (Giri et al., 2006). 
 Studies using indirect markers for phospholipid metabolism have also suggested a 
role for sPLA2 in Parkinson’s disease, a degenerative disease of the CNS characterized by 
bradykinesia and death of dopaminergic neurons in the substantia nigra (Hayakawa et al., 
2001).  More importantly, Quinacrine, a nonselective PLA2 inhibitor, significantly 
reduced MPTP-induced dopamine loss in an experimental model of Parkinson’s disease 
(Tariq et al., 2001).  Mice deficient in cPLA2 were also shown to exhibit more resistance 
to MPTP neurotoxicity than wild-type mice, supporting a role for cPLA2 in mediating 
MPTP neurotoxicity (Klivenyi et al., 1998). 
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Conclusions and Direction of Study 
sPLA2 is a family of molecules that are closely associated with inflammation.  
Secondly, the inflammatory response is thought to exacerbate the damage associated with 
secondary SCI.  Third, inhibition of sPLA2 in conditions such as arthritis and ischemic 
bowel disease lessens the inflammation and resulting pathology associated with these 
disorders.  Current evidence shows that sPLA2 is present in the naive CNS, but it is 
unknown whether neurotrauma increases its expression.  Finally, while the products of 
sPLA2 metabolism, such as lysophospholipids and AA, are neurotoxic to the CNS and 
present following SCI and other neuropathologies, it has not been determined whether 
sPLA2’s presence directly contributes to the inflammatory state following SCI and if so 
whether blockade of sPLA2 can create histological and functional improvements.   
 The focus of this research was to determine if SCI upregulate sPLA2 and whether 
other CNS insults, such as H2O2 or TNFα and IL-1β, can upregulate sPLA2 in cultured 
oligodendrocytes.  Secondly, we sought to determine whether an artificial increase in 
sPLA2, by exogenous addition of sPLA2, could damage the CNS or cultured cells.  
Finally, we assessed whether sPLA2 inhibition could produce histological and functional 







EXPRESSION OF sPLA2 FOLLOWING SPINAL CORD INJURY 
 
INTRODUCTION 
Our lab previously showed that total PLA2 enzymatic activity in spinal cord 
homogenates increases after injury, peaking at 4 hr post injury.  In the same study we 
showed that cPLA2-IVα (cPLA2α) protein expression, while increased following SCI, 
did not peaked until 7 days post injury (Liu et al., 2006).  This discrepancy led us to 
believe that other PLA2 isozymes constituted the majority of total phospholipase activity 
observed following SCI.  This lead us to investigate the expression profile of the largest 
group of PLA2s, namely sPLA2, following SCI. 
There are three rationales for investigating sPLA2’s role in SCI-induced 
oligodendrocyte death.  First, although sPLA2 is found in both neurons and 
oligodendrocytes its role in neuron death is well documented in association with cerebral 
ischemia (Yagami et al., 2002b, Yagami et al., 2005) while sPLA2’s role in 
oligodendrocytes has been effectively ignored.  Secondly, when sPLA2 was injected into 
the border zone between the grey and white matter of the ventral horn, we noticed 
substantially more inflammation within the white matter (Supp. Fig 1).  This suggested 
that sPLA2 may have a more deleterious effect on white matter.  Third, many mediators 
of secondary SCI are both activators of sPLA2 and cytotoxic to oligodendrocytes.  For 
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example, hydrogen peroxide injury triggers phospholipid metabolism and AA release in 
various cell types (Meyer et al., 1996, Tournier et al., 1997, Cane et al., 1998) and H2O2 
induced AA release is mediated, at least in part, by sPLA2-IIA (Han et al., 2003).  
Likewise, IL-1β and TNFα trigger AA release from cultured cells via a sPLA2-IIA and 
cPLA2-IVα dependent mechanism (Mounier et al., 2004, Kuwata et al., 2005).  Finally 
H2O2 (Richter-Landsberg and Vollgraf, 1998, Mronga et al., 2004), IL-1β (Takahashi et 
al., 2003), TNFα (Selmaj and Raine, 1988, Lee et al., 2000, Buntinx et al., 2004), and 
AA (Wang et al., 2004) have all been shown to damage cultured oligodendrocytes.   
Until now, the expression of sPLA2 isoforms after SCI and their possible role in 
oligodendrocyte death has not been directly studied. Here we provide cellular and 
molecular evidence that sPLA2-IIA and IIE are the two major sPLA2 isoforms that 
increase expression hours following SCI and that both isoforms are present within 
oligodendrocytes.  Moreover, administration of sPLA2-IIA in vitro can induce 
oligodendrocyte cell death.  Finally, blockade of sPLA2 can partially ameliorate culture 
oligodendrocyte cell death induced by either H2O2 or IL-1β and TNFα injury.  Thus, 
sPLA2-IIA may serve as a mediator of oligodendrocyte death and a target for therapeutic 
intervention against injury-induced oligodendrocyte cell death following SCI.   
 
MATERIALS AND METHODS 
Animals 
A total of 82, adult female Sprague–Dawley rats (Harlan, Indianapolis, IN), 
weighing 200 to 220 gm, were used in this study (Table 1). All surgical interventions and 
postoperative animal care were performed in accordance with the Guide for the Care and 
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Use of Laboratory Animals (National Research Council, National Academy Press, 
Washington, D.C., 1996) and the Guidelines of the University of Louisville Institutional 
Animal Care and Use Committee.   
 
Table 1. Animal Usage and Experimental Groups 
 Sham 15 min 1 hr 4 hr 1 day 1 week 
Contusion - + + + + + 
mRNA n=3 n=3 n=3 n=3 n=3 n=3 
Protein n=4 n=4 - n=4 n=4 n=4 
Subcellular Protein n=4 - - n=4 - - 
Histology n=5 n=5 - n=5 n=5 n=5 
 
 
Spinal Cord Injury 
Rats received either a 200 kDyn injury (measured force = 210±7 kDyn, CV = 
3.28%) between the 4th and 5th cervical vertebra level (C4-5), inflicted via an Infinite 
Horizons (IH) impactor (Scheff et al., 2003), or sham laminectomy according to a 
previously published work (Iannotti et al., 2004). Briefly, rats were anesthetized with 
Nembutal (50 mg/kg, i.p., Abbott Laboratories, Chicago, IL) and a dorsal laminectomy 
was performed at the C4-5 level to expose the spinal cord. The exposed vertebral column 
was stabilized using a rat stabilizer developed at the University of Louisville. After the 
injury, displacements were recorded and compared to insure lesion uniformity (1086±93 
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μm; CV = 8.56%).  Post-operative care followed those described previously (Iannotti et 
al., 2004). 
 
RNA Extraction and RT-PCR 
A 1.5 cm long spinal cord segment containing the injury epicenter or equivalent 
was removed 4 hr post injury, frozen in liquid nitrogen, and later homogenized in STAT-
60 solution (TelTest, Friendswood, TX). This kit was subsequently used according to the 
manufacturer’s instructions to purify RNA, which was quantified by spectrophotometric 
analysis of absorbance at 260 nm. Primers used for end point RT-PCR are listed in Table 
2. 
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Table 2. End point RT-PCR primers. 
Gene Accession No. Primer sequence 5’-3’ Product (bp) Reference 
PLA2-IB NM_031585 232–251: ACA ATC AGG CCA AGA AGC TG 250 (Kolko, 2004) 
  462–481: ACG GCA TAG ACA GGA AGT GG   
PLA2-IIA NM_031598 687-707: TTGCCATTGTGGTGTGGGTGG 300 (Molloy, 1998) 
  965-986: CAACTGGGCGTCTTCCCTTTGC   
PLA2-IIC NM_019202 1-20: CCTCCACCTCTCAAATGCTG 250 (Molloy, 1998) 
  231-250: CATTGCTGTTCCAGCCTTTT   
PLA2-IID NM_001013428 1–20: CTGCCTTGCTCTGTGCTGGA 254  
  234-253: CCATCGATCTTCAGGTGGGC   
PLA2-IIE XM_238421 401-419: GTGGGAACCTGGTCCAGTT 285 (Kolko, 2004) 
  667-687: GGCAGCTCTCTTGTCACACTC   
PLA2-IIF XM_233589 1-20: ATGAAGGAGGTTGAGTTTGC 262  
  242-261: TGGAATATCACAGAGCTGGA   
PLA2-III XM_223553 12-36: TATACTTGAGTATAAGACCTCGTGT 251  
  243-262: TCAGAAGAATTGAGCAGGAC   
PLA2-V NM_017174 380-401: CCCTAAGGATGGCACTGATTGG 172 (Molloy, 1998) 
  530-551: CCCTAAGGATGGCACTGATTGG   
PLA2-X NM_017176 461–481: TCC CCT CGG TTT TAT GTG AG 200 (Kolko, 2004) 
  640–660: GCT CCA CAG GCT CAT AGT CC   
PLA2-XIIa XM_342340 144-163: CCAGGAACAGGACCAGACCA 250  
  373-393: CTTGGTCAGGGAAGGGATGC   
 
Primers for sPLA2-IID, IIF, and XIIA were designed using Primer Express 2.0 
(Applied Biosystems, Foster City, CA).  Each primer set was validitated in mRNA 
extracted from the liver, lung, kidney, and spleen.  This led to a band in the correct 
weight for at least one of sources for each primer set tested. Total RNA (0.5 µg) was used 
in a 20 µl mixture containing 4 µl of 5x reaction buffer, 0.2 mM dNTP, 1 µM of up and 
down stream primer, 1 mM MgSO4, 0.1 u/µl AMV Reverse Transcriptase, 0.1 u/µl Tfl 
DNA Polymerase.  The reverse transcription was conducted on an Eppendorf Master 
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Cycler (Westbury, NY) with a 45 min first strand cDNA synthesis (45 °C), 2 min 
denaturation (94 °C), followed by 35 cycles of synthesis and amplification consisting of 
30 seconds (94 °C), 1 minute (60 °C), and 2 minutes (72 °C) (Access RT-PCR system, 
Promega, Madison, WI). Amplified samples were separated on a 1% agarose gel 
containing ethidium bromide in 1x TBE buffer. After electrophoresis, gels were imaged 
using an Image Station 4000R (Kodak, Rochester, NY).  Finally, each image was 
quantified using Image J software (NIH, Bethesda MD). 
 
Real-Time Quantitative PCR 
Total RNA was extracted from spinal cords, as described above, 4 hr after sham 
operation or 15 min, 1 hr, 4 hr, 1 day, or 1 week after SCI.  Primers and taqman probes 
for sPLA2-IB and IIA were designed using Primer Express 2.0 (Applied Biosystems, 
Foster City, CA) and are as follows: IB sense 5’- AACTACGGCTGCTACTGTGG-3’, 
IB antisense 5’-AGCAGTGGTCATGAGTCTGG-3’, IB probe 5’-
CGGCTCAGGCACCCCAGTGGAC-3’, IIA sense 5’-
CCAAATCTCCTGCTCTACAAACC-3’, IIA antisense 5’-
CTTTTCTTGTTCCGGGCAAAAC-3’, and IIA probe 5’- 
CGGCAGCTTTATCGCACTGGCACA-3’.  PCR products were detected by measuring 
the increase in fluorescence on a MX3000P (Stratagene, La Jolla, CA). The sequence-
detector software calculated the threshold cycle number (Ct) when signals reached ten-
fold the standard deviation of the baseline.  Primer pairs were chosen to minimize primer 
dimerization and secondary structure; and to generate an amplicon of 96 bp. After PCR, 
reaction products were electrophoresed on a 1% agarose gel containing ethidium bromide 
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in 1x TBE buffer and then visualized. This step was included to ensure that the only PCR 
product was at the desired amplicon size. To correct for possible volume differences, 
transparency of the caps, or other well-to-well differences, the passive reference dye 5(6)-
carboxy-X-rhodamine-C5-maleimide (also known as ROX; Stratagene) was used in all 
reactions. Relative expression of the PCR products was determined by using the ΔΔCt 
method (Gibson et al., 1996; Winer et al., 1999). This method calculates relative 
expression with the equation: -Fold induction = 2[ΔΔCt], where Ct = the threshold cycle, 
i.e., the cycle number at which the sample’s relative fluorescence rises above the 
background fluorescence; and ΔΔCt = [Ct gene of interest (unknown sample) – Ct β actin 
(housekeeping gene)]. Each sample was run in duplicate, and the mean Ct was used in the 
ΔΔCt equation. After a 3 min denaturation step, the PCRs were subjected to 40 cycles of 
30 sec annealing and 30 sec extension at 72 °C. 
 
Western Blotting 
Western blotting followed a previously described procedure (Liu et al., 2004b). In 
brief, whole cell lyses proteins were extracted from a 1.5 cm long spinal cord segment 
containing the injury epicenter 4 hr after sham laminectomy or 15 min, 4 hr, 1 day or 1 
week after SCI.  Additionally, subcellular protein isolation was performed on either sham 
animals or 4 hr after injury using the Focus SubCell kit (G-Biosciences, St. Louis, MO) 
according to manufacturer’s protocol.  In brief, 100 mg of fresh tissue was homogenized 
and centrifuge at 700 x g for 5 minutes to pelletize nuclei.  Supernatant was removed and 
centrifuged at 12,000 x g for 10 min to pelletize mitochondria.  Supernatant was again 
removed and centrifuged at 14,000 x g for 60min to separate the enriched cytosolic 
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membrane fraction from the soluble cytosol fraction. The protein content of all samples 
was assessed by the Bradford method (Bio-Rad Protein Assay, Hercules, CA) and 
normalized prior to adding sample buffer. 
Similar amounts of protein (40 µg) was electrophoresed on a 12% sodium 
dodecyl sulfate-polyacrylamide gel, transferred onto a polyvinylidene diflouride 
membrane, and immunoblotted with primary rabbit monoclonal anti-sPLA2-I antibody 
(1:100; “Anti-PLA2, low molecular weight” Millipore, Billerica, MA), polyclonal anti–
sPLA2-IIA antibody (1:1000; Cayman Chemical, Ann Arbor, MI), polyclonal anti-
sPLA2-IIE antibody (1:1000; Biovendor, Candler, NC), or goat polyclonal anti-sPLA2-X 
antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) and a secondary 
horseradish peroxidase–conjugated donkey anti–rabbit or anti-goat IgG antibody 
(1:10,000; Amersham Pharmacia Biotech, Piscataway, NJ). The blot was visualized using 
the ECL Plus Detection Kit (Amersham Pharmacia Biotech). Whole cell lysis membranes 
were stripped and reblotted with β-tubulin, to confirm consistent well loading (Liu and 
Xu, 2006).  Subcellular fraction membranes were stripped and reblotted with β-tubulin, 
caveolin, or histone 1 for the cytosol, membrane, and nuclear fractions.  The primary 
antibody was omitted for negative controls. Protein extracted from the rat spleen was 
used as a positive control for the expression of sPLA2-IIA.  Densitometry allowed for 
relative comparison of signal strength by Image J software.  When a doublet appeared at 




Spinal cords were removed 4 hrs after sham operation or 15 min, 1 hr, or 4 hr 
after SCI.  After perfusion with PBS and 4% paraformaldehyde, a 2 cm-long spinal cord 
segment containing the injury epicenter of each rat was removed, cryoprotected in 30% 
sucrose buffer, sectioned transversely at 40 µm on a cryostat, and mounted on 
Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA) in eight identical sets. Three 
sections were taken from each of five sample sites within the tissue, every 0.5cm, and 
were incubated with either rabbit monoclonal anti-sPLA2-IB (1:200, Chemicon) or rabbit 
polyclonal anti-sPLA2-IIA (1:300, Cayman Chemical) overnight at 4°C. On the second 
day, the sections were incubated with secondary biotinylated IgG antibody (1:400; Vector 
Laboratories, Burlingame, CA) for 1 hr at room temperature. The reaction product was 
shown by incubation for 5 minutes with 0.02% diaminobenzidine tetrahydrochloride 
(DAB) and 0.003% H2O2 in 0.05M Tris-HCl (pH 7.6). Slides were examined using an 
Olympus BX60 light microscope (Olympus America, Inc., Mellville, NY). To further 
confirm the specificity of the immunohistochemical labeling, negative controls of pooled 
antibodies from healthy adult animals (Vector Laboratories) in serum blocking solution 
were used simultaneously. 
 Using standard light and aperture settings, images were captured with MicroFire 
Digital Camera (Optronics, Goleta, California) at 2 x and staining intensities were 
determined using Image J software (NIH) by first inverting the image and then measuring 
the mean intensity.  The intensity of the negative control animal was subtracted from the 





Immunofluorescence double labeling at the injury epicenter was performed on 
different tissue sets using previously described methods (Liu et al., 2004b). In brief, a 
mixture of rabbit monoclonal anti-sPLA2-IB (1:100; Chemicon), polyclonal anti-sPLA2-
IIA (1:100; Cayman Chemical), or  polyclonal anti-sPLA2-IIE antibody (1:50; Biovendor, 
Candler, NC), and mouse anti-CC1 (1;100; Chemicon), anti–glial fibrillary acidic protein 
(1:300; Sigma), and anti-O4 (1:1; hybridoma), anti-NeuN (1:100; Chemicon, Temecula, 
CA), and anti-SMI-31 (1:2,000; Sigma, St. Louis, MO) antibodies were used to examine 
colocalization of sPLA2 in neurons, axons, oligodendrocytes, or astrocytes in vivo or 
mature oligodendrocytes in vitro respectively. The paired antibody solutions were applied 
to the sections overnight at 4°C. The following day, sections were incubated with 
fluorescein-conjugated goat anti–mouse (1:100; Jackson Immunoresearch, West Grove, 
PA) and Texas red-conjugated goat anti–rabbit (1:100; Jackson Immunoresearch) 
antibodies. Negative controls of pooled antibodies from healthy adult animals (Vector 
Laboratories) and normal serum controls were used to further confirm the specificity of 
the immunofluorescence double labeling. Images were taken using a Nikon Eclipse 90i 
confocal microscopy (Nikon Instruments; Melville, NY). 
 sPLA2-IIA signal within oligodendrocytes was quantified using Stereo 
Investigator software (Microbrightfield,Williston, VT) on an Olympus BX60 microscope 
(Center Valley, PA) under 100x oil immersion.  Under standard exposure times contour 
tracing was begun around the cells of interest while viewed through an FITC filter.  After 
switching to Texas Red filter, luminescence data was acquired for the cell of interest by 
closing the contour.  Twenty oligodendrocytes were chosen from each of three different 
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tissue sections, by systematic random sampling from the ventral funiculus of the lesion 
epicenter.  The averaged intensities were averaged to create mean florescent intensity for 
oligodendrocytes in each animal (n=5, per group).  Background intensity was gathered in 
a similar manner from primary antibody omission control section and subtracted from the 
mean intensity for that given animal.  This was done to control for non-specific binding 
of secondary antibody following contusion. 
 
Oligodendroglia Culture 
Adult oligodendrocyte precursor cells (aOPCs) were immunopanned with an anti-
O4 antibody from the adult spinal cord of rats (Kisseberth et al., 1999), using a protocol 
modified from (Cao et al., 2002).  Briefly, the dissected spinal cords were minced into 1 
mm3 pieces and incubated in HBSS containing 0.1% papain, 0.1% neutral protease, and 
0.01% DNase for 30 min at 37°C.  The digestion was stopped by the addition of an equal 
volume of DMEM containing 10% fetal bovine serum. Tissues were dissociated by 
repeated trituration with fire-polished Pasteur pipettes and were filtered through a 70 μm 
nylon mesh. The cells were then incubated on an anti-RAN-2 antibody (ATCC, 
Rockville, MA) coated dish for 30 min to deplete type-1 astrocytes and meningeal cells 
and then transferred to an anti-O4 antibody-coated dish for 45 min to select for adult 
OPCs.  
The purified adult OPCs on the dish were removed with 0.05% trypsin and 
cultured in DMEM/F12 medium containing N2 and B27 supplements, FGF2 (20 ng/ml), 
PDGF-aa (10 ng/ml), Insulin (5 μg/ml) and BSA (0.1%). An aliquot of cells was 
analyzed the next day to determine the efficiency of the immunopanning. Only those cell 
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preparations in which >95% of the bound cells expressed A2B5 were used in the 
experiments. The results were confirmed by FACS analysis. 
The cells were seeded onto either PDL / laminin coated culture dishes for survival 
experiments and western blot analysis, or chamber slides for immunocytochemistry. Two 
days after seeding or once cells reached 70-80% confluence, the FGF-2 and PDGF-aa 
were removed, and CNTF (0.001 µg / ml) was added to the OPC medium to induce 
differentiation. A2B5+ OPCs were induced to differentiate in vitro for 4 days and were 
either challenged to induce injury, lysed for western blot, or fixed for 
immunocytochemical analysis. 
Mature oligodendrocyte cultures were injured with recombinant human sPLA2-IIA 
(Biovendor, Candler, NC) and assayed at 48 hr for cytotoxicity by lactate dehydrogenase 
(LDH) present in the medium (CytoTox96 non-radioactive assay; Promega, Madison, 
WI) or reduction of (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide by 
the mitochondria of surviving cells (MTT, CellTiter 96 Cell Proliferation Assay; 
Promega, Madison, WI).   
A second set of cultures were pretreated with vehicle, or 0.25, 1.25, 6.25 µM of 
S3319, a sPLA2-IIA inhibitor diluted in 1% DMSO (Sigma Aldrich, St. Louise, MO) or 
50 µM of 4-aminophenyl α-D-mannopyranoside, non-catalytic sPLA2 receptor ligand 
(APMP, Sigma Aldrich, St. Louise, MO).  Then cells were challenged with vehicle, 
1mM, 5 mM, or 10mM H2O2, with or without sPLA2-IIA inhibitor for 30min, washed 
once with fresh medium, and the vehicle or S3319 was replaced.  Again cytotoxicity was 
evaluated by measuring LDH released in the media 48 hr after H2O2 exposure.  
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A third set of cultures were pretreated as above with S3319 but were challenged with 
the cytokines IL-1β (PeproTech Inc., Rocky Hill, NJ) and TNFα (PeproTech) at low (1 
and 2 ng respectively) or high dose (5 and 10 ng).  Again cytotoxicity was evaluated by 
measuring LDH released in the media.  Data were normalized to the amount of LDH 
released from similarly-treated cells receiving a lysis buffer and are corrected for baseline 
LDH release from blank wells. This procedure was necessary to ensure that the reported 
effects are not attributable to the various vehicles used or cell death due to pretreatment 
with S3319.  All cell culture experiments consisted of at least 4 separate wells.  All 
experiments were repeated in triplicate on separate days.  The results presented are the 
averaged of the three separate experiments.  The area of process extensions was 
calculated using three separate images take from the center of each well.  Images were 
converted to a binary by setting a common constant threshold and then the area was 
determined by Image J software.   
 
Statistical Analysis 
A Student’s t-test, two tailed, was used to compare RT-PCR results utilizing 
Levene's Test for Equality of Variances.  One-way analysis of variance (ANOVA) with 
post hoc Tukey HSD was used to determine statistical significance of three or more 
groups. A multiple analysis of variance (MANOVA) with post hoc Tukey's HSD was 
used to determine statistical significance of three or more groups when repeated measures 
were taken from each animal overtime or space.  A p value less than 0.05 was considered 
statistically significant.  Two extreme outliers were excluded from the Q-PCR data using 




sPLA2 mRNAs are differentially expressed following SCI. 
End point RT-PCR was used to scan for the expression of all the sequenced 
mammalian sPLA2 isoforms in either sham or contused animals 4 hr following surgery (n 
= 3).  Primer sets were designed for sPLA2-IB, IIA, IIC, IID, IIE, IIF, V, X, and XIIA.  
Seven of the nine mammalian sPLA2 were detected in naïve and contused animals with 
mRNA present for sPLA2-IB, IIA, IIC, IIE, V, X, and XIIA (Fig. 5).  Pictured are three 








Figure 5. Changes in secretory PLA2 mRNA following SCI. 
A) Gels shown are representative samples of mRNA levels from either 3 sham-operated 
rats (lanes 2-4) or 3 rats sacrificed at 4 hr post-SCI (lanes 5-7).  Lane 1 is a 100 bp ladder.  
Total RNA samples were reverse transcribed for all the mammalian sPLA2 isoforms.  
Statistical increases were seen in sPLA2-IIA and IIE with a decrease seen in sPLA2-X.  
No change was observed in sPLA2-IB, IIC, V, and XIIA.  B) Relative fold increase of 
sPLA2-IIA mRNA expression after real time Q-PCR at 15 min, 1 hr, 4 hr, 1 day, or 1 wk 
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Among all sPLA2 isoforms examined, sPLA2-IIA showed the most dramatic 
change after SCI.  sPLA2-IIA mRNA produced only a slight signal in the sham operated 
cord but increased (t(4) =6.44, p = .003) following contusion (Fig. 5A).  Similarly, 
sPLA2-IIE, while almost absent in the naïve cord, showed an increase in the injured cord 
(t(2.42) = 3.93, p = .043).  In contrast, PLA2-X showed a significant decrease in signal 
intensity (t(2.53) = 5.980, p = .015) (Fig. 5A). sPLA2-IB, IIC, V and XIIA were present 
in both the sham and contused cord in similar intensity following RT-PCR. Thus, we 
demonstrated, for the first time, that sPLA2 isoforms are differentially expressed 
following a contusive SCI. 
Next, real-time Q-PCR was used to quantify the qualitative increases seen after 
RT-PCR and determine the time course of sPLA2 expression following SCI.  Two sPLA2 
isoforms, IIA and IB, were  chosen for this study because of their significant association 
with inflammation or highest expression in the CNS, respectively (Kolko et al., 2004).  
Both subgroups were quantified as a fold increase from naïve animals (Fig. 5B).  In 
agreement with the RT-PCR results, sPLA2-IIA mRNA expression had a significant 4-
fold increase at 1hr following contusion compared to the sham operated animal 
(ANOVA, F6, 30 = 2.885, p = 0.02).  Similar to the end point PCR, sPLA2-IB showed no 
change at 4 hr but by one day a statistically significant 2.54 fold decrease was observed 
that persisted through one week (ANOVA, F6, 11 = 3.649, p = 0.04) (data not shown).  
This data suggests that isoforms of sPLA2 are differentially regulated following traumatic 




sPLA2 proteins are differentially expressed following SCI. 
To confirm that changes in mRNA in fact reflect changes in protein production, 
spinal cord homogenates were immunoblotted with antibodies to sPLA2-IB, IIA, IIE, or 
X. While a general increase in the mean expression of sPLA2-IB was seen, this was not 
statistically significant further confirming the PCR results (Fig. 6A & B; ANOVA, F4,15 = 
0.8335, p = 0.52).  In contrast, sPLA2-IIA showed a 3-fold increase in protein expression 
at 4 hr compared to sham controls (Fig. 2A & C, ANOVA, F4,15 = 4.860, p < 0.01).  
Significantly increased sPLA2-IIA expression was also found at both 4 hr and 1day post 
injury (Fig. 6C).  An equal amount of splenic protein was run as a positive control for 
sPLA2-IIA and showed a band about 3.6 times greater than the strongest spinal cord 
band, confirming the lower abundance in the spinal cord as compared to the spleen (Fig. 
6A).  Not surprisingly, sPLA2-IIE showed similar results to IIA with a significant 2.5 
fold-increase that peaked at 4 hr after SCI and returned to the baseline by 1 day (Fig. 6A 
& D, ANOVA, F4,15 = 5.025 , p < 0.01).  Finally,  while sPLA2-X mRNA decreased 
following SCI there was little change in the protein levels compared to the sham controls 
(Fig. 6A & E, ANOVA, F4,15 = 0.2554, p = 0.90).  These results confirm that both sPLA2-
IIA and IIE proteins are significantly increased following SCI.  Interestingly, the peak 
expression of the two sPLA2 isoforms coincides well with the peak activation of total 
PLA2, as we demonstrated previously (Liu et al., 2006). Thus, sPLA2-IIA and IIE may 








Figure 6. Temporal changes in sPLA2 protein expression following SCI. 
A) Representative western blots of whole cell lysates from sham or contused animals at 
15 min, 4 hr, 1 day, or 1 wk post injury.  The top panel in A shows a representative time 
course of sPLA2-IB (16 & 14 kDa) protein expression showing no changes following 
SCI.  SCI induced a significant increase in sPLA2-IIA (15 kDa) and IIE (18 kDa) 
expression beginning at 4 hr and continuing through 1 day post injury, but returning to 
baseline by 1 week.  Group X (13 kDa) showed no change in expression.  B - E) 
Quantification of western blots in A from four separate animals per group (n = 4/group, 
mean ± SD). β-tubulin (50 kDa) was used to confirm even sample loading in all blots. 




A Sh 15m 4h Id Iw 
lEI - 16kD - 14kD 
IIAI -1 5kD 
li E I :: := ~ :I • • _ 18kD 
xl I "11 ' .. • -1 3kD 
J3-tubulin 
I 
• - 50lO 
B C 
I , • 0 • • • • 
~ ~ 
• • 1. 1. « 
~ " • • • • ,.. 
D E 
, , 
• • 0 0 • • • • ~ ~ 
w • 1. , 
~ ~ • ~ • , w. 
 77
 
Spatiotemporal distribution of sPLA2 isozymes following SCI 
Since sPLA2 mRNA and proteins were differentially expressed post SCI, we next 
determined their temporal and spatial distribution using immunohistochemistry.  In this 
study, sPLA2-IB, IIA, IIE, and X were examined at 5 mm intervals from the injury 
epicenter.   
We chose to focus on white matter because we previously showed that bilateral 
injections of sPLA2-III (0.1 μg) into the ventral grey matter / white matter interface of rat 
spinal cords resulted in a massive destruction of white matter with a relative sparing of 
grey matter at 4 weeks (Sup. 1)(Liu et al., 2006).  sPLA2-IB showed strong expression in 
white matter (Fig. 7A & E) both before and after injury.    Quantification of labeling 
intensity using Image J showed no change in sPLA2-IB signaling either among different 
time points post SCI or distance from the epicenter (MANOVA F3, 263.806 = 4.367, p > 
0.05, Fig. 7I).  
 In contrast, sPLA2-IIA (Fig. 7, 2nd column) and IIE (Fig. 7, 3rd column) each 
showed a weak baseline staining in the white matter of sham controls. However, 
following SCI, sPLA2-IIA and IIE immunoreactivity increased markedly (Fig. 7F & G).  
Within the white matter, a strong increase in sPLA2-IIA and IIE staining in glial cells and 
axons, particularly swollen axons, was seen (Fig. 3F, arrows).  Quantification data 
showed a significant increase in sPLA2-IIA immunoreactivity at the injury epicenter in all 
SCI groups over sham controls (MANOVA F18.3, 15.575  = 46.437, p < 0.001, Fig. 7J).  
Finally, sPLA2-X showed little immunoreactivity either in sham or SCI animals (Fig. 7, 
4th column).   
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 Thus, the present study showed that IIA and IIE, but not IB and X, are the major 
sPLA2 isoforms that markedly increased following SCI and their expression was induced 
mainly at the site of injury. It should be noted that IIA and IIE are structurally and 









Figure 7. Immunohistochemical Changes in sPLA2-IB, IIA, IIE, and X Expression 
Following SCI. 
A - H) Changes in the ventral white matter in sham (A - D) or 4 hr post contusion (E - H).  
Little change in sPLA2-IB staining was seen (A & E).  In contrast, SCI induced a 
significant increase in sPLA2-IIA (B & F) and IIE (C & G) IR within the white matter. 
Both IIA and IIE showed staining of axons and glia.  However, there was little or no 
staining of sPLA2-X (D & H).  I & J) Quantification of IB and IIA staining intensity is 
shown at the epicenter and at 5 mm increments, both rostral and caudal to it.  Increases 
above sham controls were only seen in sPLA2-IIA and were only present at the injury 
epicenter of sPLA2-IIA.  Bar: A-H, 500 μm. I-J; n = 5 per group, mean ± SD; * p < 0.05; 
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Cellular localization of sPLA2 isozymes following SCI 
To better understand what cell types express sPLA2 isoforms, immunofluorescent 
double labeling of sPLA2–IB, IIA, IIE, or X and cell specific markers was performed. As 
was suggested by the immunohistochemistry, we found that oligodendrocytes (CC1/APC; 
Fig. 8) co-localized with sPLA2-IB (Fig. 8B & C), sPLA2-IIA (Fig. 8E & F), and sPLA2-
IIE (Fig. 8H & I).  However, sPLA2-X did not appear to co-localize with 
oligodendrocytes (Fig. 8J–L).  The sPLA2-X staining appeared to reside only in the 
extracellular space. This morphology is not surprising since sPLA2-X has the greatest 
secreted fraction and the lowest cytosolic fraction of any sPLA2 (Murakami et al., 2002b).  
Additionally, previous work with stably transfected cell lines yielded similar sPLA2-X 









Figure 8. Co-localization of sPLA2 Isoforms in Oligodendrocytes at 4 hr Post-SCI. 
Confocal images of immunofluorescent double labeling indicates that sPLA2-IB (A-C), 
IIA (D-F), IIE (G-I), but not X (J-L) are present within oligodendrocytes (CC1/APC) 4 hr 
following contusion.  All images are orthogonal views of confocal image stacks with the 
point of interest indicated by the green cross hairs in the merged image.  Within each 
frame the X/Y plane is represented by the square picture, the Y/Z plane is represented to 
the right, and the X/Z plane is represented along the bottom of the X/Y frame.  Scale 
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Within the white matter, astrocytes (GFAP; Sup. 2) co-localized with sPLA2-IB 
(Sup. 2B & C) and weakly with sPLA2-IIA (Sup. 2E & F) but showed no co-localization 
with sPLA2-IIE (Sup. 2H & I).  Similar to staining seen in oligodendrocytes sPLA2-X 
again did not appear to co-localize with any astrocytes (Sup. 2J–L).  Neurons within the 
ventral grey matter (NeuN; Sup. 3), showed similar staining to oligodendrocytes with the 
presence of sPLA2-IB (Sup. 3B & C), sPLA2-IIA (Sup. 3E & F), and sPLA2-IIE (Sup. 3H 
& I), but not sPLA2-X (Sup. 3K & L).  Almost all axons (SMI-31; Sup. 4) within the 
ventral white matter showed co-localization with sPLA2-IB (Sup. 4B & C) and sPLA2-
IIA (Sup. 4E & F).  sPLA2-IIE staining was weak and confined mainly in axons that 
appeared to be swollen (Sup. 4H & I, arrows) and no axons appeared to co-localize with 
sPLA2-X (Sup. 4K & L). 
To further confirm that sPLA2-IIA was not merely present in oligodendrocytes 
but increases following contusion, we compared sPLA2-IIA labeling intensities within 
oligodendrocytes at the injury epicenter 4 hr after either sham surgery (Fig. 9A-C) or SCI 
(Fig. 9D-F).  A significant increase in sPLA2-IIA expression was found within 
oligodendrocytes (t(5.947) = -3.517, p = 0.01, Fig. 9G).  Increased expression of sPLA2s, 
particularly IIA, opens a new possibility that it may play a role in the death of 
oligodendrocytes following SCI. 
 
sPLA2-IIA increases in membrane fraction following SCI.  
To determine whether sPLA2, particularly IIA, play a role in increased 
phospholipid hydrolysis, we determined the co-localization of sPLA2 with its 
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phospholipid substrate, which is most abundant in the membrane fraction of cells. 
Subcellular fractions of sham and contused spinal cords were immunoblotted for sPLA2-
IIA expression.  Four hours following contusion, sPLA2-IIA increased about 4-fold 
within the cytosolic membrane fraction (Fig. 9H). While the non-membrane fraction of 
the cytosol did show a strong band for sPLA2-IIA there was little increase following 
contusion.  Additionally, the nuclear fraction showed no sPLA2-IIA expression.  These 
results suggest that the increase in sPLA2-IIA protein expression observed in the whole 
cell lysates after SCI is within the membrane fraction which is rich in phospholipid 








Figure 9. sPLA2-IIA Expression Increases in Oligodendrocytes Following SCI and 
Increases Within the Membrane Fraction. 
A-C) In a sham-operated rat, sPLA2-IIA was localized in a CC1-positive oligodendrocyte 
at a baseline level.  D-F) However, at 4 hr post-injury, sPLA2-IIA expression increased in 
CC1-positive oligodendrocytes (E versus B).  Images were taken under identical 
conditions within one session.  G) Quantification of the sPLA2-IIA staining intensity in 
oligodendrocytes at the injury epicenter (n = 3 animals per group, mean ± SD; ** 
p<0.01).  H) Western blots of subcellular fractions taken from either sham or contused 
spinal cords 4 hr following injury showing the increase of sPLA2-IIA observed in A is 
predominantly within the membrane bound fraction and not the soluble cytosolic or 
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sPLA2-IIA induces oligodendrocyte death in vitro. 
Since sPLA2-IIA increased globally and within the membrane fraction following 
SCI, we next examined what effect increased sPLA2-IIA might have on 
oligodendrocytes. These studies focused on oligodendrocytes for two reasons.  First, 
whereas sPLA2-IIA induced neuronal apoptosis has already been shown (Yagami et al., 
2002b, DeCoster, 2003, Yagami et al., 2003), the role of sPLA2-IIA in oligodendrocyte 
cell death remains unknown. Secondly, our previous observation indicates that sPLA2 is 
potentially more destructive to white than grey matter (Sup. 1). 
To determine whether sPLA2-IIA can directly affect oligodendrocyte viability, 
recombinant human sPLA2-IIA was added to differentiate adult oligodendrocyte 
precursor cultures.  sPLA2-IIA triggered a dose-dependent increase in LDH within the 
culture medium corresponding to an increase of cell cytotoxicity from 16.0 ± 5.3 % in 
control wells to 34.3 ± 6.3 % in wells treated with 2 µM of sPLA2-IIA at 48 hr (F3,16 = 
13.04, p < 0.001; Fig. 10E).  Similarly, the MTT assay showed a corresponding change 
with control wells showing an optical density (OD) of 0.040 ± 0.005 and the 2 µM 
sPLA2-IIA dose resulting in an OD of 0.027 ± 0.005 (F3,16 = 13.04, p < 0.001; Fig. 10F).  
Phase contrast images of these wells confirmed oligodendrocyte damage with a decreased 
arbor in the 0.01 and 0.1 µM concentrations and a complete degradation of the cell soma 
and processes at the 2µM concentration (Fig. 10A–D).  Since sPLA2-IIA administration 
can induce oligodendrocyte cell death in vitro, blocking sPLA2-IIA expression or activity 
may prevent such cell death following injury. 
To determine the relative specificity of sPLA2-IIA’s effect on oligodendrocytes, 
identical concentrations were added to primary astrocytes and Schwann cells cultures.  
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Interestingly, no cell death was noted in either culture suggesting that sPLA2-IIA has 
little effect on other glia within the CNS and that the myelinating cells of the peripheral 
nervous system show resistance to sPLA2 activity.  These findings might explain why 
sPLA2 injections into the spinal cord white matter result in oligodendrocyte death but 
shows strong gliosis and delayed Schwann cell remyelination (Titsworth et al., 2007).  
Since sPLA2-IIA administration can induce oligodendrocyte and neuron death in vitro, 








Figure 10. Oligodendrocytes show sensitivity to sPLA2-IIA triggered cell death 
relative to Schwann cells and astrocytes.   
Low levels of exogenously added sPLA2-IIA (0.01 and 0.1 μM; B & C) result in a 
loss of processes extending from the soma and a higher dose (2 µM; D) triggers loss of 
process and cell death as shown by phase contrast images.  An 18.2 % increase in 
cytotoxicity as measured by an increase in lactate dehydrogenase within the media (LDH, 
E), and a 33.1% decreased conversion of tetrazolium into a formazan product (MTT, F) 
suggesting decreased cell survival.  In contrast the 2 μM had no effect on either LDH 
release or MMT conversion in cultured Schwann cells (F-G) or astrocytes (H-I) 
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sPLA2 attenuates H2O2 induced oligodendrocyte death in vitro. 
To address what effects injury induced sPLA2-IIA expression might have on 
oligodendrocytes, an in vitro Hydrogen peroxide (H2O2) injury model was developed.  
When adult oligodendrocytes were challenged with a 30 min pulse of H2O2, there was a 
dose dependent increase in sPLA2-IIA expression over the vehicle control 48 hr after 
H2O2 insult (Fig. 11A).  Immunoflorescence staining confirmed the presence of sPLA2-
IIA-IR in oligodendrocytes in naïve (Fig. 11B–D) and following H2O2 treatment (Fig. 
11E–J).  Interestingly, sPLA2-IIA staining in naïve oligodendrocytes were homogenously 
distributed (Fig. 11D insert) whereas in H2O2 treated cells showed sPLA2 aggregates in 
perinuclear puncta (Fig. 11G & J inserts).  It should be noted that the cells showing 
sPLA2-IIA aggregation also show nuclear fragmentation stained by Hoechst 33342, a 









Figure 11. H2O2 Injury Induces sPLA2-IIA Expression in Cultured 
Oligodendrocytes. 
A) Western blots showing a dose dependent increase in sPLA2-IIA 48 hr following a 30 
min injury with vehicle, 1mM, or 10mM of H2O2.  B-J) Confocal images of 
oligodendrocytes 48 hr following treatment with vehicle (B-D) or 10 mM of H2O2 (E – 
J).  Dead or dying cells showed either a fragmentation of the nuclei, loss of arborization, 
and micro-puncta (E – G) or a round nuclei, swelling of primary processes, and larger 
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Next, differentiated oligodendrocyte cultures were challenged with either 1 mM 
or 10 mM H2O2 for 30 min prior to the administration of various doses of S3319, a small 
molecule inhibitor designed to block the sPLA2-IIA enzymatic site.  48 hr following 
H2O2 injury, wells containing the sPLA2-IIA inhibitor S3319 showed reduced 
cytotoxicity in both H2O2 injury intensities (MANOVA F3,48 = 26.63, p < 0.0001; Fig. 
12A).  In the 10 mM H2O2 treated wells; cells treated with vehicle showed LDH levels 
suggestive of 46.3 ± 9% cell death as compared to 28.4 ± 3% cell death in the S3319 
treated wells (p < 0.001).  These results suggest that increased sPLA2-IIA enzymatic 
activity partially mediates H2O2 induced oligodendrocyte cell death. 
Independent of its enzymatic site, the binding of sPLA2 to its receptor (sPLA2-R) 
has been shown to have limited pro-survival functions.  To assess the receptors role in 
cell survival, oligodendrocytes were pretreated with either vehicle or 50 µM APMP, a 
non-catalytic sPLA2 receptor ligand 30 min prior to the addition of vehicle or 5 mM H2O2 
for 30 min.  In contrast to its enzymatic blockade, inhibition of the sPLA2-R resulted in 
increased cell death (ANOVA F3,44 = 364.5, p < 0.0001, Fig. 12B), approximately 14% 
more cytotoxicity compared to the vehicle controls (59.9 ± 7.9 % vs. 46.0 ± 5.3 %).  
Similarly, when the same cultures were assessed with MTT reduction assay, treatment 
with APMP reduced the optical density from 0.189 ± 0.02 to 0.154 ± 0.03 (ANOVA F3,34 
= 50.79, p < 0.0001, Fig. 12C).  Thus, in contrast to blockade of the enzymatic site which 








Figure 12. sPLA2-IIA Enzymatic Inhibition Partially Reversed H2O2 Induced 
Oligodendrocyte Cell Death.   
(A).  The highest dose of sPLA2-IIA inhibitor S3319 (1.25 µM) was able to decrease by 
17.9 % the amount of cytotoxicity induced by a 30 min treatment with 10 mM H2O2.  
Blockade of the sPLA2-IIA receptor in contrast appears in increase cell death in both the 
vehicle and H2O2 treated oligodendrocytes (B & C).  Following addition of 5 mM of 
H2O2, cell cytotoxicity increases by 13.9% in the APMP treated condition (p < 0.001, B).  
Within the same wells, cell viability as measured by MTT reduction reduces by 18.9% 
among uninjured cells treated with APMP (p < 0.001,C). Note doted line in C denotes 
O.D. of wells that were lysed prior to addition of MTT.  (n = 7 wells per group in A, n = 
6 wells per group in B & C, all in vitro studies repeated in triplicate, mean ± SD; ** p < 
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sPLA2 mediates IL-1β and TNFα induced oligodendrocyte injury in vitro. 
To investigate whether the beneficial effects of sPLA2 blockade mediate more 
than H2O2 induced oligodendrocyte injury, we developed a cytokine injury model for 
oligodendrocyte.  IL-1β and TNFα were chosen because both are suggested mediators of 
secondary SCI (Hostettler and Carlson, 2002, Demjen et al., 2004) and exogenous IL-1β 
and TNFα induces sPLA2-IIA dependent AA release in many cell lines (Kuwata et al., 
1998, Kuwata et al., 2000, Kuwata et al., 2005).  Similarly, we found that treatment with 
IL-1β and TNFα created a time dependent increase in sPLA2-IIA expression in cultured 
oligodendrocytes (Fig. 13A).  When high doses of IL-1β and TNFα were added to 
oligodendrocyte cultures, pretreatment with S3319 showed a decrease in cytotoxicity, as 
measured by LDH release after treatment (MANOVA F1,30 = 16.85, p < 0.0001; Fig. 
13H).  More dramatic than the observed sparing was the morphological changes 
associated with this injury model.  IL-1β and TNFα treatment results in a dramatic 
decrease in oligodendrocyte processes extending from the soma at 48 hr (Fig. 13B-D).  
Interestingly, this process loss was similar to that observed following addition of 0.01 and 
0.1 μM of sPLA2-IIA to oligodendrocyte cultures (Fig. 10B & C).  When cultures were 
pretreated with S3319, this loss of oligodendrocyte processes was almost fully prevented 
(Fig. 13E-G).  Quantification of area covered by oligodendrocyte processes confirms this 






Figure 13. Blockade of sPLA2 in Oligodendrocyte Cultures Prevents Morphological 
Changes and Death Associated with IL-1β and TNFα Injury. 
A) Representative western blot showing time dependent sPLA2-IIA expression following 
treatment with low doses (1 and 2 ng/ml) or high doses (5 and 10 ng/ml) of IL-1β and 
TNFα.  B-G) Phase contrast images showing oligodendrocyte cultures 72 hr after injury 
with either vehicle, low doses (1 and 2 ng/ml) or high doses (5 and 10 ng/ml) of  IL-1β 
and TNFα.  Cultures were either pretreated with vehicle (B-D) or 1.25 µM S3319 (E-G).  
Note the decrease in oligodendrocyte process extension.  H) IL-1β and TNFα injury 
resulted in very mild cytotoxicity at 72 hr, but there was a significant sparing when 
pretreated with the sPLA2 inhibitor S3319.  I) Quantification of process area in (B-G) 
showing that 1.25 µM S3319 significantly prevents the destruction of oligodendrocyte 
processes after IL-1β and TNFα injury. 
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sPLA2 expression following SCI 
We previously showed that cPLA2-IVα (cPLA2α) protein expression increased 
following SCI and peaked at 7 days post injury.  However, measurements of total PLA2 
enzymatic activity in spinal cord homogenates, while increasing after injury, peaked at 4 
hr (Liu et al., 2006).  This led us to believe that PLA2 isozymes, other than group IV, 
most likely contribute to the increase in phospholipases activity observed following SCI.  
To this end we used RT-PCR to screen for which mammalian isoforms of sPLA2 were 
expressed in the naïve and contused spinal cord at 3hr post injury.  We found that of the 
seven isoforms expressing mRNA, two were up regulated (IIA and IIE), one was down 
regulated (X), and four were unchanged (IB, IIC, V and XIIA).  These results were 
further confirmed at the protein level with a peak expression at 4 hr which coincides with 
both apoptosis following SCI (Liu et al., 1997) and the time of peak phospholipase A2 
activity following SCI (Liu et al., 2006).  Next we showed that IIA and IIE increased 
within the lesion area and that groups IB, IIA, and IIE were present in oligodendrocytes 
as well as axons and neurons while group X was only found extracellularly.   
The presence of sPLA2-IB, IIA, IIC, IIE, V, and X is well established within the 
mammalian brain (Molloy et al., 1998, Suzuki et al., 2000, Kolko et al., 2004) as is 
upregulation of certain isoforms following CNS injury (Kolko et al., 2004, Kolko et al., 
2005, Adibhatla and Hatcher, 2007).  However, only one study has demonstrated sPLA2-
IIA and V protein in naïve spinal cords (Svensson et al., 2005).  Therefore this was the 
first study to document differential changes of sPLA2 isoforms following CNS trauma.  
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Interestingly, in separate studies sPLA2-IB increased following KA injection and 
electroconvulsive shock (Kolko et al., 2005), IB, V, and X increased after retinal damage 
(Kolko et al., 2004), and IIA increased following cerebral ischemia (Yagami et al., 
2002b, Lin et al., 2004, Adibhatla and Hatcher, 2007).  In comparison, this study found 
only the group II enzymes increased, while no change was observed in IB, and group X 
decreased following traumatic SCI.  Consistent with this tight regulation, the promoter 
region of sPLA2-IIA gene contains TATA and CAAT boxes as well as several elements 
homologous with consensus sequences for binding of transcription factors such as AP-1, 
C/EBPs, CREB, NF-κB, STAT, and PPARγ (Touqui and Alaoui-El-Azher, 2001).  The 
differential regulation of sPLA2 groups suggests a possible injury and isoform specific 
induction mechanism and varying cellular functions for sPLA2 isoforms in 
neuropathogenesis.   
In addition to demonstrating an induction of sPLA2-IIA following SCI, we also 
demonstrated an increase of sPLA2 within the membrane fraction of cells and a 
perinuclear compartmentalization of sPLA2-IIA following H2O2 injury.  This is 
significant since sPLA2-IIA, while being a secreted molecule, actually displays extremely 
low enzymatic activity toward the phosphatidylcholine-rich external membrane of cells 
because this enzyme cannot bind to the zwitterionic interface.  As a result sPLA2-IIA 
shows a marked preference for anionic phospholipids located on the inner leaflet of the 
bi-lipid membrane.  This results in group II enzymes having a decreased ability to act on 
the external membranes when added exogenously (Bezzine et al., 2000, Murakami and 
Kudo, 2001). This is supported by the fact that cytotoxicity was initiated by µM levels of 
exogenously added sPLA2-IIA in this study as opposed to nM levels of sPLA2-III 
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(unpublished observation), which shows little preference for anionic phospholipids.  
Recent studies have confirmed that AA release by sPLA2-IIA transfected cells occurs 
within the Golgi compartment following synthesis but prior to its initial secretion to the 
extracellular fluid or binding to anionic heparin sulfate chains on the cell surface 
(Mounier et al., 2004).  Therefore, these authors believe that our observations of 
increased mRNA levels and increased protein within the cytosolic membrane fraction, in 
conjunction with a perinuclear punctuate appearance of sPLA2-IIA following injury 
indirectly supports the prevailing theory of sPLA2-IIA synthesis and activation.  
However, further enzymatic studies will be needed for conclusive confirmation.   
 
sPLA2-IIA’s effect on oligodendrocytes 
Since we demonstrated sPLA2 induction following SCI, our next question was 
whether different injury mediators could induce sPLA2-IIA upregulation in 
oligodendrocytes and whether blockade of sPLA2-IIA could reverse injury induced 
oligodendrocyte cell death.  We narrowed our focus to group IIA because of its acute 
induction following SCI both within the cord and more specifically in oligodendrocytes; 
as well as its known association with inflammation (Kudo and Murakami, 2002, Pinto et 
al., 2003, Thwin et al., 2004, Moses et al., 2006).   
Most significantly, H2O2 or IL-1β, and TNFα injury induce sPLA2-IIA expression 
in cultured oligodendrocytes and that blockade of sPLA2 attenuates H2O2 or IL-1β, and 
TNFα induced cell injury. ROS damage is a pervasive injury mechanism involved not 
only in SCI (Liu et al., 1999a, Liu et al., 2004a, Park et al., 2004) but also Multiple 
Sclerosis (Lev et al., 2006), Alzheimer Disease (Reddy, 2006), Parkinson Disease 
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(Everse and Coates, 2005), and Huntington Disease (Rego and Oliveira, 2003).  It was 
previously shown that H2O2 (Richter-Landsberg and Vollgraf, 1998) and AA (Wang et 
al., 2004) can trigger oligodendrocyte death and that H2O2 injury utilizes cPLA2α and 
sPLA2-IIA for AA release in non-CNS cell lines (Han et al., 2003).  However, this was 
the first study to demonstrate that blockade of sPLA2-IIA could partially ameliorate the 
cytotoxic effects of H2O2 in oligodendrocytes.   
Likewise, IL-1β and TNFα have been known to increase sPLA2-IIA expression 
and trigger AA release from cultured cell lines via sPLA2-IIA and cPLA2-IVα dependent 
mechanisms (Mounier et al., 2004, Kuwata et al., 2005).  Additionally these cytokines 
have been shown to damage cultured oligodendrocytes (Selmaj and Raine, 1988, Lee et 
al., 2000, Takahashi et al., 2003, Buntinx et al., 2004).  However, this was the first study 
to demonstrate that blockade of sPLA2-IIA could partially ameliorate the cytotoxicity and 
morphological damage created by IL-1β and TNFα in oligodendrocytes.  It must be 
noted that although S3319 was developed as a specific inhibitor of sPLA2-IIA, its activity 
against other isozymes has not been fully assessed.   This being said, sPLA2 induction in 
oligodendrocytes following ROS and cytokine injury could be a novel target for 
therapeutic intervention.    
While the contradictory results achieved from the blockade of the sPLA2-R are at 
first troubling, these findings are not surprising.  First, the sPLA2 isozymes show varying 
affinities for the sPLA2-R in different species.  Within rats, the sPLA2-R only binds 
sPLA2-IB (Cupillard et al., 1999) which was present, but not increased following SCI.  
Secondly, the generalized functions of the sPLA2-R are far reaching, often grossly 
beneficial, and include cell growth (Arita et al., 1991), proliferation (Kinoshita et al., 
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1997), and migration (Kanemasa et al., 1992).  Finally, others have suggested that sPLA2-
R might function as a clearance mechanism for extracellular sPLA2s to protect against 
enzymatic over activity (Lambeau and Lazdunski, 1999, Yokota et al., 2001).  
In this study we chose to focus on the direct cytotoxicity of sPLA2 in isolated 
oligodendrocytes.  A second, equally compelling, yet unexplored hypothesis is that 
sPLA2 could increase secondary SCI not merely by direct cytotoxicity, as demonstrated 
here, but also by exacerbating the recruitment of neutrophils and macrophages to the 
injury site which has been previously reported (Popovich et al., 1997).  Following sPLA2 
hydrolysis, phospholipids generate a free fatty acid, such as arachidonic acid (AA), and a 
lysophospholipid such as lysophosphatidyl choline (LPC, a.k.a. lysolechithin).  AA can 
later form epoxides via the cytochrome P450 pathway, leukotrienes via the lipoxygenase 
pathway, or thromboxanes or prostaglandins via the cyclooxygenase pathway.  Many of 
these products, such as prostaglandin E2 (PGE2), can subsequently act as potent 
chemoattractants that increase the endogenous immune response (Tonai et al., 1999, 
Resnick et al., 2001).  Furthermore, LPC has been shown to transiently demyelinate both 
the central and peripheral nervous system (Blakemore et al., 1977) and act as a 
proinflammatory chemoattractant for macrophages (Lauber et al., 2003).  Taken together, 
sPLA2 could have detrimental effects on the spinal cord by two means.  First, sPLA2-IIA 
could directly induce tissue damage as we have shown here in isolated oligodendrocytes.  
Secondly, sPLA2-IIA could increase inflammation following SCI and exacerbate 
secondary spinal cord injury, a hypothesis that is under current investigation.   
The results presented here suggest that the expression of sPLA2, particularly IIA, which 
is seen following SCI, might participate in oligodendrocytes death mediated by several 
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cytotoxic pathways.  More importantly the blockade sPLA2, could provide a crucial 
therapeutic intervention for not only SCI but other CNS injuries in which H2O2, IL-1β 
and TNFα mediate damage.  Whether inhibition of sPLA2 following SCI in vivo creates 






sPLA2 INJECTIONS INTO THE NAÏVE SPINAL TISSUE RESULT IN A DOSE 
DEPENDENT LOSS OF FUNCTION AND TISSUE DAMAGE 
 
INTRODUCTION 
After confirming that sPLA2 presence in the naïve spinal cord and increases in 
oligodendrocytes following SCI, we next determined what effect an increase in sPLA2 
could have on the naïve spinal cord.  PLA2 hydrolysis of phospholipids generates a free 
fatty acid, such as arachidonic acid (AA), and a lysophospholipid such as 
lysophosphatidyl choline (LPC, a.k.a. lysolechithin).  AA can later form epoxides via the 
cytochrome P450 pathway, leukotrienes via the lipoxygenase pathway, or thromboxanes 
or prostaglandins via the cyclooxygenase pathway.  Many of these products, such as 
prostaglandin E2 (PGE2) can subsequently act as potent chemoattractants increasing the 
endogenous immune response and subsequent secondary damage.  Furthermore, LPC has 
been shown to transiently demyelinate both the CNS and peripheral nervous system 
(PNS) (Blakemore et al., 1977) and has been shown to be a chemoattractant as well 
(Lauber et al., 2003). 
It is well established that following spinal cord injury a breakdown of 
phospholipids and a release of free fatty acids occurs (Demediuk et al., 1985, Demediuk 
et al., 1989).  To determine whether phospholipases are sufficient to create damage in 
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normal CNS tissue, Group III secretory PLA2 (sPLA2-III), an extract of bee venom, was 
injected into the rat thoracic spinal cord (Liu et al., 2006) which created a broad 
demyelination at 24 hr post-injection.  What still remains unclear how sPLA2 might affect 
the fate of axons and glial cells within the demyelinated white matter over time.  
Additionally it is unknown whether increased sPLA2 within the spinal cord could produce 
a dose dependent loss of function.  Therefore, in this study nano-gram doses of sPLA2-III 
were injected into the rat cervical spinal cord to induce confined lesions in the 
dorsolateral funiculus (DLF) to better understand the time course of functional and 
histological damage.  It was anticipated that sPLA2-III would create a dose dependent 
demyelination of the spinal cord, as well as destroy oligodendrocytes, astrocytes, and 
axons within the lesion area.  Accordingly, this dose dependent pathology should produce 
a graded loss of forelimb function as measured by both pellet retrieval and footprint 
analysis. 
 
MATERAILS AND METHODS 
A total of 47 female Sprague-Dawley rats (Harlan Sprague Dawley, Inc.), 190-
220 g, were used in this study (Table 3). All behavior testing, surgical interventions and 
postoperative animal care were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals (1996) and were approved by the University of Louisville 
Institutional Animal Care and Use Committee.   
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Table 3. Experimental groups 
Groups 1 week 2 weeks 3 weeks 4 weeks 
Sham 3 3 3 4 
Vehicle 3 3 3 4 
1.5 ng - - - 4 
3.0 ng 3 3 3 4 
6.0 ng - - - 4 
Behavior No No No Yes 
 
 
Pellet Retrieval Acquisition and Assessment 
Twenty female rats were diet restricted to promote acquisition of the pellet 
retrieval behavior.  Animals were intermittently fasted on alternate-nights for 18 hr and 
allowed ad libitum feeding on weekends.  Food was removed from the cages at 5:00 p.m. 
prior to randomized testing between 8 and 11 am the next morning.   
The modified pellet retrieval device consisted of a large Plexiglas holding 
chamber connected to a smaller feeding chamber (Montoya et al., 1990, Montoya et al., 
1991)  The rat laid on an elevated (50 mm) platform, removing the need for the injured 
rat to weight support and any interference by truncal or hindlimb dysfunction (Onifer et 
al., 1997).  Unlike the original “Staircase Test” (Montoya et al., 1990, Montoya et al., 
1991), each rat in the present study randomly used its left or right forelimb to retrieve 
pellets from the simultaneously loaded left or right feeding tubes instead of from stairs on 
either side of the elevated platform.  Rats reached 1cm into shoulder-high feeding tubes 
to grasp chocolate-flavored dustless precision purified food pellets (45 mg, Bio-Serv, 
Inc., Frenchtown, NJ).  The contralateral limb was prevented from reaching into the 
opposite tube by extension of their inner wall.  Removal of the staircase allowed the rats 
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to use the same movement for each pellet retrieved, instead of different movements for 
retrieving pellets on different stairs.  It also allowed rats to eat as many pellets as possible 
within the testing period (mean = 63.4 at baseline) rather than just 24 pellets as in the 
“Staircase Test” used by Onifer and colleagues (Onifer et al., 1997). This increased 
volume should allow for increased test sensitivity.  Care was taken to insure that animals 
unable to perform the task were given the same level of reward in their home cage 
following testing. 
Once limb dominance was determined, the dominant limb was exclusively used 
for further acquisition training, injury, and testing.  At the end of each acquisition trial, an 
observer blinded to the treatment groups calculated the percentage of pellets retrieved by 
dividing the difference between the number of pellets retrieved from the feeding tube and 
the number remaining on the floor of the feeding chamber by the number of pellets 
retrieved.  Careful attention was given to dismiss any pellet that was eaten from the floor 
of the chamber.  This consisted of < 1% of all pellets retrieved from the feeding tubes 
since pellets typically fell out of reach.  The objectivity of this score was viewed as a 
benefit over more commonly used behavior assessments.  All rats were given two 5-min 
training sessions a day for 10 days.  Once a rat met training criteria, training was reduced 
to one session per day.  The training criteria were defined as at least 20 pellets retrieved 
from the feeding tube within 5 minutes with at least 70% of pellets successfully eaten.  
One animal that failed to reach training criteria within the 10 day training period was 
removed from the study.  On the last day of the training period, baseline data was 
collected. After surgery, the rats were tested without diet modification for one session on 
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day 3 and weekly for 4 weeks. Sessions were videotaped and images presented were 
enhanced with Adobe Photoshop for clarity. 
 
Footprint Analysis 
Following pellet retrieval testing, walking track footprint data was collected. Its 
analysis was modified from the method of de Medinaceli and colleagues (de Medinaceli 
et al., 1982). The animal’s forepaws were dipped in blue dye (nontoxic). Hindpaws were 
not evaluated since pilot studies showed only minor behavioral changes and only inking 
the forepaws increased print clarity.  The rats moved from a brightly illuminated starting 
box to a darkened box containing a food reward by walking through a narrow Plexiglas 
trough (8.7 cm wide by 60 cm long). Three separate traverses of the track (trials) were 
recorded per testing session.  The trough provided unimpeded movement with ample 
room on both sides and above the animal.  Trials were excluded and repeated if the 
animal touched the wall of the trough or if the animal turned around at any point.  
Additionally, two marks were placed 40 cm apart, centered on the trough, to ensure the 
rat footprints were not analyzed during the beginning (acceleration) or ending 
(deceleration) of the task. To insure constant velocity, the rats were timed as they passed 
from mark 1 to mark 2. If the animal failed to complete the test within 1–2 sec or paused 
while traversing the trough, the trial was excluded from analysis and repeated. Each 
animal (observer was blind to treatment conditions) performed one training session 
without paws being dipped in dye, followed by two separate baseline testing sessions on 
three consecutive days prior to surgery.  After surgery, animals were tested on day 3 and 
weekly for 4 weeks. The footprints were scanned, and digitized images were measured 
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using Photoshop version 6.0 (Adobe Systems, Ottawa, Ontario, Canada). Digit spread 
was measured as the distance between the second digit and fourth digit of the forepaw.  
Angle of forepaw rotation was measured as the angle made by the third digit, center of 
the footpad, and a line parallel to the direction of travel. Forepaw length was the distance 
from the tip of the third digit to the furthest spot on the back of the forepaw print.  Stride 
length was measured from the center of the footpad to the next footpad from the same 
forepaw.  Stance width was determined by drawing two lines connecting two consecutive 
right forepaw prints and two consecutive left forepaw prints and then measuring the 
distance between these two lines at the midpoint. To assess digit spread, the maximal 
digit spread index (DSI) was calculated according to the Brown Toe Spread Index 
formula (Brown et al., 1989): DSI = (EDS - NDS)/NDS, where EDS is experimental digit 
spread, and NDS is normal digit spread. Similar to digit spread, an index was used to 
calculate angle of forepaw rotation, forepaw length, stride length, and stance width. 
Results for each parameter are reported as a percentage of baselines.  At least three 
footprints per side were assessed to determine the value for the trial and the 3 trials were 
averaged to determine the values of each parameter assessed per session. 
 
sPLA2–III Injection 
Following behavior acquisition training and baseline behavior assessments, the 19 
trained rats were allowed ad libitum food for 48 hr to return to control weight.  Trained 
rats were randomly assigned to the following groups. Animals received either a sham 
operation (n = 3) or injection of 0.2 μl of Hank’s Balanced Salt Solution (Invitrogen 
Corp., Carlsbad, CA) containing no sPLA2-III (vehicle control), 1.5, 3, or 6 ng of sPLA2-
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III extracted from bee venom (Cayman Chemical Co., Ann Arbor, MI) unilaterally into 
the C2/C3 spinal cord (n = 4 per injection group, Table 3 “4 weeks”).  Similarly an 
additional 27 animals that did not undergo behavioral assessments were randomly 
assigned to sham, vehicle injection, or 3 ng of sPLA2-III injection groups and sacrificed 
at either 1, 2, or 3 weeks post surgery (n = 3 per group per sacrifice time; See Table 1).  
sPLA2-III, a commercially available sPLA2, was used because its enzymatic activity has 
been we characterized.  Injection doses were determined by estimating the mass of 
sPLA2-III that produced enzymatic activity equal to the increase in phospholipases 
activity seen 4 hr following contusive spinal cord injury (Liu et al., 2006).   
Surgical anesthesia was induced with sodium pentobarbital 50 mg/kg, i.p. (Henry 
Schein, Indianapolis IN).  After exposure and stabilization of the spinal column using a 
device developed at the University of Louisville, the ligament of flavum and 
intervertebral ligaments were removed between the C2 and C3 vertebrae to expose the 
dorsal spinal cord surface.  The dura was carefully opened then, using a stereotaxic 
apparatus, a beveled glass micropipette (external diameter, 10–20 μm) was lowered 1.3 
mm lateral to the midline and 0.8 mm ventral to the pial surface.  Next, 0.2 μl of vehicle 
or sPLA2-III was injected into the spinal cord by a PV800 Pneumatic Pico Pump (World 
Precision Instruments Inc., Sarasota, FA). The needle was left in place for 30 seconds to 
allow for diffusion into the surrounding tissue.   
 
Tissue Preparation 
After 1, 2, 3, or 4 weeks post-surgery, the rats underwent transcardial perfusion 
with 4% paraformaldehyde in PBS. A 2 cm cervical spinal cord segment containing the 
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injection site and a similar one from sham operation rats was cryoprotected in 30% 
sucrose, embedded, and cut transversely at 40 μm.  Eight consecutive sets were created 
with samples every 320 μm. Additionally, one animal from each group at the 4 week time 
point was processed for toluidine blue staining. 
 
Luxol Fast Blue Staining 
One complete set of slides were stained with luxol fast blue for myelin as has 
been previously reported (Liu et al., 2006).  The demyelinated area was identified as 
white in blue stained sections then measured using an Olympus BX60 microscope 
(Olympus America, Inc., Mellville, NY) equipped with a Neurolucida system 
(MicroBrightField, Colchester, VT).  The maximal cross-sectional area of demyelination 
(i.e. lesion epicenter) was determined by identifying the section with the largest area of 
demyelination within the lateral funiculus.  Lesion epicenter was additionally confirmed 
by identifying the needle tract when present. A section at a similar location was identified 
in each rat that underwent sham operation or vehicle injection and was used for these 
measurements.  
Three dimensional (3-D) reconstruction and unbiased estimation of the white and 
grey matter was calculated using Neurolucida software utilizing the Cavalieri method 
(Michel and Cruz-Orive, 1988). The total volume of spared white matter, gray matter, 
and lesion were calculated by summing their individual subvolumes (Oorschot, 1994). 
Individual subvolumes of spared tissue were calculated by multiplying the cross-sectional 




Immunostaining was performed on sections at the lesion epicenter and 320 µm 
rostral, and caudal to the epicenter of each animal. Three sections at similar locations in 
each rat that underwent sham operation or vehicle injection were used. A mixture of 
mouse anti-SMI-31 (1:1000; Covance Research Products, Berkeley, CA) and rabbit anti-
glial fibrillary acidic protein (GFAP; 1:200; Sigma, St. Louis, MO) antibodies or mouse 
anti-SMI-31 and rabbit anti-P0 (1:300; gift from Dr. J.J. Archelos) antibodies allowed 
examination of axons, astrocytes, and Schwann cells, respectively.  Paired antibody 
solutions in blocking solution were applied to the sections overnight at 4οC.  On the 
following day, the sections were incubated with secondary antibodies, goat anti-rabbit 
FITC and goat anti-mouse Texas Red (1:100; JacksonImmuno) using methodologies 
previously described (Liu et al., 2006). Hoechst 33342 (10 µg/ml; Sigma) was added to 
the mounting medium to label nuclei.  Primary antibody omission controls were used to 
evaluate non-specific binding of secondary antibodies.  Images were taken using a Nikon 
Eclipse 90i confocal microscope (Nikon Instruments; Melville, NY).  
Axons profiles and Schwann cell myelin rings were quantified within the lesion 
area of 3 ng animals and the complete DLFs of vehicle and sham operated rats using an 
Olympus BX60 microscope equipped with Stereo Investigator (MicroBrightField, 
Colchester, VT). The lesion area, defined by increased cellularity when viewing Hoechst 
staining and noticeable changes in tissue morphology, was outlined on three separate 
sections immunostained for SMI-31 and P0, at the epicenter and 320 µm rostral and 
caudal to it. A systematic random sampling grid (vehicle controls = 133 x 175 µm, 
experimental = 127 x 100 µm) yielded approximately 30 sampling sites per section.  All 
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profiles were counted under oil with a 100x optical magnification using a 10 x 10 µm 
unbiased counting square.  Axons and myelin rings were counted simultaneously by 
alternating between Texas red and FITC filters.  The number of axon profiles and myelin 
rings per spinal cord section was estimated using a fractionator probe with a resulting 
Schmitz-Hof Coefficient of Error = 0.08 and an average of 212 profiles counted per 
animal. Results are presented as number of profiles per mm2. 
Additionally sections from the lesion epicenter were incubated with mouse 
monoclonal anti-APC antibody (CC1) (1:1000; Calbiochem, San Diego, CA) overnight at 
4°C. On the second day, the sections were incubated with secondary biotinylated IgG 
antibody (1:400; Vector Laboratories, Burlingame, CA) for 1 hr at room temperature. 
The reaction product was shown by incubation for 5 minutes with 0.02% 
diaminobenzidine tetrahydrochloride (DAB) and 0.003% H2O2 in 0.05M Tris-HCl (pH 
7.6).  Non-binding IgG was used in primary antibody omission controls. 
 
Toluidine Blue Staining 
To further examine myelination (Xu et al., 1999a), spinal cord segments from one 
animal in each of the groups sacrificed at 4 weeks were fixed overnight in a solution 
containing 2% glutaraldehyde and 5% sucrose in 0.1M sodium cacodylate buffer, pH 7.4, 
followed by 1% osmium tetroxide in the same buffer for 1 hour. The tissues were 
embedded in Spurr’s epoxy resin and cured at 70°C. Transverse semi-thin sections (1 
µm) were stained with a mixture of 1% toluidine blue and 1% sodium borate. Images 
were captured with MicroFire Digital Camera (Optronics, Goleta, California) attached to 




 One-way analysis of variance (ANOVA) with post hoc Tukey’s HSD was used to 
determine significant differences in histological outcome measures between three or more 
groups. A repeated measure multiple analysis of variance (MANOVA) was used to 
analyze behavioral data, followed by Tukey’s HSD.  Chi square analysis using the 
Kaplan and Meier method was used to determine significant differences in behavior 
acquisition curves.  Pearson’s Product Moment Correlation was used to determine the 
degree of relatedness between lesion area and behavioral outcome.  Data are reported as 
mean ± SD except where noted.  A p < 0.05 was considered statistically significant.   
 
RESULTS 
sPLA2-III Creates a Consistent Demyelination and Remyelination of the Spinal Cord 
sPLA2-III was found to create a consistent and dose dependent lesion when 
injected into the cervical spinal cord.  The maximal cross-sectional area of the lateral 
white matter demyelination in luxol fast blue-stained sections significantly increased with 
the dose of sPLA2-III injected (ANOVA, F4,19 = 39.785, p < 0.001, Figs. 14A-C & Table 
4).  The lesion area created by 1.5 ng and 3 ng of sPLA2-III was significantly smaller at 4 
weeks than the lesions in 6 ng sPLA2-III animals upon post hoc analysis (Table 4, p < 
0.001). No lesions were found in vehicle or sham-operated groups.  After 3-D 
reconstruction of the lesion with Neurolucida, the lesion volume differed significantly 
among the three doses of sPLA2-III and all injury groups differed from controls 
(ANOVA, F4,19 = 126.9, p < 0.001, Figs. 14D-H & Table 4).  Animals injected with 3 ng 
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had a significantly larger lesion than animals injected with 1.5 ng (p < 0.01) and a 
significantly smaller lesion than those injected with 6 ng (p < 0.001; Fig 14 H).  
Similarly, the 1.5 and 3 ng injection groups showed a greater rostral caudal extent of their 
lesion than the controls and less than the 6 ng group (ANOVA, F4,19 = 76.6, p < 0.001).   
 










Sham 3 0 0 0 
Vehicle 4 0 0 0 
1.5 ng 4 0.78 ± 0.23 3.02x105 ± 0.2 x105 3.04 ± 1.06 
3.0 ng 4 1.3 ± 0.09 5.32 x105 ± 0.7 x105 3.44 ± 0.31 
6.0 ng 4 2.4 ± 0.31 7.82 x105 ± 0.9 x105 5.28 ± 0.41 




Figure 14. Demyelination Occurring After Unilateral Cervical (C2/3) Spinal Cord 
Injections of sPLA2-III. 
A-C) Representative sections stained with luxol fast blue for myelin showing graded 
demyelination at the lesion epicenters 4 weeks post-sPLA2-III injections at doses of 1.5 
ng (A), 3 ng (B), or 6 ng (C).  Dotted line in A-C demarks the lesion area. Note that the 
lesion is complete within the DLF.  D-G) 3-D reconstruction of a 2 cm segment of Luxol 
Fast Blue stained spinal cords taken from vehicle (D), 1.5 ng (E), 3 ng (F), or 6 ng 
injected animals (G). H) Graphical representation of 3-D volume reconstructions (D-G) 
showing significant differences between 1.5 and 3 ng (** p < 0.01) and 3 ng and 6 ng 
groups (*** p < 0.001). Scale bar: A-C = 500 µm 
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The cell populations within the lesion decreased following spinal cord injury.  
CC1 staining indicated that there was a marked decrease in mature oligodendrocytes 
within the lesion (Figs. 15A & B).    Similar to other types of spinal cord injury, an 
astrocytic border formed at the site of sPLA2-III-induced damage.  Immunostaining with 
anti-GFAP antibody revealed a well defined border of reactive astrocytes surrounding the 
lesion area by 4 weeks with very few astrocytic somas within the lesion (Fig. 15C).    
 In toluidine blue-stained semi-thin sections, massive demyelination and 
axonopathy could be seen in the lesion area (Figs. 15D-G).  Considerably fewer 
myelinated axons existed in the lesion at 4 weeks (6 ng injection; Figs. 15F & G) than in 
the uninjured contralateral white matter (Fig. 15E).  While there was less myelin both in 
the lesion epicenter (Fig. 15F) and in the lesion periphery (Fig. 15G), compared to 
control regions, myelin was present in all parts of the lesion at 4 weeks post injection 
with increasing density further from the epicenter.  Nuclei were usually associated with 
myelin rings (arrows in Figs. 15F & G), suggesting that myelin within the lesion was 
most likely from Schwann cells and not regenerating oligodendrocytes.  Within the 
lesion, large nucleated granular cells, most likely macrophages, were prevalent (double 
arrow in Fig. 15F) and blood vessels with their endothelial lining could also be seen 






Figure 15. Histological Results Occurring 4 Weeks After Unilateral Cervical (C2/3) 
Spinal Cord Injections of sPLA2-III. 
A) Low power image of CC1 stained section shows the lesion area within the DLF 
between the ventral horn (VH) and dorsal horn (DH)  B) The high power image shows 
the clear demarcation of the lesion boarder with a decrease of CC1-positive 
oligodendrocytes (arrows) within the lesion and a sparing of labeled mature 
oligodendrocytes outside the lesion.  C) Similar to other types of spinal cord injury, there 
is an astrocytic scar around the lesion confirmed by GFAP labeling (3 ng injury).  D-G) 
Representative toluidine blue-stained semi-thin section at the lesion epicenter of a 6 ng 
sPLA2-III injected animal.  Note that at the higher dose (D) there is damage within the 
ipsilateral dorsal horn and dorsal funiculus (arrow).  Letters on the section represent the 
approximate location of images E-G.  E) The intact contralateral lateral funiculus has 
oligodendrocyte myelinated axons.  F) At the lesion epicenter there is a prodigious loss of 
axons and remyelination of spared axons by Schwann cells (arrows). Many large granular 
cells (double arrow), most likely macrophages, were also seen.  G) At the lesion 
periphery there are many spared axons that have been almost exclusively remyelinated by 
Schwann cells (arrows).  There were also a high number of blood vessels in the lesion 
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To confirm axonal loss, sections were labeled with anti-SMI-31 (Figs. 16A & B).   
The density of axons (number per mm2) within the lesion area was then compared to that 
within the lateral funiculi of vehicle-injected rats.  Four weeks after 3 ng injections of 
sPLA2-III, there were 70-77% fewer axons per mm2 within sPLA2-III lesions (3 ng 
sPLA2-III = 30,586 ± 5,100; Fig. 16C) than in matched areas of vehicle injected controls 
(120,099 ± 22,483; ANOVA, F1, 22 = 325.1, p < 0.001; Fig. 16C).  Of note, among the 
animals that were injected with sPLA2-III, the number of axons within the lesion area did 
not significantly change during the four weeks tested (F3, 14 = 0.88, p = 0.48, Fig. 16C) 
suggesting that axons observed in the fourth week were predominantly original structures 
and not regenerated.  While there was a near significant difference in the density of axons 
within the vehicle injected animals this is most likely due to increasing total area of the 
spinal cord as the animals increased in size (F3, 14 = 3.276, p = 0.063, Fig. 16C).  
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Figure 16. Immunofluorescent labeling and quantification of axons during 4 weeks 
after unilateral cervical (C2/3) spinal cord injections of sPLA2-III. 
A, B) Representative SMI-31-immunostained sections in the lateral funiculus of a vehicle 
control rat (A) and in the lesion area of a rat that received an injection of 3 ng sPLA2-III 
(B) 4 weeks earlier. The circular spaces are most likely micro cyst-like cavities (asterisk 
in B).  C) Quantification of axon loss.  Rats that received an injection of 3 ng sPLA2-III 
had an approximately 70% decrease in the number of axons per mm2 within the lesion 
area at 1 week after injury compared to the number of axons in the lateral funiculi of 
vehicle injected rats.  Note that the number of axons within the lesion area remained 
constant over the period of the study, suggesting that these are spared axons and not 




To confirm the source of myelin within the lesion, sections were double-labeled 
with anti-SMI-31 and anti-P0 antibodies (Figs. 17A-F).  Positive P0 staining confirmed 
that myelin within the lesion was from Schwann cells.  Confocal images from the lesion 
epicenter show P0 myelin rings wrapping around SMI-31 axon profiles (Figs. 17D-F).  
Interestingly, this remyelination was time-dependent.  No P0 staining was observed 
within the lesion area of any animal sacrificed at week 1. P0 staining was seen in only 
one of the three animals sacrificed at week 2; however, labeling was extremely weak.  
There was a dramatic increase in P0 staining within the lesion area by week 3 that 
persisted at week 4 (ANOVA, F2,11 = 17.37, p < 0.001; Fig 17G). Since P0 was only 
observed around SMI-31 labeled axons, it was estimated that by weeks 3 and 4, 72% - 
56% of axons were myelinated by Schwann cells, respectively (Fig. 17H).  
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Figure 17. Immunofluorescent double labeling shows a progressive remyelination of 
spared axons by Schwann cells over a 4 week period.   
 
A-C) Representative P0 and SMI-31-immunostained section at the lesion epicenter of a 3 
ng sPLA2-III injected animal at 4 weeks post injury.  A) P0 signaling is strong within the 
lesion area.  Note that P0’s specificity for Schwann cell myelin is confirmed by staining 
of Schwann cells in both the dorsal and ventral roots (white arrows).  B) Axons are also 
present within the lesion area.  C) The merged image of A & B shows that some P0-
immunoreactive myelin in the lesion area is associated with SMI-31-immunoreactive 
axons.  (D-F) Orthogonal views of confocal images from the 4 week old lesion area of a 3 
ng injected animal.  Note, the X/Y plane is presented in the center panel, X/Z plane is 
presented in the bottom panel, and Y/Z plane is presented in the left panel. The area of 
interest is indicated by green crosshairs in (F).  Schwann cell myelin rings, positive for 
P0 (D), can be clearly seen encircling axons (F), identified by SMI-31 immunostaining 
(E), within the lesion area.  G, H) Quantification of Schwann cell remyelination.  G) 
While no P0 myelin is seen within the lesion area at weeks 1 and 2 after injection of 3 ng 
sPLA2-III, there is a dramatic increase between weeks 2 and 3 that remains constant 
during week 4. H) The majority of spared axons are remyelinated by Schwann cells by 
weeks 3 and 4.  Scale bars: Scale bars: A-C = 500 µm; D-F = 5 µm. G & H, mean ± SD; 
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sPLA2-III Injury Affects Behavior 
Qualitatively, differences existed between the rodents’ performance before and 
after sPLA2-III injections. The naïve (Figs. 18A-D), sham operated, and vehicle control 
rodents retrieved pellets using previously described movements (Mckenna & Whishaw, 
1999) in four stages.  First, the animals approached (Fig. 18A), then reached into the 
feeding tube grasping the pellet with extended digits (white arrow indicates pellet in Fig. 
18B).  Because of the positioning of the tube and an extension along the inner wall, a 
rodent could not use its tongue or contralateral limb or scrape the pellet into its mouth.  
Therefore, the naive rodent grasped the pellet and supinated the closed paw (Fig. 18C).  
Finally, the rodent completed supination and ate the pellet with the palm facing vertically 
(Fig. 18D).  By 1 week following injections of 1.5 and 3 ng sPLA2-III (3 ng rat shown in 
Figs. 18E-H), these rodents approached the tube (Fig. 18E) and reached (Fig. 18F) in a 
similar manner to naïve animals.  However, they were unable to open the digits, pronate 
the paw, and close their forepaw around the pellet (Fig. 18G). Upon retraction of the arm, 
the pellet was dragged from the tube and fell to the chamber floor (Fig. 18H).  Two out of 
four rodents injected with 6 ng were unable to elevate their shoulder to the level of the 
feeding tube at any time post-injection and so were given a 100% pellet drop score on 
each of the testing days.  It was found that these 6 ng animals had damage not only of the 
DLF but also extending into the ipsilateral gray matter and corticospinal tract in the 
dorsal funiculus (see arrow in Fig. 15D).  This loss of function is not surprising since 
large dose injections into the C2/3 white matter could cause death of interneurons and 
motorneurons which would correspond with control of the acromiotrapezius and levitor 








Figure 18. Video captured images of pellet retrieval test performance prior to injury 
(A-D) and 1 week following 3 ng injection of sPLA2-III (E-H).   
Forelimb lift (A), reach, forepaw digits open (B), pronation, grasp, and supination (C) 
movements were required for successful pellet (white arrow in B) retrieval (D) by naïve 
rats.  The 3 ng sPLA2-III injected rats could reach into the feeding tubes (E) and open 
their digits (F) for the pellets (white arrows in F-H). However, they could not grasp them 
(G). As the pellets were dragged out of the feeding tube, they fell to the floor out of reach 
(white arrow in H).  Counts of dropped pellets were used to determine the percentage of 
pellets retrieved resulting in a quantitative and objective measure of forelimb function. I) 
Schematic showing the plunger used to deliver a pellet for a rat that is lying on the 
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Injection of sPLA2-III into the cervical spinal cord DLF had a significant 
quantitative effect on pellet retrieval performance as well (Fig. 19A).  A significant main 
effect was observed between time post-op and the percentage of pellets retrieved 
(MANOVA, F2.6,70.3 = 22.427, p < 0.001). Tukey’s HSD post hoc analysis revealed a 
significant difference from baseline pellet retrieval in all sPLA2-III injected animals.  The 
6 ng group decreased precipitously on day 3 (p < 0.001) and never returned to baseline.  
The 3 ng group showed decreased pellet retrieval on day 3 (p < 0.001) but was 
statistically indistinguishable from baseline after 3 weeks (p = 0.20).  Similarly, animals 
injected with 1.5 ng of sPLA2-III decreased by day 3 (p < 0.01) but were 
indistinguishable from baseline levels by 1 week (p = 0.32) or later after injury.  No 
difference was seen in the sham (p = 0.97) or vehicle (p = 0.89) groups.  This general 
trend of improvement was confirmed by a significant time/group interaction (MANOVA, 
F10.4, 70.3 = 5.104, p < 0.001) and post hoc analysis revealing that the 3 ng group 
significantly improved from its day 3 deficit by weeks 3 and 4 (p < 0.05).  Additionally, 
at day 3 the 6 ng (p < 0.001), 3 ng (p < 0.001), and 1.5 ng (p < 0.05) rodents performed 
significantly worse than the vehicle injected animals.  Afterwards this pattern continued 
for the 6 ng and 3 ng groups with the 1.5 ng group returning to baseline by 1 week.  Most 
importantly the pellet retrieval test detected differences among the sPLA2-III injected 
animals.  For example, at day 3 there was a significant difference between the 1.5 ng 
injury group and the 6 ng (p < 0.001) and 3 ng (p < 0.05) animals a pattern which 
continue through all time points.  A difference in pellet retrieval was also seen between 
the 3 ng and 6 ng groups at week 3 (p < 0.01). Most importantly, the lesion area was 
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inversely correlated with the averaged pellet retrieval ability for each animal (R2 = 
0.7285; Fig. 19B).  
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Figure 19. Behavioral results occurring after unilateral cervical (C2/3) spinal cord 
injections of sPLA2-III. 
A) Only groups injected with sPLA2-III showed decreased pellet retrieval ability at 3 
days post injury.  The 6 ng rats showed a significant difference from baseline at all time 
points with 3 ng animals recovering by 3 weeks and 1.5 ng by 1 week post injection.  A 
dose-dependent decrease in pellet retrieval was also observed 3 days post-injection with 3 
ng and 6 ng animals. Pellet retrieval performance improved in all injury groups, however, 
at 4 weeks this was still significantly impaired in the 3 ng and 6 ng groups compared to 
all other groups. B)  The pellet retrieval performance decreased as the lesion area 
increased.  Therefore, this test is sensitive to graded demyelinating and axon injuries in 
the upper cervical spinal cord lateral white matter. C & D) The 6 ng sPLA2-III injected 
rodents rotated their forepaw less 3 days post-surgery.  Additionally the 6 ng rats 
maintained this lower rotation through weeks 1 and 2.  At day 3 only the 6 ng animal had 
a significantly lower angle of rotation than all other groups.  At 2 weeks the vehicle and 
sham animals were both significantly higher than the 6 ng and the 3 ng.  By 3 and 4 
weeks post-injection there was no difference among injured groups. A difference in digit 
spread was only detected on day 3, with 3 ng and 6 ng animals showing significant 
narrowing of the digits. E & F) Representative forepaw prints from either a vehicle (E) or 
3 ng (F) right side injection, 3 days post injury.  Note the difference in both paw rotation 
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Similarly, footprint analysis could detect behavioral changes following sPLA2-III 
injection but not as well as the pellet retrieval assessment. Of the five footprint analyses, 
forepaw length (MANOVA, F4, 54 = 2.25, p = 0.09), stance width (MANOVA, F4, 54 = 
0.639, p = 0.637), and stride length (MANOVA, F4, 54 = 0.460, p = 0.765) were not 
significantly different for any group or time point.  Forepaw rotation varied significantly 
over time (MANOVA, F14, 97 = 2.04, p < 0.05) and between groups (MANOVA, F4, 54 = 
6.11, p < 0.001; Figs. 19C, E, F).  All three injury groups were found to vary significantly 
from baseline initially but, in contrast to pellet retrieval performance, recovered to 
baseline by 3 weeks.  The 6 ng group differed significantly from baseline at 3 days (p < 
0.001), 1 week (p < 0.001), and 2 weeks (p < 0.01) post injury.  The 3 ng and 1.5 ng 
group differed from baseline only at 1 week post injury (p < 0.05).  Of note, while no 
significant difference was seen from baseline there was a significant recovery between 1 
week and 2 weeks for both sham (p < 0.05) and vehicle controls (p < 0.01).  Significant 
differences between injury groups were only detected at 3 days (p < 0.05) and 2 weeks (p 
< 0.001) post injury.  At 3 days post injury, forepaw rotation in the 6 ng group was 
significantly worse than sham operated rats (p < 0.05). At week 2, the 6 ng group was 
significantly worse than sham (p < 0.001), vehicle (p < 0.01) and 1.5 ng (p < 0.05) 
animals and the 3 ng group was significantly worse than sham (p < 0.001) and vehicle (p 
< 0.05) rats.  It is worth noting that the only detectable difference among sPLA2-III 
injected groups was at one time point (2 weeks) and between the 6 ng and 1.5 ng groups.    
There was a significant difference in the digit spread over time (MANOVA, F13.26, 
179 = 4.506, p < 0.001) and between injection groups (ANOVA, F4, 19 = 4.168, p < 0.005; 
Figs. 19D, E, F).  Further analysis of time revealed that all differences were confined to 
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day 3 (p < 0.001). At day 3, the 3 ng and 6 ng groups were both significantly different 
from baseline (p < 0.001, E, F).  A difference among groups could be seen on day 3 (p < 
0.001) and 2 weeks (p < 0.05) following injury.  At day 3, the 6 ng group was 
significantly narrower than the sham (p < 0.01), vehicle (p < 0.01), or the 1.5 ng groups 
(p < 0.05).  The 3 ng group was significantly narrower than the vehicle group only (p < 
0.05).  At two weeks, only a near significant difference existed between the 6 ng and 
vehicle control groups (p = 0.06).  As with forepaw rotation, digit spread detected a 
significant difference among sPLA2-III injected groups at day 3, but in contrast was 
unable to detect group differences at 2 weeks.   
 
DISCUSSION 
Initially, this study showed that nanograms of sPLA2-III were sufficient to 
demyelinate the normal rodent spinal cord.  Secondly, the previously observed 
axonopathy was quantified, revealing it to be more pervasive than originally thought, 
with an approximately 75% loss of axons.  Thirdly, we confirmed that oligodendrocytes 
and astrocytes die within the lesion area.  However, this conclusion is based on one two 
stains and the fate of precursor cells still remains unclear.  Most importantly, for the first 
time, we observed a prodigious remyelination of 72% of spared axons by Schwann cells 
between 2 and 3 weeks after injection of sPLA2-III.   
Schwann cells have been shown to remyelinate the spinal cord in small numbers 
following traumatic SCI in rats (Bresnahan, 1978) and humans (Bunge, 1994).  
Unfortunately, a large percentage of the spinal cord remains demyelinated after contusion 
(Cao et al., 2005) suggesting that further remyelination could be beneficial.  In previous 
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experiments we and others showed that transplanted Schwann cells increased axonal 
regeneration, were neuroprotective, and improved functional recovery following SCI in 
rats (Xia et al., 1995, Xu et al., 1995, Xu et al., 1997, Xu et al., 1999b, Takami et al., 
2002, Pearse et al., 2004).  Given the previous work showing functional recovery 
following Schwann cell transplantation and the lack of appreciable axon regeneration 
within the lesion, it is tempting to hypothesize that the observed recovery in this study 
was due to remyelination by Schwann cells.  However, Schwann cells’ exact role in 
functional recovery following sPLA2 injection remains to be investigated. 
Schwann cell immigration into the injured human and experimental animal spinal 
cord is still controversial.  Some authors suggest that Schwann cells enter from dorsal and 
ventral roots and contiguous peripheral nerves (Jasmin et al., 2000). Other groups believe 
that these cells immigrate either through porous blood vessels (Talbott et al., 2005) or 
through breaches in the dura (Guest et al., 2005).  It has also been suggested that cells 
possessing a Schwann cell-like phenotype are actually the result of altered maturation of 
endogenous oligodendrocyte precursors due to the absence of astrocytes (Talbott et al., 
2006).  The latter hypothesis is particularly intriguing since the present results show a 
lack of astrocytes within sPLA2-III-induced lesions.   
Interestingly, sPLA2-III-induced demyelination bears some striking similarities to 
other demyelination models.  Intraspinal LPC -injection, a common 
demyelination/remyelination model described by Blakemore and colleagues (Blakemore 
et al., 1977, Blakemore, 1978, Blakemore, 1982, Jeffery and Blakemore, 1995) also leads 
to loss of oligodendrocytes, astrocytes, and axons.  Moreover, LPC is a product of sPLA2  
digestion, providing a logical connection between these two models (Dutta et al., 1979).  
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However, this LPC induced remyelination occurs at 2 weeks post injection and is much 
less robust. Furthermore, when Woodruff and Franklin (1999) compared remyelination 
following injections of LPC, ethidium bromide, and anti-galactocerebroside antibody into 
the brainstem, oligodendrocytes dominated the remyelination in all cases with only 10 - 
40% attributable to Schwann cells. Further more remyelination occurred at 3.5 weeks, 
later than in the present study.  Finally, these models had greater axonal sparing than was 
observed after sPLA2-III injections.  While these differences could be due to dose 
variations, they also suggest additional molecular processes might be involved in sPLA2 
–induced injury.  
There are several advantages to using the current model of sPLA2-III induced 
demyelination over previously mentioned methods.  First, the use of phospholipases, 
which are increased in many CNS disorders, are a closer parallel to natural inflammatory 
processes than synthetic molecules such as ethidium bromide.  Second, we have shown 
that sPLA2 injections produce a highly focal and controllable lesion that can be used to 
create a graded lesion of the white matter with little grey matter damage at lower doses.  
When sPLA2 injections are used in conjunction with the pellet retrieval task one can 
produce very controlled cervical spinal cord injury model, with low mortality, and a 
functional outcome measure.  Third, previous models have shown only slight P0 
remyelination, making this a superior model for investigation of Schwann cell 
remyelination.   However, the presence of P0 remyelination could be viewed as an 
unwanted experimental artifact detracting from this models appeal.  Another 
disadvantage is that while sPLA2–III does have a potent phospholipase activity; the 
presence of this particular group has not been shown in the mammalian CNS. 
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In this study, the modified pellet retrieval task was a sensitive and quantifiable 
behavioral measure able to detect both differences in functional loss and recovery 
following graded sPLA2-III-induced cervical DLF lesions.  Previously, the “Staircase 
Test” was used to show forelimb dysfunction without significant recovery in rats 
following a single force C7 contusion injury (Onifer et al., 1997). Similarly, Schrimsher 
and Reier (Schrimsher and Reier, 1993) found that following a C4 laceration of the dorsal 
column, dorsolateral funiculus, or ventrolateral funiculus a similar pellet retrieval task 
was able to detect deficits only after DLF laceration without any notable recovery after 4 
weeks.  We believe that this report is the first record of a reaching task being able to 
discriminate between various grades of cervical white matter damage and the first to 
show significant recovery following injury.  The modified pellet retrieval test also was 
more sensitive than the more commonly used footprint analysis.  While the footprint 
analysis revealed sPLA2-III-induced forelimb dysfunction during locomotion, this 
assessment was largely unable to discriminate between injection groups and behavioral 
deficits were only observed in 2 of 5 measures.  This finding emphasizes the need to 
perform multiple assessments when examining dysfunctions of the nervous system and 
evaluating repair strategies.   
The greatest drawback of the modified pellet retrieval test is an inability to assess 
severe cervical SCI.  In our device some of the 6 ng sPLA2-III-injected animals were not 
able to reach into the feeding tubes and perform the task.  This could have been a result 
of lesion encroachment on the corticospinal tract (Fig. 15D) or undetected destruction of 
motor neurons and interneurons within the C2/3 gray matter.  The latter is more likely 
since injections into the C2/3 interface would correspond with motor neurons controlling 
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the acromiotrapezius and levitor claviculae, which would greatly compromise shoulder 
elevation (McKenna, 2000).  Also, as stated above, only laceration of the dorsolateral 
funiculus and not the corticospinal tract effected the retrieval ability in the “Staircase 
Test” (Schrimsher and Reier, 1993).  Following severe contusions the original “Staircase 
Test” may be more useful.  However, it must be noted that the 6 ng animals showed some 
improvement at 4 weeks and the possibility of further improvements beyond 4 weeks 
could not be eliminated.  While there was no expansion of the lesion area beyond the 
DLF in both 1.5 and 3 ng injuries, there was a significant difference in behavioral 
measures.  This could be explained by partial destruction of the rubrospinal tract in the 3 
ng group with sparing of some fibers in the 1.5 ng animals.  While the lesions may appear 
homogenous, the loss of axons increased from the periphery to the center with the sparing 
of some axons seen in the center of the 1.5 ng group. 
In conclusion, injection of at least one type of sPLA2 into the cervical white 
matter seems to have a bimodal effect on tissue and function.  Initially normal tissue 
architecture is destroyed followed by the immigration of what is typically characterized 
as a beneficial cell type leading to remyelination.  Similarly, our modified pellet retrieval 
device detected an initial dose-responsive dysfunction followed by recover between 2 and 
3 weeks post injury.  It is tempting to hypothesize what factors produced each facet of 
this bimodal response.  With the knowledge that phospholipases are increased following 
CNS injury, current investigations in our lab are attempting to block the destructiveness 
of sPLA2 while harnessing the beneficial effects of increased Schwann cell immigration 







sPLA2 INHIBITION PRIOR TO SPINAL CORD INJURY RESULTS IN 
FUNCTIONAL AND HISTOLOGICAL SPARING 
 
INTRODUCTION 
In the previous chapters we have shown that many of the sPLA2 isoforms are 
present in the naïve spinal cord and within oligodendrocytes.  We next showed that 
following spinal cord injury groups IIA and IIE increase by several fold and that sPLA2-
IIA similarly increases within oligodendrocytes following two models of in vitro injury.  
We also showed that exogenously added recombinant human sPLA2-IIA is cytotoxic to 
both oligodendrocyte cultures and to naïve rodent spinal cords.  Finally we demonstrated 
that blockade of sPLA2-IIA by pharmacological inhibition partially ameliorated the 
deleterious effects of TNFα and IL-1β or H2O2 in oligodendrocyte cultures.  What 
remains to be seen is whether blockade of sPLA2 can create tissue and functional sparing 
following SCI in vivo.   
Several inhibitors of sPLA2 have shown in vivo efficacy in rodent models of 
neuropathology.  Indoxam, a specific sPLA2 inhibitor, was shown to offer protection 
against cerebral ischemia (Yagami et al., 2002b).  Similarly, CDP-choline significantly 
restores phosphatidylcholine levels by differentially affecting sPLA2 and phosphocholine 
cytidylyltransferase after stroke (Adibhatla et al., 2006).  Quinacrine / mepacrine, a non-
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specific inhibitor of PLA2 activity and anti-malarial drug, also showed sparing of 
hippocampal neurons (Phillis, 1996) and reduced infarct size following transient focal 
ischemia (Estevez and Phillis, 1997) and showed sparing of hippocampal neurons 
following kainite-injection (Ong et al., 2003).  Finally membrane bound inhibitors of 
sPLA2 showed decreased inflammation in experimental autoimmune encephalomyelitis, a 
rodent model of multiple sclerosis (Pinto et al., 2003).  Similarly, the small (487.63 MW) 
lipophilic molecule S3319 has been shown to be both a potent inhibitor of sPLA2-IIA 
with an IC50 = 0.029 μm (Church et al., 2001, Hansford et al., 2003) and orally active 
against infiltrating neutrophils following reperfusion injury in mice (Arumugam et al., 
2003).  However, this final compound has not been tested against CNS pathologies nor 
has any sPLA2-IIA inhibitor ever been assessed following neurotrauma either in the brain 
or spinal cord.     
The results presented here show that inhibition of sPLA2 activity prior to 
traumatic SCI results in increased oligodendrocyte survival, increased sparing of white 
matter, increased axons at the lesion epicenter.  Accordingly, sPLA2 inhibition also 
decreased the lesion size and number of infiltrating cells migrating into the lesion.  
Finally, sPLA2 inhibition increased voluntary locomotion and accelerated recovery of 
voluntary bladder function.  
  
MARTERIALS AND METHODS 
Animals 
A total of 20 female BALB/c mice (Charles River, Wilmington, MA) and 10 
female 129/sv mice (Taconic, Germantown, NY) 6-8 weeks old, were used in this study. 
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All surgical interventions and postoperative animal care were performed in accordance 
with the Guide for the Care and Use of Laboratory Animals (National Research Council, 
National Academy Press, Washington, D.C., 1996) and the Guidelines of the University 
of Louisville Institutional Animal Care and Use Committee.   
 
Experimental groups and dosing 
It has been previously determined that certain mouse strains have a natural 
disruption of the sPLA2-IIA gene (e.g. 129/sv) (Kennedy et al., 1995).  Mice were 
divided into 5 groups (see Table 5) based on sPLA2-IIA expression, the state of spinal 
cord injury, and pharmacological inhibition of sPLA2-IIA.  Beginning two days prior to 
surgery and for 2 weeks afterwards animals were give either S3319 (10 mg/kg i.p.; 
Sigma-Aldrich, St. Louis, MO), a potent sPLA2-IIA enzymatic inhibitor (Hansford et al., 
2003), or vehicle (70% DMSO) mixed fresh daily.  The dose was reduced to 5 mg/kg 
during the second week post injury.  This dose was selected based on previous in vivo 
efficacy and physiologically activity (Arumugam et al., 2003).   
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Table 5.  Experimental Groups 
Group # Strain sPLA2-IIA gene Injection SCI n 
1 BALB/c +/+ S3319 0.45 mm 8 
2 BALB/c +/+ Veh 0.45 mm 8 
3 BALB/c +/+ Veh Sham 4 
4 129/sv -/- Veh 0.45 mm 8 
5 129/sv -/- Veh Sham 4 
  
 
Contusive spinal cord injury 
 Mice were injected with ketamine and xylazine (90 + 10 mg/kg, i.p., Lloyd 
Laboratories, Shenandoah, IA), 1 ml of normal saline (s.c.), and placed on a 
homeothermic blanket.  The back was shaved and skin was cleansed with betadine.  Skin 
was incised and the underlying muscles were dissected to expose the dorsal halves of the 
T7-T13 vertebrae.  The exposed vertebral column was stabilized using bilateral 
transverse supports placed underneath the spinal column which were developed at the 
University of Louisville (Zhang et al., 2004, Cao et al., 2005, Onifer et al., 2005, Iannotti 
et al., 2006, Liu et al., 2007, Onifer et al., 2007). A dorsal laminectomy was performed at 
the T8-11 level to expose the spinal cord and bleeding was controlled. The body was 
immobilized with a horizontal brace gently secured over the middle of the back to 
prevent it from moving upward during the SCI.  Rats received either a 0.45 mm 
displacement injury between the 9th and 10th thoracic vertebra, inflicted via the Louisville 
Imapct System Aparatus (LISA) or sham laminectomy as previously published by our 
 145
center.  After the injury, displacements were recorded and compared to insure lesion 




During the week prior to baseline recordings mice were gentled and then 
acclimated to all devices.  Voluntary over ground locomotion was assessed by the Basso 
Mouse Scale for locomotion (BMS) as previously described (Basso et al., 2006).  The test 
was performed by two blinded scorers on day 3 and weeks 1 through 9 post surgery.    
 As is common following severe spinal cord injury, bladder function was lost in all 
injured animals for at least one day following injury.  Bladders were manually expressed 
twice daily and the volume of expelled urine recorded.  When expressing bladders, an 
experienced handler gave each mouse a bladder score determined by size and outflow.  A 
void bladder received a score of 0, small = 1, medium = 2, large = 3, and very large = 4.  
Scores were summed over 48 hrs to eliminate feeding variability. 
 
Tissue preparation 
After week nine assessment all mice were given a lethal dose of ketamine (180 
mg/kg) and xylazine (20 mg/kg) and then transcardially perfused with 5 ml of 4 ºC PBS 
followed by 20 ml 4 % PFA.  A 2 cm section of spinal cord containing the injury 
epicenter was removed and samples were post fixed for 3 hrs in 4 % PFA and transferred 
to 30 % sucrose for 3 days.   The spinal cords were then embedded in tissue freezing 
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medium and sliced transversly at 40 μM to create eight consecutive sets with sections in 
each set separated by 320 μm.   
 
Luxol fast blue staining 
To determine the area of spared white matter, one complete set of slides was 
stained with luxol fast blue for myelin as has been previously reported (Liu et al., 2006, 
Titsworth et al., 2007).  Briefly, sections were dehydrated through 95% ethanol and then 
submerged in Luxol Fast blue solution (0.1% luxol fast blue, 0.05% acetic acid, in 95% 
ethanol) at 65ºC for 2 hr.  Slides were then differentiated in 0.05% lithium carbonate 
solution and 70% ethanol.  Sections were dehydrated through graded ethanol, rinsed with 
xylene, and mounted. 
 
Cresyl Echt Violet-Eosin staining 
 A second set was stained as previously reported (Liu et al., 2006).  Briefly, 
sections were stained with 0.5% cresyl echt violet (Sigma, St. Louis) in 20% ethanol for 8 
min followed by eosin solution (25% eosin, 70% ethanol, 0.5% acetic acid) for 20 sec.  
Sections were then dehydrated, rinsed with xylene, and mounted.   
 
Immunofluorescence double labeling 
Immunofluorescence double labeling at the injury epicenter was performed on 
different tissue sets using previously described methodologies (Liu et al., 2004b). In 
brief, various combinations of antibodies were used (see Table 6). The paired antibody 
solutions were applied to the sections overnight at 4°C. The following day, sections were 
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incubated with fluorescein-conjugated goat anti–mouse (1:100; Jackson Immunoresearch, 
West Grove, PA) and Texas red-conjugated goat anti–rabbit (1:100; Jackson 
Immunoresearch) antibodies. Primary antibody omission controls and normal mouse, 
rabbit, and goat serum controls were used to further confirm the specificity of the 
immunofluorescence double labeling. Images were taken using a Nikon Eclipse 90i 
confocal microscopy (Nikon Instruments; Melville, NY). 
 
Table 6. Antibodies Used 
Antibody Clone Source Working Dilution Vendor/lot No. Reference 
anti-sPLA2-IIA Rabbit 1:100 Cayman Chemical (Moses et al., 2006) 
anti-SMI-31 Mouse 1:1000 Covance (Liu et al., 2006) 
anti-GFAP Rabbit 1:300 Sigma (Liu et al., 2006) 




 Three-dimensional (3-D) reconstruction and unbiased estimation of tissue 
volumes were calculated using the Cavalieri method (Michel and Cruz-Orive, 1988) on 
an Olympus BX60 microscope (Olympus America, Inc., Mellville, NY) equipped with a 
Neurolucida system (MicroBrightField, Colchester, VT).  Areas were calculated by 
drawing contours to define regions of interest on each section.  Individual subvolumes of 
spared tissue were calculated by multiplying the cross-sectional area A×d, where d 
represents the distance between sections (either 320 μm or 960 μm). The volume of total 
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of tissue was calculated by summing their individual subvolumes of each section 
measured.   
In luxol fast blue stained sections the area of spared white matter in each section 
was determined by subtracting the unstained region of each spinal cord section from the 
total spinal cord area.  The percentage of spared tissue was calculated by dividing the 
total volume of spared white matter in experimental animals to that on controls 
(Oorschot, 1994).  Similarly, the lesion volume was defined as the GFAP negative area 
within the lesion core.  The lesion epicenter for each animal was defined as the spinal 
section in each animal with the least amount of spared myelin or the greatest percentage 
of GFAP negative area.   
 
Stereology 
 Unbiased stereological counts were made using the probes in Stereo Investigator 
(MicroBrightField, Colchester, VT).  SMI-31 positive axons passing through the lesion 
epicenter were counted as well as oligodendrocytes and infiltrating nuclei within a 4 mm 
section of cord centered on the lesion epicenter (Table 7).  In brief, a systematic random 
sampling grid was overlaid on a traced spinal section yielding approximately 5 - 20 
sampling sites per section.  Next, profiles were counted within either an unbiased 
counting square or cube under 100× oil immersed optical magnification.  In the optical 
fractionator probe the height was 20 μm with at least a 5 % guard zone.  The resulting 




Table 7. Stereology Parameters 
Object of interest Stain Probe SRS grid (μm) Dissector (μm) 
Axons SMI-31 IF Fractionator 
Cnt = 305 x 274 
Exp = 195 x 162 
15 x 15 
15 x 15 
Oligodendrocytes Olig-1 IF 
Optical 
Fractionator 
Cnt = 325 x 330 
Exp = 226 x 195 
60 x 60 
95 x 95 
Inflilt. Nuclei Cresyl Eosin 
Optical 
Fractionator 
Cnt = 305 x 274 
Exp = 195 x 162 
60 x 60 
15 x 15 
 
Statistical Analysis 
One-way analysis of variance (ANOVA) with post hoc Tukey’s HSD was used to 
determine statistical significance of three or more groups. A multiple analysis of variance 
(MANOVA) with post hoc Tukey’s HSD was used to determine statistical significance of 
three or more groups when repeated measures were taken from each animal overtime or 
space.  A p < 0.05 was considered statistically significant.   
 
RESULTS 
Inhibition of sPLA2 Increases Behavioral Recovery Following SCI. 
Overgrown locomotion as assessed by the BMS showed a significant difference 
among experimental groups (MANOVA F4, 349 = 1769, p<0.0001) and over time 
(MANOVA F10, 349 = 113, p<0.0001; Fig. 20).  Post hoc analysis revealed that 129svj 
mice receiving a spinal cord injury (sPLA2-/-  SCI) did significantly better than their wild 
type counterparts BALB/c (Veh SCI) at week 5 (p<0.05), week 7 (p<0.001), week 8 
(p<0.001), and week 9 (p<0.05).  Similarly, inhibition of sPLA2 with S3319 in contused 
BALB/c mice resulted in significantly improved BMS scores over vehicle controls at 
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week 7 (p<0.05), week 8 (p<0.001), and week 9 (p<0.01).  At week 9 the BMS scores for 
sPLA2-/- and S3319 treated mice receiving a spinal cord injury was 2.58±0.51 and 
2.66±0.78 respectively, while among vehicle control mice receiving a spinal cord injury 
the week 9 score was 1.43±0.85.  Within the BMS a score of 1 given for slight ankle 
movement, a score of 2 correlates to extensive ankle movement, and a score of 3 
corresponds to plantar placing of the paw or dorsal stepping.  At week 9 all animals 
within the S3319 group scored were able to plantar place at least one paw except for one 
animal.  While only two animals in the vehicle treated control plantar place at least one 
paw.  Interestingly the sPLA2-/- mice were each able to place one paw, with the 
exception of one who could place both.  However, their stepping ability seemed relatively 
intact indicating that their low scores were more a function of severe scoliosis that 
developed in this group resulting in a defined foot preference.   
Bladder dysfunction has consistently been ranked as one of the top concerns 
among paraplegics and quadriplegics, usually of higher importance than the loss of 
locomotion (Benevento and Sipski, 2002, Anderson, 2004).  In this study bladder 
function following SCI also showed significant difference among experimental groups 
(MANOVA F4, 388 = 97.74, p<0.0001) and over time (MANOVA F15, 388 = 8.095, 
p<0.0001; Fig. 20).  Post hoc analysis revealed that contused 129svj (sPLA2-/- SCI) mice 
had a significantly lower bladder volume than untreated BALB/c mice expressing sPLA2-
IIA (Veh SCI), between days 3 (p<0.001) and day 25 (p<0.001).  Similarly, 
pharmacological inhibition of sPLA2 by S3319 resulted in significantly lower bladder 
volumes at days 19 (p<0.05) through 25 (p<0.001) when compared to vehicle control 
BALB/c mice receiving contusion.  Stated differently, the bladder volumes of contused 
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129svj (-/-) mice became statistically similar to sham animals at day 7 post injury 
(p>0.05).  With S3319 the bladder function returned on day 13.  However, bladder 
function in the vehicle controls did not mirror sham animals until day 31. This suggests 
that both the pharmacological and genetic manipulation of sPLA2 following severe SCI 
resulted in a return of bladder function between two and three weeks earlier than controls.  
Since this experiment utilized a thoracic lesion, far above the sacral micturition center 
(S2-4), any improvement suggests an increased signaling from the higher centers passing 






Figure 20. sPLA2 Inhibition Increases Functional Recovery Following Severe Spinal 
Cord Injury. 
In the top graph sPLA2 inhibition by i.p. injection with S3319 prior to injury results in 
significantly improved voluntary over ground locomotion at weeks 7, 8, and 9 (+ - +++).  
Similarly, a frame shift mutation in the sPLA2-IIA gene (sPLA2 -/-) results in statistically 
significant increases in locomotion at weeks 5, 7, 8, and 9 (* - ***).  The bottom graph 
shows the average voiding volume of urine.  Mice lacking the sPLA2 gene returned to 
baseline volumes on day 7.  Mice injected with S3319 returned to baseline by day 13.  
While vehicle control mice only returned to baseline on day 31. Graphs are presented as 
x ± SE.  Between comparisons of injured animals at a single time point, “+ or *” = 
p<0.05, “++ or **” = p<0.01, “+++ or ***” = p<0.001. 
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Inhibition of sPLA2 Increases Histological Recovery Following SCI. 
 To confirm the observed behavioral improvements have a histological correlate, 
mice were sacrificed and tissue was sectioned.  First luxol fast blue and cresyl eosin 
staining was performed as a general measure of white matter sparing and inflammation 
respectively.  At 9 weeks post injury, significant differences existed among groups with 
respect to total volume of shared myelin within an 16 mm section of cord centering on 
the epicenter (Fig. 21 top right; ANOVA F4, 35 = 91.44, p<0.0001).  Both the 129svj mice 
lacking sPLA2 expression (sPLA2-/- SCI; p<0.001) and the S3319 treated BALB/c mice 
(S3319 SCI; p<0.05) showed significantly more spared myelinated tissue than the vehicle 
treated BALB/c mice.  Furthermore the area of spared myelin was calculated at each 0.96 
mm interval rostral and caudal from the lesion (Fig. 21 bottom right).  Again this showed 
significant differences among the injury groups (MANOVA F4, 595 = 488.7, p<0.0001) 
and among distances from epicenter (MANOVA F16, 595 = 116.8, p<0.0001).  Post hoc 
analysis revealed that 129svj mice (sPLA2-/- SCI) were significantly different from 
vehicle treated BALB/c mice (Veh SCI) at all points rostral (varying significance from 
p<0.001 to p<0.05) and at -0.96 mm caudal (p<0.001) and -1.92 mm caudal (p<0.01) to 
the lesion epicenter.  In contrast differences in the sparing of myelinated tissue was only 
seen between S3319 treated BALB/c mice (S3319 SCI) and vehicle treated controls (Veh 
SCI) at 1.92 mm (p<0.05) and 0.96 mm (p<0.001) rostral to the injury epicenter. Sparing 
of white matter rostral to the lesion epicenter has also been seen in other treatments for 
spinal cord injury such as bFGF (Rabchevsky et al., 1999, Rabchevsky et al., 2000) and 
implantation of FGF2 secreting cells (Zai et al., 2005).   
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 Interesting pronounced demyelination was noted to extend rostrally much further 
in the dorsal columns of the untreated animals (Fig. 21 graph bottom right). Pictured is 
demyelination of the dorsal column 10 mm rostral to the lesion epicenter (Fig. 21 arrow 
in right composite).  Similarly differences in white matter sparing were observed in 
various mice strains following SCI and was attributed to longer lesion extension observed 
in the dorsal columns (Kigerl et al., 2006).   Not surprisingly the areas of demyelination 
correlated strongly with those areas expressing increased sPLA2-IIA at 9 weeks (Fig. 22). 






Figure 21. sPLA2 Inhibition Increases Myelin Sparing 
A composite (A) of a representative animal from each group showing consecutive luxol 
fast blue stained sections at epicenter and various distances rostral to the epicenter.  Note 
the greater spared myelin in the S3319 treated and sPLA2-/- mice as compared to the 
vehicle control with SCI.  Note that demyelination of the dorsal columns extends rostrally 
at least 10mm (arrow). Quantification of the total volume of spared white matter (B) in a 
16 mm section of spinal cord centering on the epicenter and a graph of the subvolumes 
(C) confirm the observed demyelination.  Note the decreased sparing of white matter 
present in the rostral but not the caudal direction.  sPLA2-/- mice show significant white 
matter sparing at all points rostral to the epicenter measured (C; +) while mice injected 
with S3319 only show increased sparing at 0.96 mm and 1.92 mm rostral to the epicenter 
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Figure 22.  sPLA2-IIA Immunoreactivity Co-localizes with Demyelinated Tissue 
Sections from different tissue sets stained for either sPLA2-IIA immunoreactivity (A & 
D) or luxol fast blue stain for myelin (B & E).  Images are from two different S3319 
animals either 1.6 mm rostral (A-C) or 1.28 mm rostral (D-F) to the lesion epicenter. 
Note that in D-F the three distinct areas of demyelination in the dorsal columns and both 
lateral funiculi correlated with that of demyelination with very little immunoreactivity in 
the dorsal horns.   
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Following spinal cord injury there is a migration of millions of small infiltrating 
cells into the lesion area that are easily seen in CE stained sections.  The infiltration of 
inflammatory cells whose nuclei is dark blue corresponds nicely with the areas of 
demyelination seen in luxol fast blue stained sections (Compare Fig 21A & Fig 23A).  
Also similar to a LFB stained section, increased inflammation is again seen in the dorsal 
columns rostral to the lesion epicenter (arrow in Fig 23A & B).  Stereological 
quantification of these cell’s nuclei allow for a rough approximation of how different 
conditions affect inflammation.  At 9 weeks post injury, significant differences existed 
among groups with respect to number of infiltrating nuclei within a 4 mm section of 
spinal cord centering on the epicenter (Fig. 23C; ANOVA F4, 25 = 137.8, p<0.0001).  
There was virtually no infiltrating nuclei seen in either of the sham conditions however 
1.25x106 ± 203,000 cells were counted in the vehicle control mice while only 0.82x106 ± 
157,000 cells (S3319; p<0.001) and 0.93x106 ± 70,000 cells (sPLA2-/-; p<0.001)  were 
seen in the treated conditions.  This signifies a 34% and 25% decrease inflammation in 
the S3319 and sPLA2-/- groups respectively.  Suggesting that as was seen in other in vivo 








 Figure 23. sPLA2 Inhibition Results in Decreased Inflammation Following SCI 
A composite (A) of the same representative animal from each group that is shown in Fig. 
21, showing sections at epicenter and various distances rostral to the epicenter stained 
with cresyl eosin stain.  Note the decreased infiltration of infiltrating cells in the S3319 
and sPLA2-/- mice as compared to the vehicle control with SCI.  Note that similar to the 
demyelination, inflammation extends 10 mm rostrally in the dorsal columns of the 
vehicle control animal (arrow).  3-D reconstructions (B) of the same cords in A.  
Quantification of the infiltrating cell nuclei (C) in the spinal cord centering on the 
epicenter shows that inhibition of sPLA2 results in decreased infiltration of small 





 To measure the volume of a lesion we used GFAP stained sections and measured 
the area within the reactive glial border which was the spinal cord lesion epicenter.  The 
GFAP- lesion area was quantified at 320 µm intervals as a percentage of total spinal cord 
area.  Again, there was significant differences existed among groups (Fig. 25A-C & J; 
MANOVA F2, 273 = 43.09, p<0.0001) and with respect to distance from the lesion 
epicenter (MANOVA F12, 273 = 86.37, p<0.0001).  Mice lacking sPLA2-IIA expression 
showed significantly smaller lesions at 1.28 mm (p<0.001), 0.96 mm (p<0.001), 0.64 mm 
(p<0.001), 0.32 mm rostral (p<0.001) and at 0.32 mm caudal (p<0.05) to the lesion.  
Similarly, pharmacological inhibition of sPLA2-IIA by S3319 resulted in significant 
sparing rostral to lesion at 1.28 mm (p<0.001) and 0.96 mm (p<0.001).  It is interesting to 
note that once again there appears to be a preferential sparing of tissue rostral but not 
caudal to the lesion epicenter.  Quantification and analysis of tissue area showing 
astrogliosis yielded virtually identical significance.   
However the decrease in lesion size and white matter sparing is superfluous in a 
thoracic lesion if the number axons traversing the lesion epicenter is unaltered.  
Therefore, the number of axons found in the lesion epicenter was quantified using 
unbiased stereology with a fractionator probe revealing a significant difference among 
injury groups at 9 wks post injury (Fig. 25G-I & K; ANOVA F2,15=6.198, p<0.01).  
Almost double the number of axon profiles were counted at the lesion epicenter in both 
Balb/c mice treated with the sPLA2 inhibitor S3319 ( x = 11,285 ± 2880) and 129svj mice 
lacking sPLA2-IIA expression (sPLA2 -/- SCI; x = 11,450 ± 3817) when compared to 
vehicle controls receiving spinal cord injury ( x = 6,206 ± 1713) (p<0.05).  However 
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neither of the treated animals achieved 10% of axon counts in the uninjured control 






Figure 24.  sPLA2 Effect on Glial Lesion and Axons Within the Epicenter 
A-C) Low power images taken from 960 μm rostral from the lesion epicenter showing 
decrease in lesion size after sPLA2 inhibition.  D-F) low power images of the lesion 
epicenter showing no difference in lesion size.  White boxes indicate areas from which 
the high power images G-L were taken.  Images G-I show double labeling of GFAP (red) 
and SMI-31 (green) at the lesion epicenter.  J-L) Single labeled images showing an 
increase in SMI-31 labeled axons in both the S3319 group (K) and the sPLA2-/- animals 
(L).  M) Quantification of GFAP negative lesion area over a 4 mm section centered on 
the epicenter.  Note the significantly smaller lesion size between sPLA2-/- mice at 1.28 
mm, 0.96 mm, 0.64 mm, and 0.32 mm rostral as well as 0.32 mm caudal to the lesion.  
Similarly, mice injected with S3319 show smaller lesion size rostral to lesion at 1.28 mm 
and 0.96 mm.  N) Quantification of the axon profiles at the lesion epicenter revealed 
almost twice as many spared axons at the lesion epicenter in both treated condition than 
in the vehicle control (p < 0.05).  Scale bar = 300 mm A-B;  200 mm C-D;  50 mm E-H.   
p<0.05 *, p<0.001 *** 
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Since there seemed to is preservation of Luxol fast blue staining in the rostral 
dorsal columns in both the S3319 treated and 129svj mice (arrow in Fig. 21), we next 
need to determine if axons were present in these areas.  Three consecutive sections, 8 mm 
rostral to the lesion epicenter, were stained in each animal.  The first was LFB strained 
for myelin (Fig. 25 A-C), the second was CE stained (Fig. 25 D-F), and the third was 
GFAP/SMI-31/Hoechst triple labeling (Fig. 25 G-U).  First, this comparison revealed that 
the lesion area took up less of the dorsal column in both the S3319 and 129svj groups.  
Secondly, axons were present both the S3319 treated and 129svj animals (Fig. 25 Q, R, 
T, & U), when the lesion was defined as the area with increased gliosis.  Suggesting that 
treatment with S3319 resulted in at least partial sparing of both white matter and axons 
rostral to the lesion epicenter.  However, the LFB sapring appeared to be much greater, 
suggesting that some axons were lost while their myelin sheaths were spared.  An 
alternative hypothesis that has been proposed by some authors is that all axons were 












Figure 25. Dorsal Column Injury 
A-F are from different sections stained with luxol fast blue (A-C) and crestyl eosin (D-F).  
G-R are triple immuno-labeled with anti-SMI-31 (green), anti-GFAP (red), and hoechst 
(blue),  All sections are from 8 mm rostral to injury epicenter.  Scale bar in R = 100 μm.   
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 In previous work we noted that injections of sPLA2 at the grey and white matter 
interface had a greater impact on white matter injury.  Additionally, we showed that 
inhibition of sPLA2 by S3319 was able to partially protect differentiated oligodendrocyte 
precursor cells in vitro in two injury models.  Therefore we first used 
immunohistochemistry to confirm that sPLA2-IIA was in fact present in oligodendrocytes 
(Fig. 26A-C).  We next used unbiased stereological measurement to count the number of 
spared oligodendrocytes within a 2 mm section of spinal cord centering on the lesion 
center.  Since Olig1+ stains the entire cell body sections were counter stained with 
Hoechst to prevent over counting.  There was a significant difference in the number of 
oligodendrocytes at 9 weeks post injury (ANOVA F2,15=17.67, p<0.0001; Fig. 26D).  
Post hoc analysis revealed that among the injured animals, S3319 ( x = 14,200 ± 3,536) 
and sPLA2-/- ( x = 24,200 ± 7,181) animals had a significantly higher number of Olig1+ 
oligodendrocytes than vehicle controls ( x = 6,360 ± 4,179).  This suggests that as was 
seen in vitro, inhibition of sPLA2 could result in partial sparing of oligodendrocytes 
following injury.  However, it remains to be seen if this results from prevention of 
apoptosis or rather a decrease in inflammation resulting in a more permissive 





Figure 26.  sPLA2 Inhibition Increases Oligodendrocytes Numbers Following SCI. 
A-C) Confocal images showing oligodendrocytes (A; Olig1+) co localized with sPLA2-
IIA (B) in the ventral white matter.  D) Mice with decreased sPLA2 activity either by 
S3319 inhibition or by a frame shift mutation (sPLA2-/-) have significantly more Olig1+ 
oligodendrocytes within a 4 mm section of cord centering on the epicenter at 9 weeks 
post injury.   
 171
Finally, the week 9 BMS scores and the date of voluntary bladder control were 
collected for each animal and normalized.  Then the normalized scores were averaged to 
produce an average behavior score for each animal at week 9.  Then each histological 
outcome measured in this study was compared to the behavior score to insure that there 
were no outliers or non-responders, to confirm the precision of the injury device, and to 
assess the amount of correlation between the outcomes and behavioral improvement.  
The presence of SMI-31 positive axons at the lesion epicenter (r(23) = 0.87, p<0.0001), 
the amount of spared white matter (LFB; r(23) = 0.95, p<0.0001), the number of Olig1+ 
oligodendrocytes (r(22) = 0.90, p<0.0001) all correlated highly with behavioral outcomes 
at nine weeks.  Accordingly the size of the GFAP negative lesion area showed a similarly 
strong negative correlation with behavioral function at 9 weeks (r(23) = -0.90, p<0.0001).  
Since the inclusion of normal controls in Pearson product moment correlation can 
artificially inflate significance the analysis was repeated with non-injured animals 
removed and again each histological outcome highly correlated with behavioral outcomes 
at nine weeks (SMI-31, r(16) = 0.70, p<0.01; LFB, r(16) = 0.87, p<0.0001; Olig1+, r(16) 
= 0.72, p<0.01; GFAP, r(16) = -0.75, p<0.001).  While all measures demonstrated a high 
significance the amount of spared myelin showed the highest level of correlation with 
behavior function at 9 weeks.  Additionally, despite the high severity of the injury, which 
most likely muted recovery, the high correlations testify to the precision of both the 









Figure 27.  Comparison of Histological Outcomes to Behavioral Function 
Each of the histological measures used in this study showed a high level of correlation 
with the behavioral outcomes at nine weeks.  Histological measures are reported as the 
average normalized percentage.  A) Normalized volume of spared white matter in an 8 
mm segment of cord.  B) shows the normalized volume of GFAP negative lesion within a 
4 mm segment.  C) Normalized number of SMI-31+ axons at the lesion epicenter.  D) An 
enlargement of the dotted box in C that truncates the graph to remove non-injured 
animals presenting a more accurate representation.  E) Number of Olig1+ 
oligodendrocytes in a 4 mm segment of cord.  Note the relatively tight correlation present 
in each graph.  Note only 6 animals are shown for the S3319 group because the two 
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Previously we have shown that sPLA2-IIA and IIE are increased following SCI 
and that direct injection of nanogram doses of sPLA2 results in demyelination and loss of 
oligodendrocytes within the white matter.  However, a gain of function had yet to be 
demonstrated following the inhibition of sPLA2.  In this study we were the first to show 
that inhibition of sPLA2-IIA prior to severe neurotrauma results in moderate but 
significant sparing of behavioral function and histology.  Inhibition resulted in 
significantly improved overground locomotion after pharmacological inhibition by the 
small molecule S3319.  Additionally, those mice with muted sPLA2 activity showed on 
onset of a neurogenic bladder 2-4 weeks before vehicle control mice although it is 
unclear if this result is due to systemic effect of sPLA2 inhibition.  
The most important finding of this study was the significant functional recovery 
observed after S3319 inhibition.  Moreover this recovery correlated highly with tissue 
sparing.  Upon histological examination, significant differences were found in white 
matter sparing rostral to the lesion, increased sparing of axons at the lesion epicenter, 
decreased size of lesion volume, and increased number of spared oligodendrocytes within 
the lesion.  The high correlation between behavioral and histological measures served 
two purposes.  First it supports the behavioral observations by external validation and 
secondly it suggests that the mechanism of functional recovery might be through either 
direct neuroprotection or tissue repair.  Two factors point to the possibility that S3319 
might facilitate regeneration.  First, the severe spinal cord injury model used in this 
experiment would lead one to believe that most axons were destroyed by mechanical 
trauma and therefore these axons would not be candidates for neuroprotection.  However, 
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S3319 treatment resulted in a doubling of axon profiles within the lesion epicenter.  This 
is exciting since many other authors have found that only modest improvements in axons 
passing through the lesion can result in significant motor gains.  The circuitous nature of 
these axons and the relative distribution of these fibers throughout the entire spinal cord 
suggest regenerating fibers.  Secondly, the gradual increase of function over 9 weeks and 
the lack of any significant gains until weeks 7 through 9 suggests a regenerating process 
rather than a neuroprotection which would show a dramatic increase following recovery 
from spinal shock and a leveling off of gains after week 3.  However, treatment with 
S3319 could have protected only a ring of spared axons along the ventral periphery of the 
spinal cord.  More conclusive methods such as axonal tracing following contusion would 
be required to determine if the observed recovery is from regeneration or 
neuroprotection.  See Chapter V for a more rigorous discussion of regeration.  
One limitation of the current study is that we pretreated the animals with S3319.  
In the present study we utilized pretreatment with S3319 rather than post treatment to 
seek a “proof of principle” for sPLA2 inhibition in SCI.  Further studies will be conducted 
to test its efficacy and optimal time window for post-injury treatment.  Our work does 
indicate a possible window of efficacy though.  In the initial studies of sPLA2 expression 
(See study #1; chapter 2), rats showed peak expression at 4 hr post injury with levels 
returning to baseline at 1 week.  While this allows a short window of efficacy, this is not 
beyond the realm of current clinical protocols.  For example, the standard protocol in 
most certified stroke centers for patients with ischemic stroke is reperfusion within 3 hr 
of onset with intravenous recombinant tissue plasminogen activator (TPA; alteplase), 0.9 
mg/kg over 1hr which has been shown to reduce death and dependency (odds ratio 0.64, 
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95%CI 0.5-0.8) (Hankey, 2007b, Hankey, 2007a).  In contrast, sPLA2-IIA levels, which 
peak at 4 hrs, do not return to baseline levels until one week after injury, suggesting an 
even longer window of opportunity if inhibition of this enzyme is deemed effective.  One 
possible merit of S3319 in a clinical setting is its oral activity, suggesting that the average 
time to treatment initiation could be shortened even more than TPA drugs which require 
intravenous administration by a specialist in a controlled setting. 
Whether S3319 penetrates into the CNS in sufficient quantities to decrease sPLA2 
activity still remains an important control to perform.  However, it is likely that S3319 
will be present in sufficient doses.  First, S3319 has been shown to be an extremely 
potent inhibitor of recombinant human sPLA2-IIA with an IC50 = 0.029 μm (Hansford et 
al., 2003).  Additionally S3319 has been shown to be orally active and efficacious in the 
treatment of reperfusion injuries in vivo (Arumugam et al., 2003).  Finally, the small 
molecular weight (487.63) and extreme lipophilic nature of S3319 should facilitate its 
passage across the blood brain barrier.  However, what remains to be conclusively proven 
is whether the given dose in this study results in decreased sPLA2 activity within the 
injury site following SCI.  This can be achieved by assessing the sPLA2 activity present 
in homogenized spinal tissues by a chromatic assay similar to that which was used in our 
lab to assess total PLA2 activity (Liu et al., 2006).  The study in question is currently 
underway.   
An alternate explanation for the effects of S3319 in these animals is an inhibition 
of systemic inflammation rather than as a centrally acting agent.  For example, the delay 
in initiation of neurogenic bladders in the injured animals treated with vehicle could be 
explained by increased inflammation within the bladders.  Bladder inflammation 
 177
following SCI is common secondary to infections due to loss of bladder function.  In a 
study of human SCI patients, bladder biopsies revealed that 91.5% of patients had 
inflammation of the bladder wall with 67% showing chronic inflammation hallmarks 
(Janzen et al., 2001).  This inflammation could then prevent bladder emptying or inhibit 
the bladder emptying reflex thus resulting in larger voiding volumes when bladders are 
emptied in comparison to the S3319 treated animals.  Muting of systemic inflammation 
could possible explain the BMS scores as well, in that animals treated with S3319 could 
have lower inflammation of the extremities and thus more movement following SCI.  
This explanation is less likely since no evidence has been found that SCI increases joint 
inflammation of the extremities in either humans or animals.  While osteopenia and 
osteoporosis are common problems in SCI (Jiang et al., 2006, Maimoun et al., 2006) 
there is no reason to assume that S3319 would of altered bone densities of calcium 
handling in the body.  A possible method for excluding these possibilities would be to 
only administer S3319 through an intrathecal pump thus limiting its systemic effects. 
   The beneficial effects of sPLA2-/- data come with one major caveat.  During the 
initial characterization of the Basso Mouse Scale, it was noted that different strains of 
mice performed significantly better following a standard contusion.  Interestingly, in their 
original study 3 of the 4 sPLA2 -/- mice strains scored significantly better than the only 
sPLA2 +/+ strain (Basso et al., 2006).  However, the fact that differing strains 
demonstrated various recoveries following moderate SCI suggests that the differences 
observed in this study could be due to the sPLA2 gene or any other genetic difference 
between the two strains of mice used.  While the data presented here does support our 
hypothesis it does not conclusively demonstrates a role for sPLA2-IIA in spinal cord 
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injury.  Therefore future studies should use solid genetic techniques to conclusively 
determine whether sPLA2-IIA is specifically responsible for the observed effects.    
 Another question that was beyond the scope of this study was the mechanisms 
behind the functional gains associated with sPLA2-IIA inhibition.  It is currently 
unknown whether the gain of function resulted from the prevention of direct cytotoxicity 
on cells such as oligodendrocytes, a more general suppression of the immune response, or 
from a facilitation of axonal sprouting through the lesion epicenter.  These questions will 
remain for future studies and must be at least partially addressed in an immunosuppressed 
mouse model.  None the less, the use of a sPLA2 inhibitor did result in at least partial 








Review of Findings 
This research began with a simple question posed to me. “What is the brain made 
of?”  Fat is the answer.  The CNS is roughly 60% fat and has a disproportionately high 
concentration of lipids compared to other tissues of the body and 44% of those lipids are 
phospholipids (Morell, 1984).  Therefore any destruction of the CNS would require in 
part the destruction of lipids in general and phospholipids in particular.  Many 
experiments have proven this to be true.  Following severe SCI biphasic increases in free 
fatty acid levels is seen, with levels peaking at 15 min and 24 hr post-trauma before 
declining over the next 6 days (Demediuk et al., 1989).  Even within the first few minutes 
after SCI, free fatty acids have increased in the grey matter and later increase within the 
white matter (Demediuk et al., 1985, Faden et al., 1987, Demediuk et al., 1989).  These 
findings suggested that acute PLA2 activity may be present following SCI.   
Aside from the obvious effects of phospholipases activity on membrane 
breakdown, PLA2 presents a tantalizing therapeutic target since its metabolites are also 
neurotoxins.  PLA2 hydrolyze the ester bond at the sn-2 position of membrane 
phospholipids producing a free fatty acid, such as arachidonic acid (AA), and a lyso-
phospholipid, such as lysolechithin (a.k.a. lysophosphatidyl choline, L-PC).  AA has been 
shown to damage cultured oligodendrocytes and neurons (Wang et al., 2004)  and LPC 
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can induce demyelination of the CNS and PNS (Blakemore et al., 1977) and act as a 
macrophage chemoattractant (Lauber et al., 2003).  Therefore, our lab investigated the 
role of phospholipases A2 following SCI.  First the total phospholipase activity was 
shown to increase following SCI and peak at four hours post injury.  It was next 
determined that the well know cytosolic PLA2 (cPLA2) increased following SCI but 
cPLA2 protein expression did not peak until 7 days post injury, well after total PLA2 
activity crested.  This paradox led us to believe that another PLA2 isozyme was most 
likely responsible for the majority of phospholipase A2 activity seen following injury.  
Therefore we began to investigate the sPLA2 subfamily of enzymes. 
We first showed that sPLA2 mRNAs and proteins were present in the mammalian 
nervous system and increased following neurotrauma and cytotoxic injury.  While others 
have demonstrated the presence of selected sPLA2 mRNAs in the brain (Molloy et al., 
1998, Kolko et al., 2005, Kolko et al., 2006) our study was the first demonstration that 
several sPLA2 isoforms are present in oligodendrocytes at low levels in the naïve 
mammalian spinal cord.  Additionally, this was the first study to identify increases in 
sPLA2 protein synthesis and expression following neurotrauma.  Interestingly, only group 
II mRNA and protein levels show an increase following SCI.  Most importantly, sPLA2-
IIA protein peaked at 4 hr post injury in conjunction with the peak of total phospholipase 
activity suggesting that it might be the phospholipases responsible for a majority of 
activity increase following neurotrauma.  Similarly, the induction of sPLA2 synthesis 
following nervous system injury was confirmed in vitro.  We showed that cultured spinal 
oligodendrocytes increase sPLA2-IIA expression when challenged with proinflammatory 
molecules present in spinal cord injury such as TNFα and IL-1β or H2O2. While other 
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authors have shown an increase in AA production following H2O2 injury in other cell 
lines (Han et al., 2003), this was the first study to directly link free radical injury to 
sPLA2-IIA production.  Other authors had already confirmed that sPLA2-IIA present in 
μM levels could trigger apoptosis in cultured neurons (Yagami et al., 2002b) and we 
showed that exogenously adding sPLA2 triggered a loss of oligodendrocyte process 
extensions at low doses and death at μM levels as well.  Most importantly, 
pharmacological inhibition of sPLA2 appears to partially ameliorate oligodendrocyte 
death following challenge with TNFα and IL-1β or H2O2 suggesting a critical role for 
sPLA2 in the convergence of injurious signals. 
After confirming the upregulation of sPLA2 following SCI and cell culture, we 
next determined that increases in sPLA2 resulted in a loss of function.  To this end we 
showed that direct injections of nanogram doses of sPLA2 into the naïve spinal cord 
resulted in extensive demyelination, axonopathy, oligodendrocyte death, and immune cell 
infiltration. Not surprisingly the tissue damage correlated with a behavioral loss of 
function in both the pellet reaching behavior and footprint analysis.  Interestingly, the 
observed damage remained predominantly within the white matter when injected at the 
grey and white matter intersection.  This led us to believe that blockade of sPLA2 
following SCI could partially ameliorate the spreading white matter degeneration 
observed with secondary spinal cord degeneration. 
 Finally, we needed to determine if inhibition of sPLA2 in conjunction with SCI 
resulted in an observable gain of function.  While sPLA2 inhibition had shown 
neuroprotective effects following a stroke model in rodents (Adibhatla et al., 2006), this 
was the first study to demonstrate its efficacy following neurotrauma in general and the 
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first demonstration of  S3319’s efficacy in the CNS.  In our final set of studies, we 
showed that pharmacological inhibition of sPLA2 decreased inflammation and GFAP 
negative lesion cavity, as well as increased white matter sparing, oligodendrocyte 
survival, and axons coursing through the lesion epicenter.  Additionally, we showed that 
inhibition of sPLA2 resulted in a very small but statistically significant gain of function in 
voluntary over ground locomotion and an increase in bladder voiding volumes 2 – 4 
weeks earlier than controls.   
Another interesting observation is the apparent specificity of sPLA2’s action in 
the CNS to post mitotic cells.  Previous work by other authors demonstrated sPLA2-IIA 
expression in neurons and its ability to trigger apoptosis in the μM range (Yagami et al., 
2002b).  In study #1 (chapter 2) we demonstrated that oligodendrocytes express sPLA2-
IIA when injured and that it can induce cytotoxicity at levels identical to those seen in 
other studies utilizing neurons.  Interestingly, astrocytes and Schwann cells show no 
increase in LDH or decrease in MTT production following injury with 2 μM of sPLA2-
IIA.  This indicates that inhibition of sPLA2 following injury could be specific to neurons 
and oligodendrocytes and could explain why lesioning of the spinal cord with injections 
of sPLA2 results in a death of oligodendrocytes but a gliosis and remyelination with 
Schwann cells (see study #2; chapter 3).  Within study #3 (chapter 4), this idea is 
supported by the increased number of oligodendrocytes and axon profiles seen after 
S3319 treatment.  However exact quantification of neurons within the lesion needs to be 
performed.    
 
Limitations of Current Findings 
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The first study simply designed and executed; however some comments must be 
made about the specificity of our sPLA2-IIA inhibitor, S3319.  S3319 was specifically 
developed as a highly potent inhibitor of sPLA2-IIA.  This was done by designing a 
theoretical back bone that would intercalate into the group IIA enzymatic site.  Then the 
side chain structures were varied to empirically determine the compound with the highest 
affinity and lowest Kd.  In the orinal publication detailing this molecule it was stated that 
a 2.2Å crystal structure of the resulting structure shows … 
“… an inhibitor that is bound in the active site of the enzyme, 
chelated to a Ca2+ ion through coarboxylate and amide oxygen 
atoms, H-bonded through an amide NH group to His48, with 
multiple hydrophobic contacts, and a T-shaped aromatic – His6 
interaction.” (Hansford et al., 2003) 
While the highly specified binding site and 3-D structure analysis suggest a 
selective inhibition of IIA over other sPLA2s, S3319’s activity against other isoforms has 
not been directly assessed.  In general the use of pharmacological agents in studies 
introduces the possibility that said agent can have unintended activities on other 
molecules, often times wholly unrelated to the target of inhibition.  Consequently these 
unintended interactions are the result of the observed effects.  However, the high potency 
of S3319, low concentrations used, and its unique development suggest that the observed 
effects were from sPLA2-IIA inhibition.  However, future studies should confirm the 
above observations either through knock down or knock out studies such as was shown 
by Han et al., (2003).  
 184
In the second study, sPLA2-III was used to assess the effects of sPLA2 activity on 
the naïve central nervous system.  sPLA2-III extracted from bee venom and was selected 
because its enzymatic activity is well characterised and quantified and therefore could be 
used to reproduce the total phospholipase activity that was calculated in earlier studies 
(Liu et al., 2006).  However, in the first study one can note that sPLA2-III was not found 
in the rat CNS and to date a mammalian group III has only been confirmed in humans 
(Valentin et al., 2000a).  Interestingly both human group III (Masuda et al., 2008) and 
group X sPLA2 (Ikeno et al., 2005) have been shown to increase neurite outgrowth in 
cultured PC12 cells at very low doses.  These finds further complicate the generalizability 
of sPLA2 inhibition following SCI, especially if S3319 or any other sPLA2 inhibitor is 
found to have non-specific inhibition.  However, the fact that histological changes were 
seen in the third study following S3319 treatment in SCI suggests that either the drug is 
specific for sPLA2-IIA or that the detrimental effects of IIA outweigh the neurogenic 
properties of groups III and X.  None the less it will be crucial to evaluate the specificity 
of an inhibitor on sPLA2 isoforms before studies are performed in higher animals.  The 
cross inhibition of various inhibitors could help to explain the mixed success of previous 
sPLA2-IIA inhibitors in clinical trials (Reid, 2005).   
In the third study there are several matters of extreme concern that limit the 
inclusion of any of the 129svj (sPLA2-/-) mice in future publications resulting from this 
work.  First any comparison of sPLA2-/- mice to those possessing the sPLA2-IIA gene 
must be called into question because no proper control was included for the sPLA2-/- 
mice.  Therefore any differences observed between the SCI groups could be attributable 
to either sPLA2-IIA or any of the thousands of other genetic variations between these 
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species.  Secondly, due to the poor design of this experiment, we elected not confirm the 
absence of sPLA2-IIA activity or expression of the truncated protein and absence of the 
full length protein in these animals.   
In a broader sense the lack of any developmental defects in 129svj mice suggests 
that sPLA2-IIA may not play a crucial role in the CNS.  However, I would argue that this 
is not true.  If, as we suggest here, that sPLA2-IIA is primarily an initiator and/or 
propagator of inflammation, than one would expect to see few defects in a normally 
reared animal without pathology.  To this end, I feel that any constitutive KO animal is a 
poor model for SCI investigation.  It makes little since to deprive an animal of a gene for 
its entire development when one is interest in an acute event such as SCI or stroke.  
Following injury if a difference is detected it is unclear whether this observation is due to 
loss of function during the time of injury (and therefore a suitable therapeutic target) or 
rather a result of altered development (and of less utility).  In my opinion it is of greater 
value to utilize one of the inducible KO systems such as utilizing doxycycline in a “Tet-
Off” system to inhibit sPLA2-IIA expression just prior to SCI (Kistner et al., 1996).  
Unfortunately this strain has yet to be developed. 
In any paper showing functional improvements the likelihood of regeneration 
should be rigorously addressed.  An article by Steward, Zheng, and Tessier-Lavigne 
(2003) laid out criteria for distinguishing regenerated axons from spared axons in the 
central nervous system.  They are as follows; 
(I) The axon extends from the CNS into a non-CNS environment, 
specifically, the tissue environment of the scar that develops at the 
injury site. 
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(II) The axon extends from the host CNS into a nonhost graft or 
transplant. 
(III) The axon originates at or near a site of amputation. 
(IV) The axon takes an unusual course through the tissue 
environment of the CNS. 
(V) The axon extends no further than could be accounted for by 
plausible regeneration rates. 
(VI) The axon is tipped with a growth cone. 
(VII) The axon has a morphology that is not characteristic of 
normal axons of its type (for example exhibiting unusual branching 
patterns).  (Steward et al., 2003) 
Since axons were seen evenly spaced throughout the lesion epicenter, GFAP- 
core, and axons are present in what should be both grey and white mater criteria I and IV 
are met suggesting regeneration.  Secondly, since histological samples were not made 
until 9 weeks post injury and since behavioral recovery was not seen until weeks 7 - 9, it 
can be assumed that if regeneration occurred and it is playing a role in any observed 
functional increases, it did so at plausible growth rate (criteria V).  However, since the 
injury model was a contusion and not hemisection and no graft tissue was placed in the 
lesion site, criteria II and III are irrelevant.  Finally, the presence of growth cones and the 
branching patterns were not investigated due to the age of the lesion and that no tracing 
was performed in this study leaving criteria VI and VII unknown.  Taken in total 
increased regeneration could have happened in the S3319 treated animals, but there is 
simply insufficient evidence to suggest that it occurred based on the data presented here. 
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Application of Findings to Future sPLA2 Research: 
It must be noted that sPLA2 does not function as a phospholipase in isolation.  
Rather than focusing on sPLA2 in CNS injury, current literature has focused on role of 
cPLA2 in ischemia/stroke (Bonventre et al., 1997, Saluja et al., 1997, Arai et al., 2001, 
Tabuchi et al., 2003), multiple sclerosis, and  the mouse correlate experimental 
autoimmune encephalomyelitis (Kalyvas and David, 2004, Marusic et al., 2005).  
However, there appears to be a reciprocal accentuation of activity among the PLA2s 
(Murakami et al., 1998, Han et al., 2003).  This suggests that inhibition of sPLA2, cPLA2, 
and possibly even iPLA2 in unison could result in a synergistic increase in neurological 
sparing which merits further study.  Additionally, variations in the biological functions 
and species specificities of various sPLA2 isoforms complicate the issue further 
(Cupillard et al., 1999, Kudo and Murakami, 2002).    
For example, the rabbit sPLA2-R is very promiscuous, binding to almost all 
sPLA2 tested to date.  The mouse sPLA2-R on the other hand binds only IB, IIA, and X, 
while the rat sPLA2-R only binds sPLA2-IB (Cupillard et al., 1999).  Likewise sPLA2-IIA 
does not seem to bind to the sPLA2-R in humans (Cupillard et al., 1999).  What seems to 
be important is that within each species at least one isoform of sPLA2 plays an important 
role in inflammation.  In mice that lack sPLA2-IIA activity, sPLA2-V takes it place in the 
propagation of the immune response to infection (Kudo and Murakami, 2002).  However, 
any further work in SCI would need cautious experimentation up the phylogenetic tree 
before experiments in humans could be initiated.   
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Unpublished work from our lab has confirmed that sPLA2-IIA is at least present 
in the human CNS after SCI.  However, any findings found in sub-human species will 
need to be interpreted conservatively when applied to preclinical research.   
 
Future Directions 
sPLA2, particularly group IIA, shows promise as a therapeutic target.  It has been 
strongly associated with many types of inflammation and disease states in various 
species(Kudo and Murakami, 2002).  These studies indicate that sPLA2-IIA might play a 
role in SCI and that its inhibition could result in some histological and functional sparing.  
However work still remains in unlocking the mechanism of action and pushing sPLA2 
inhibition from the bench to the bedside.   
First sPLA2-IIA action needs to be confirmed by genetic manipulation with a 
controllable down regulation.  This will involve not only measuring the expression of 
sPLA2-IIA protein but the enzymatic function of sPLA2 following knock down.  The 
latter experiment will aid in determining group IIA’s role in total sPLA2 and total PLA2 
activity.  Secondly, this will remove any ambiguity that results from use of a 
pharmacological agent and its possible actions on other PLA2s or unrelated molecules. 
Secondly, the pharmacological effects of S3319 in the CNS will need to be 
investigated further.  While protein expression suggests at least a 4 hr window, S3319 
will need to be administered at different time points after SCI to determine if a 
therapeutic window does exist and how long it takes S3319 to buildup to adequate levels 
in brain tissue.  Additionally, while the serum half-life of sPLA2 is rather short (12 - 
24hr); investigating the half life of S3319 enzymatic inhibition in the CNS could easily 
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yield a lower optimal dose.  It is easy to imagine that the lipophilic nature of S3319 could 
result in build up in fatty tissues.    
Third, the mechanism of S3319 inhibition in SCI should be investigated further.  
In general three mechanisms of action could be envisioned with the data available; 
observable gains following sPLA2-IIA inhibition could result from 1) decreased 
inflammation, 2) increased axon regeneration across the lesion site, or 3) inhibition of 
direct cytotoxicity to neurons and/or oligodendroglia.   
While the current study showed increased axons at the lesion epicenter, it is 
unknown whether these axons are regenerative and whether these axons contribute to 
functional recovery.  The most crucial study will be to compare the retrograde labeled 
axons in a more controlled lesion.  For example counting the number of anterograde 
labeled axons coursing through a lesion and the number of retrograde labeled neurons in 
central nuclei following selective tract lesioning in either treated or vehicle animals.  This 
study could additionally be augmented with a relesioning group to demonstrate a return 
to baseline of any observable gains. 
Given sPLA2-IIA’s role in inflammation and S3319’s previously observed anti-
inflammatory effects its role in inflammation should be further investigated.  First, simple 
quantification of OX-42 positive macrophages and microglia in the current tissue sections 
should be assessed if adequate samples remain.  Additionally, replication of this study in 
immunologically suppressed animals would help elucidate what role the anti-
inflammatory effects of S3319 play in the observed histological changes.  Similar studies 
have already been performed in SCI using either administration of immunosuppressant 
(Rabchevsky et al., 2001, Nottingham et al., 2002) or depletion of peripheral immune 
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cells (Popovich et al., 1999).  These experiments would better determine the contribution 
of sPLA2-IIA in the mobilization of the immune response.  Of course the possibility 
exists that all of the aforementioned mechanisms or some combination therein, contribute 
to the observed behaviors in which case testing of each mechanism will show partial 
involvement.   
In the third study it was noticed post hoc that the animals given S3319 showed 
subjectively smaller bladder volumes on twice daily voiding.  While the effect was 
dramatic, it needs to be repeated and more rigorously studied.  Evaluation of lower 
urinary tract function by urodynamic cystometry would allow for measures of contraction 
amplitudes and duration, intercontraction interval, voiding pressure, while use of a 
Ballman cage would allow rigorous quantification of voided volumes and residual 
bladder volumes and would more readily confirm the above observation (Leung et al., 
2007).  Also histological sampling of the bladder wall could show that S3319, 
systemically administered medication, could have simply reduced cystitis and thus 
facilitated the neurogenic bladders.   
Finally, the intracellular mechanisms utilized by oxidative stressors and cytokines 
to upregulate sPLA2 after SCI remain obscure.  In several cell types, sPLA2-IIA 
expression is dependent on prior activation of cPLA2-α, where certain products generated 
by the cPLA2α-12/15-lipoxygenase pathway may play a critical role (Kuwata et al., 1998, 
Couturier et al., 1999, Kuwata et al., 2000).  It has been demonstrated in murine 
mesangial cells that H2O2 injury upregulates MEK-1 and ERK 1/2 that in turn stimulates 
cPLA2-α production. cPLA2-α was subsequently shown to increase sPLA2-IIA 
expression via the 12/15 lipoxygenase pathway and form a positive feedback loop 
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through PKC (Han et al., 2003).  The regulatory mechanisms for sPLA2-IIA induction by 
cytokines differ according to cell type.  For example, the activation of NF-κB, C/EBPβ 
and C/EBPδ, and STAT3 are necessary for sPLA2-IIA induction in rat mesangial cells, 
rabbit chondrocytes, and human arterial smooth muscle cells respectively (Kennedy et al., 
1995, Massaad et al., 2000).  Therefore further studies will need to assess the exact 
mechanism of sPLA2 mediated CNS injury to determine if it is a common convergence 
mechanism.   
 
Conclusions 
James W. Fawcett, Ph.D. closed his recent seminar at the University of Louisville 
with a picture of the profoundly complex control panel of the supersonic Concorde Jet.  
He then explained that current SCI research is equivalent to flipping one switch while the 
Concorde is flying at top speed.  The switch could lower the landing gear which would 
inadvertently slow the airplane.  However, the purpose of the landing gear is not to slow 
the plane but rather allowing it to land safely.  Within this work we hypothesized that the 
purpose of sPLA2-IIA was to increase inflammation and degrade neural tissue following 
SCI, which we have shown that it can do.  However, whether this is the end all purpose 
of this molecule remains for further study but what is assured is that the results presented 
here show a histological and possible behavioral change that merits further study and 
consideration.   
 
Quod erat demonstrandum 
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